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14 -3 -3 is an abundant, predominantly phospho- binding protein, intimately 
involved in the regulation of many diverse signal transduction events including cell 
cycle regulation, nucleo- cytoplasmic targeting of essential transcription factors and 
regulation of catecholamine synthesis. The 14 -3 -3 family consists of 7 isoforms 
(denoted a, ß, y, 8, c, rl and in mammals and shows a degree of isoform specificity 
in binding target proteins. 14 -3 -3 is phosphorylated in an isoform specific manner, for 
example SDK1 /PKD phosphorylates 14 -3 -3 11,13 and (, but not cs and T. Our 
laboratory has previously identified in vivo 14 -3 -3 phosphorylation sites, S185 and 
S233. Phosphorylation of S233 by the serine /threonine protein kinase Casein kinase 
la (CK1 a) was shown to negatively affect the interaction with Raf kinase. The group 
of Gotoh have recently shown that phosphorylation of S185 by the stress activated 
kinase c -Jun NH2- terminal kinase (JNK) negatively effects the interaction with Bax. 
During studies in our laboratory that identified CKla as a 14 -3 -3 kinase, several other 
proteins co- purified through four steps of chromatography, including centaurin -a1 and 
CPI -17, suggesting a protein complex - these interactions have subsequently been 
characterised. CK1 has a potential phosphorylation dependent 14 -3 -3 binding site 
within the same region previously shown to be the interaction site for centaurin -al 
and the aim of this investigation was to examine the possible interaction. 
14 -3 -3 was found to associate with CK1 isoforms, with CKIa being studied 
further to reveal an interaction through serine residues 218 and 242 in a 
phosphorylation dependent manner, in vivo. Centaurin -a1 was found to interact with a 
region corresponding to residues 214 -226, only if S218 was in a dephosphorylated 
state, suggesting a possible regulatory mechanism. Mutagenesis of CKIa suggests 
that S242 is a high affinity binding site for 14 -3 -3, with S218 being of lower affinity. 
Investigations to identify possible kinase(s) responsible for phosphorylation of CK1 
showed that stimulation of PKA can increase CKla:14 -3 -3 association in cells, but 
PKA does not appear to phosphorylate CKIa in vitro. 
As phosphorylation of 14 -3 -3 itself is an important regulatory mechanism, 
attempts were made to produce antibodies to phosphorylated S185 and S233 on 14 -3- 
3. A phospho -specific antibody to S185 was successful, but antibodies to a- phospho- 
iv 
S233 had no preference to the phosphorylation state of 14 -3 -3, although they were of 
high selectivity and affinity for 14 -3 -3 isoforms. 
The kinase BCR (Breakpoint cluster region) is an important, but poorly 
understood protein that has been shown to associate with and phosphorylate 14 -3 -3. 
Investigations showed that BCR phosphorylates 14 -3 -3 on Ser233 in vitro. 
Additionally, BCR is shown to associate with another two isoforms of 14 -3 -3 (e and 
rl) both in vitro and in vivo. However 14 -3 -3 a did not associate with BCR in vitro. 
BCR selectively phosphorylates 14 -3 -3 r more than , in contrast to CK1. 
In summary, Interactions with CK1 and 14 -3 -3 are characterised in detail and 
a possible regulatory mechanism discussed for CK1:centaurin- a1:14 -3 -3 interaction. 
Further insights into BCR signalling are revealed by identification of the 
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Introduction 
Chapter 1 - Introduction 1 
1. Introduction 
1.1. Preamble 
The introduction provides a general overview of 14 -3 -3 biology, giving brief 
accounts of recent relevant developments and details on how 14 -3 -3 modulates the 
activity of bound proteins. The 14 -3 -3 interacting proteins examined in this study - 
BCR kinase (Break point Cluster Region) and CK1 (formerly casein kinase I) are also 
discussed. The aim of this study was three fold. First was to identify the site of 
phosphorylation on 14 -3 -3 by the protein kinase BCR and examine in detail the 
interaction with 14 -3 -3 isoforms. The second aim was to further investigate a protein 
complex involving CK1, previously identified in our laboratory. In particular a 
possible CKl a: 14 -3 -3 interaction was examined and studies carried out to identify 
possible binding sites. Thirdly was to develop phospho -specific antibodies to 14 -3 -3 
to probe how the phosphorylation status of 14 -3 -3 can affect binding to ligands. 
Data shown here demonstrates that BCR can interact with the 14 -3 -3 y and E 
isoforms in addition to the previously reported 14 -3 -3 ß, and i isoforms. The site of 
phosphorylation is mapped to S233 on zeta 14 -3 -3 and T233 on tau 14 -3 -3. 
CKl a is shown to associate with all 14 -3 -3 isoforms in a phospho- dependent 
manner and the CKl a residues involved in this interaction are mapped to S218 and 
S242. This interaction occurs in vitro and in vivo. A model and possible function for 
this interaction is proposed. 
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1.2. 14 -3 -3 
1.2.1. Discovery of 14 -3 -3 
The name 14 -3 -3 was given to a group of small (28- 33kDa), acidic proteins 
identified in a systematic screen of brain proteins by Moore and Perez in 1967 [1]. A 
combination of DEAE -cellulose chromatography and 2D starch electrophoresis 
resulted in the name 14 -3 -3, derived from the migration pattern [1]. A further 
systematic screen of cellular proteins from transformed human amnion cells by Celis 
et al [2] provides a good reference as to the location of 14 -3 -3 on a 2D gel. The first 
function ascribed to 14 -3 -3 was the activation of tryptophan hydroxylase by 
Yamauchi and co workers [3], however at this time, the `activating protein' was not 
actually identified as 14 -3 -3 - it was not until several years later, when Ichimura et al, 
discovered the two are identical [4]. Shortly after, the same group identified and 
purified seven isoforms of 14 -3 -3 and denoted them a, ß, y, S, s, ri and after their 
respective elution position by HPLC [5]. They were also the first to clone 14 -3 -3 (the 
r isoform) [5]. At around the same time the laboratory of Aitken and co- workers 
identified a class of proteins that inhibited protein kinase C (PKC) as 14 -3 -3 [6]. 
Further studies into amino acid sequence of 14 -3 -3 by Aitken et al [7] revealed that 
the alpha and delta isoforms identified previously from brain, were the 
phosphorylated versions of beta and zeta respectively, bringing the actual number of 
isoforms to five. Subsequent studies have identified two further isoforms, named: 14- 
3 -3 i from T -cells [8] and 14 -3 -3 a from epithelial cells (from stratafin; the first name 
given to this isoform) [9], bringing the total number to seven. 14 -3 -3 z has since been 
shown to be expressed in multiple cell types, whereas 14 -3 -3 a has been found almost 
exclusively in epithelial cells. 
Figure 1.1 shows a schematic of 14 -3 -3, outlining domain organisation and 
highlighting key regulatory phosphorylation sites. The existence of 14 -3 -3 as a dimer 
was one of the first insights into 14 -3 -3 structure and key residues required for 
dimerisation subsequently identified [10] and shown in figure 1.1. Also highlighted 
here are residues essential for phospho- peptide binding, as discussed in 1.2.3. 
Phosphorylation of 14 -3 -3 can have a significant affect on its ability to bind other 
proteins and is discussed in detail in section 1.2.6. 
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Figure 1.1 14 -3 -3 Domain organisation 
14 -3 -3 is phosphorylated by a number of different kinases at different residues, with 
different consequences. DD represents the dimerisation domain. P in a circle 
represents phosphorylation sites with the respective kinase shown above. See text for 
specific details. Short bars indicate residues shown to be essential for phosphopeptide 
binding. Residues M202, D2°4, H206 are unique to a and when mutated to I, G and D 
respectively, as in other 14 -3 -3 isoforms, gives a the ability to bind the previously 
non -interacting ligand, Cdc2SC [11]. 
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1.2.2. 14 -3 -3 Sequence 
14 -3 -3 isoforms shows a high degree of sequence conservation across a broad 
range of organisms [12, 13]. Sequence analysis reveals homologous sequences in 
most eukaryotes examined, indeed they are found in four of the major evolutionary 
lineages: fungi, Alveolata, plants and animals [13], whereas none so far have been 
found in prokaryotic organisms. The diversity of the organisms where 14 -3 -3 
isoforms are found is sizable and indicates an ancient origin [12]. Evolution of such a 
large number of isoforms - at least 153 isoforms /alleles in 48 species of multicellular 
organisms (correct in 2000 [13]) is not obvious, but there are several possibilities why 
such a large number is expressed, as discussed by Rosenquist et al [13]. Among the 
possible reasons are: (i) to simply increase the amount of 14 -3 -3 available within a 
cell, (ii) to allow isoform -specific targeting (of 14 -3 -3) to a subcellular location, (iii) 
to allow isoform -specific binding of target proteins (e.g. enzymes) to modulate 
activity and (iv) differential expression during stages of development, allowing 
regulation of the process (see [ 13] for review). Many independent studies have 
identified 14 -3 -3 isoforms having different binding affinities to a number of target 
proteins, suggesting a requirement for so many isoforms. An alignment of the human 
isoforms is shown in figure 1.2, with conserved residues in red and conservative 
substitutions in yellow. This alignment reveals several blocks of highly conserved 
residues with 48% sequence identity between these 14 -3 -3 isoforms (gap penalty of 
3). Examining the same isoform across different mammalian species can give a 
sequence identify of 96 -100% [13]. The majority of conserved residues are essential 
for dimerisation and ligand binding, as discussed below. The alignment of 14 -3 -3 
sequences here uses the alternatively processed, longer, 14 -3 -3 ß isoform and also the 
longer epsilon isoform. This gives consistent numbering allowing more 
straightforward comparison of residues between isoforms (see figure 1.2). Pertinent 
residues are indicated in boxes, with the numbering as used in the literature and text 
here. Many functionally important residues are found in the conserved regions, but 
there are subtle differences in sequence within the 14 -3 -3 isoforms, including 
phosphorylation sites, that may lead to isoform binding specificity, discussed further 
in section 1.5. 
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Figure 1.2 Alignment of Human 14 -3 -3 isoforms 
A, Human 14 -3 -3 sequences were aligned using the ClustalW server at: http: / /npsa- 
pbil.ibcp.fr Black bars above sequences indicate a- helices. Residues involved in 
contacting bound ligands and phosphorylation sites are indicated and explained in the 
text. 
B, shows relationships between 14 -3 -3 isoforms, produced using the facility at 
http: / /pir.georgetown.edu /pirwww /aboutpir /aboutpir.html. Sigma is the most distinct 
from other 14 -3 -3 sequences. Gamma and eta are very similar and distinct. These 
differences may explain different binding affinities to 14 -3 -3 ligands, as discussed in 
1.2.2 and 1.5. Similarity between sequences is shown in arbitary units (0.1 scale bar). 
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1.2.3. Binding motifs 
1.2.3.1. Phosphorylated ligands 
Initial investigations into 14- 3- 3:Raf -1 interaction, using sequences derived 
from Raf -1, identified 14 -3 -3 as a specific phospho- serine binding protein, with an 
apparent Kd of 122nM [14]. To find optimal 14 -3 -3 binding sites, oriented peptide 
libraries were screened and identified a general consensus of: RSXpSXP and is called 
a `mode l' motif [14]. This was later refined to RXXXpSXP and is called a `mode 2 
motif', then further refined to RS[ + /Ar]pS[L /E /A/M]P and RX[Ar][ +]pS[L/E /M]P, 
where X =any amino acid, + = a positively charged amino acid and Ar = an aromatic 
amino acid [15]. Arginine at -3 or -4 from pSer is crucial for 14 -3 -3 interaction, 
whereas P at +2 is dispensable, although the Kd is decreased [16]. These general 
consensus motifs have greatly aided the identification of potential 14 -3 -3 binding 
partners, allowing computer based searches of protein databases, refinement of 
known 14 -3 -3 interactions and identification of candidate binding site(s). However 
not all proteins conform to this consensus, a list of proteins found experimentally to 
interact with 14 -3 -3 is found in table 1.1. For example, examination of the interaction 
of 14 -3 -3 with the proto -oncogene Cbl generated a further motif consisting of RX1_ 
2SX2_3S, where x is any amino acid and at least one S is phosphorylated [17]. 
Recently a further motif, pS /TX1_2 -COOH dubbed `mode 3', was discovered 
in arylalkylamine N- acetyltransferase (AANAT) [18] -a protein already known to 
contain a mode 1 motif When doubly phosphorylated, two site binding of 14 -3 -3 to 
AANAT lowers the Km of AANAT for serotonin -40 fold to 30µM [19] and see 
section 1.2.4. This motif is similar to another, atypical binding motif found in the 
plant H +- ATPase - QQYpT948V -COOH [20], where both motifs require the COOH at 
the C- terminus. However, phosphorylation does not always increase the association 
with 14 -3 -3, for example when p53 is doubly phosphorylated within the 14 -3 -3 motif 
(KGQPS376TpS37$RH) the association is actually reduced, compared to 
phosphorylated S378 alone [21]. Another word of caution is that 14 -3 -3 does not 
always bind the optimal motif, even within the same protein. For example, 14 -3 -3 
binds Gem through the two motifs RWpS23IP and KSKpS289CH, whereas another, 
more canonical motif (RKEpS261MP) does not. The result of 14 -3 -3 binding is to 
increase the half life of Gem [22]. 
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1.2.3.2. Unphosphorylated ligands 
14 -3 -3 has been shown to interact specifically with a number of non - 
phosphorylated proteins and with a similar affinity to phosphorylated proteins. One 
set of interactions appears to be through cysteine rich domains (CRD), e.g. the CRD 
domain of Raf -1 [23, 24] and the platelet GPIa [25]. Other ligands interact through 
acidic residues, e.g. ExoS ADP -ribosyl transferase [26, 27] and the 43KDa inositol 5- 
phosphatase [28] see table 1.1 for sequences. 
During screens for optimal peptides, a peptide known as R18 
(PHCVPRDLWLDLEANMCLP, underlined residues bind in the basic pocket) was 
found to bind 14 -3 -3 with an affinity of 70 -90nM [29]. It has been demonstrated by 
Yaffe et al [15] that the combination of two phosphopeptides (RSApSEP), separated 
by a linker region, had a -30 fold increased association with 14 -3 -3 [15]. The result 
was presumably through bidentate binding, as each peptide can bind into each 14 -3 -3 
monomer. Based on this observation, the laboratory of Fu et al designed a DNA 
construct that produces two R18 peptides that are separated by a linker region [30]. 
The purpose of using a peptide that does not require phosphorylation to interact with 
14 -3 -3 was appealing, as it should remain a potent 14 -3 -3 interactor, when transfected 
into cells. Transfection of a construct containing these two sequences, known as 
Difopein (Dimeric fourteen three three peptide inhibitor), induced apoptosis within a 
few hours, by sequestering all 14 -3 -3 - placing 14 -3 -3 as an essential antiapoptotic 
factor [30]. The mode of interaction of an unphosphorylated ligand may not be that 
different than that of a phosphorylated one, as the R18 peptide can clearly compete 
out binding to many ligands. Interaction through non -phosphorylated ligands may 
confer more isoform binding specificity due to involvement of other residues on 14- 
3-3 not usually involved in binding phosphorylated ligands. 
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1.2.4. Interacting partners 
The number of binding partners for 14 -3 -3 is growing rapidly. The group of 
MacKintosh and colleagues recently identified over 200 binding partners in an in 
vitro binding screen whereby HeLa extracts were passed through an immobilised 14- 
3-3 column and eluted with a generic mode 1 phospho -peptide (ARAApSAPA) 
[31]. Of course, whilst direct binding of 200 proteins to 14 -3 -3 is not claimed in this 
study, as protein complexes are certain to exist; it does reinforce the large repertoire 
of 14 -3 -3 binding proteins identified over the years. Currently more than 100 proteins 
have been well characterised and the binding motif identified (see section 1.2.3 and 
table 1.1, below). This table only includes proteins that have been proven 
experimentally to interact with 14 -3 -3, where the site(s) have been determined and is 
not a list of all 14 -3 -3 interacting proteins. It includes interacting proteins with 
phosphorylated, non -phosphorylated and `atypical' binding motifs. 
Table 1.1 Sequences within mammalian proteins experimentally determined to 
bind 14 -3 -3. Adapted and updated from [32]. 
Target protein by category binding sequence Reference 
Protein kinases 
Big mitogen- activated kinase 1 (BMK1 /ERK5) 
Caz+ /calmodulin -dep. myosin light -chain kinase 
CamKll 
GSK3I3 (Glycogen synthase kinase 3[3) 
KIF1C (Kinesin like protein KIF1C) 
Mei2P (S. pombe) 
PCTAIRE -1, protein kinase 1 
p90 ribosomal S6 kinase 1 (RSK1) 
PKC.t (PK)) 
PKCÇ 
c -Raf -1 kinase 
B -Raf kinase 
Testicular protein kinase (TESK1) 
Weel, cell -cycle Y kinase 
Phosphatases 
PTPH 1, tyrosine phosphatase 
Cdc25A, cell -cycle dual -specificity phosphatase 
Cdc25B, cell -cycle dual -specificity phosphatase 
Cdc25C, cell -cycle dual -specificity phosphatase 
Slingshot -1L (SSH1L) 
a -Chain of interleukin 9 receptor (IL -9R) 
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Exoenzyme -S, ADP -ribosylation DALDL428 [27] 
[56] GPIb a subunit of platelet membrane glycoprotein Ib RLpS166LTDP, RYSGHSL610 -cooH 




GEF -H 1 
Grb 10 
Insulin growth factor I receptor S 
Iip35, major histocompatibility complex- associated 




Na + /H+ exchanger isoform -1 (NEHI) 
Na +, K+- ATPase al -subunit 
Nicotinic acetylcholine receptor a 4 subunit 
Nuclear receptor (Nur77) 
Phosducin (photoreceptor Gbc- binding protein) 
prolactin receptor (Pr1R) 
RAS effector protein RINI 
Regulators of G- protein signalling, RGS3, RGS7 
Rem2 
Ron 
p190RhoGEF, guanine nucleotide exchange factor 
Apoptosis- regulating proteins 
c -Abl, tyrosine kinase 
Apoptosis signal -regulating kinase I (ASKI) 
BAD, (Bel- XL /Bcl -2 associated death promoter) 






KSR ( kinase suppressor of Ras) 
p 130cas (Crk- associated substrate) 
tau 
Transcription factors and nuclear proteins 
Ataxin -1 
BRF1 (butyrate response factorl) 
Cabinl 
E2F1 
Forkhead transcription factor (FKHRL1) 
Histone deacetylase, HDAC4 
Histone deacetylase, HDAC5 









RSKpS270QS, NHSRpS374IP, PKSVpS641AP [62] 
RRSpS393V-COOH [64] 
RRKPS373V-cOOH [64] 
QQRWpS22IP, KLKSKpS289CH [65] 
RIGpS703DP [66] 
KKpS 18KK [67] 
RSLpS441 VQ [68] 
RLPpS35oKP [69] 
RQMpS54SP [70] 
KCSpT391 WP [71] 
RSMpS351AA [72] 
EKDpS496YP, KSDpS434YP [73] 
RRGpS69M, QRSRpS334C [74] 
RPLpS'394EP [75] 
I' 370QAIQNL [76] 
RSVpT735LP [77] 
RSIpS967LP [78] 
RHSpS I 2YP,RSRpS' 36AP,RRMpS' 55DF[79, 80] 
RHRpS118HS [81] 
RSTpS939LN, KSLpS1210VP [82-84] 
RHpS619LPFpS623, RLGpS639TFpS642 [17] 
MApS3GVAV, RKSpS24TP [85-87] 
RRApS 16AP [88] 
RSKpS297HE, RTEpS392VP [89] 






RPRSCpT32WP, RRRAVpS253MD [97, 98] 
RKTApS246EP, RTQpS467Ap RAQpS632SP [99] 
RKTApS259EP, RTQpS498SP [100] 
RKTVpS178EP, RTRpS344EP, RAQpS479SP[101 ] 
RSHpS89SP [ 102] 
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Mizl 
Nuclear factor of activated T -cells (NFAT3) 
13271<'p1 
(p27) 
p53 tumour -suppressor /transcription factor 
TORC2 
YAP (Yes- associated protein) 
Enzymes and others 
43 kDa inositol polyphosphate 5- phosphatase 
Endopeptidase 24.15 
PFK -2 
K1FIC, kinesin -like protein 
Keratin 18 cytoskeletal component 
Middle T antigen, polyoma virus 
Nedd4 -2 (E3 ubiquitin ligase) 
NUDEL 




Phosphodiesterase 3B (PDE3B) 
Phospholipase A2 
Plakophilin 2 (PKP2) 
Rep68 
Rim l (Rab3 interacting molecule a) 
Rimla (Rab3 interacting molecule a) 
Rim2 
Rabphilin 3 
Serotonin N- acetyltransferase (AANAT) 
Stannin (Snn) 
Tyrosine hydroxylase 
Plant related proteins 
RSG (Repression of shoot growth) 
Fructose 2,6- bisphosphate (Fru- 2,6 -P2) 
H +- ATPase (plant plasma membrane) 














RTpS644ILRP [ 108] 






























RRHpT31LP RRNpS2o5DR-cooH [19, 123] 
RISQpS45EP [124] 









Abbreviations: pS, phosphoserine; pT, phosphothreonine; GM -CSF, granulocyte /macrophage colony - 
stimulating factor; TNF, tumour necrosis factor. PFK2, 6- phosphofructo -2- kinase /fructose -2,6- 
bisphosphatase; Sgkl - serum- and glucocorticoid- inducible protein kinase, KIF1C; TAZ, 
Transcriptional co- activator with PDZ- binding domain; 
Summary of 14 -3 -3 binding motifs: 
There are 25 14 -3 -3 binding proteins with no Arg at pS -3/4, 6 with a pSx -coox motif, 
4 with a non -phosphorylated motif and 15 with an Arg at pS -2. 
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1.2.5. 14 -3 -3 structure 
The crystal structures of 14 -3 -3 i [131] and [ 132] revealed near identical 
structures consisting of nine antiparallel alpha helices in each monomer, in a curved 
arrangement, that foul' a `cup shaped' structure (see figure 1.3). From these studies, 
the size of the amphipathic central groove formed by the dimers was ascertained to be 
35A wide and 35A long, with a depth of 20A [131]. Also evident is the different 
charges clustered along the central groove, forming a hydrophobic patch at one end, 
with a charged, polar group at the other. It is in this amphipathic groove where 
binding was predicted to occur. Due to the high sequence conservation, solving the 
structures of 14 -3 -3 i [131] and [132], serves as a good template for other 14 -3 -3 
isoforms. 
Residues 5 -21 of one monomer, form contacts with residues 58 -89 of the 
opposing monomer, forming an area of 2150A2 making up the dimer interface, of 
which 70% of this area (1520 A2) is composed of hydrophobic residues [131], more 
than the area covered by a typical antibody:antigen interaction [132, 133]. These 
structural studies help explain biochemical data gathered on 14 -3 -3. For example, 
protease digestion of 14 -3 -3 s, followed by gel filtration identified a 17KDa region 
that forms a dimer [10]. Deletion of the N- terminal 26 amino acids, disrupted 
dimerisation and also was less effective as an inhibitor of PKC [10]. It is clear from 
the structure that this domain represents the dimer interface. 
Whilst the crystal structure of 14 -3 -3 provides very useful insights, 
crystallisation with bound ligands is needed for more complete understanding. After 
identifying optimal binding peptides for 14 -3 -3 (see section 1.2.3.1) crystallographic 
studies were performed on `Mode 1' and `Mode 2' peptides bound to 14 -3 -3 -3 
identifying key residues involved in binding. A `mode l' peptide is shown binding in 
the 14 -3 -3 dimer in figure 1.3 and 1.4, the peptide is shown in yellow, with the 
phosphorylated serine in purple. Here the residues highlighted in red are directly 
involved in ligand binding; most have been shown experimentally to be essential for 
binding. There is a basic pocket that binds the phosphorylated serine (seen more 
clearly in figure 1.4, monomer). Within this pocket, residues K49, R56 and R60 have 
been shown experimentally to be essential for binding, although to differing degrees 
[134, 135]. 
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14 14 -3 -3 
1 QJ B 
Figure 1.3 14 -3 -3 in Complex with a `Mode 1' Peptide 
Each 14 -3 -3 monomer is represented in different colours, one orange, the other green, 
showing the nine alpha helices that make up each 14 -3 -3 monomer. The `mode l' 
peptide is coloured yellow, with phosphorylated serine in purple. Red colouring 
indicates the basic pocket and other residues that make contact with bound peptide 
[16, 131]. 
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Figure 1.414 -3 -3 monomer bound to a type 1 peptide 
One monomer from co- ordinates 1 QJB is shown represented with spheres. Key to 
residue colouring: 
Purple: pSER of bound peptide 
Blue: S58, involved in dimer formation 
Turquoise: R18 juxtaposed to S58 of the second monomer 
Yellow: mode 1 phospho -peptide, ARSHpSYPA, with the 14 -3 -3 mode 1 motif 
listed.Pink: S185 and S233 phosphorylation site. 
Red coloured spheres are residues that have been shown experimentally [ 16, 131 ] to 
contact bound ligands. 
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Indeed salt bridges are formed from the phosphoserine to each of these 
residues, with a hydrogen bond to the hydroxyl group of Y128 [15]. Specifically, a 
charge reversal mutation of Lys49 to Glu leaves 14 -3 -3 unable to bind Raf -1 kinase 
and Exoenzyme S both in reticulolysates and in yeast [134]. Charge reversal mutation 
of R56E partially reduced binding to Raf with R6OE having only a subtle difference 
[134]. Further studies revealed mutations of several hydrophobic residues that also 
reduce the ability of 14 -3 -3 to associate with binding partners [135]. Hydrophobic to 
acidic mutations consisting of: L172D, V176D, and L220D drastically reduced Raf -1, 
Cbl and BCR binding to 14 -3 -3 in Jurkat T -cells [135]. More extensive studies 
where the structure of 14 -3 -3 was solved with `mode l' and mode 2' peptides and a 
refined structure to 2A, allowed detailed analysis of electrostatic interactions with 
bound peptides. Comparing `mode l' and `mode 2' peptides revealed the proline 
induces a sharp twist, turning the peptide out of the binding pocket and back toward 
the central groove. The orientation in which `mode l' and 2 peptides are bound, 
however, is quite different. `Mode l' peptide is in the cis- conformation, whereas 
`mode 2' adopts a trans -conformation, causing the peptides to contact different 
residues within 14 -3 -3 [16]. The formation of salt brides and hydrogen bonds with the 
peptides showed El 80, N224, W228 would also be critical for binding ligands [16]. 
This was later tested, as mutation of Glul 80 to Lys allowed 14 -3 -3 c to bind a 
different subset of binding partners, in particular A -, B- and C -Raf could not bind 
El 80K mutant, but IRS -1 could, albeit with lower affinity [16]. 
In this study a double mutation of R56A/R60A was used with the intention of 
reducing the necessity of requiring a phosphate, without affecting or repelling binding 
of ligand per se. This charge reversal mutant has been used before to investigate 
PKUa localisation and regulation [136] and place 14 -3 -3 with an anti -apoptotic role 
increasing JNK and p38MAPK activation [137]. 
The structure of 14 -3 -3 is unique and few proteins share homology, however 
the recent solution of a protein involved in targeted RNA destruction, SMG7, was 
found to have a region with near identical tertiary structure to 14 -3 -3 [138]. 
Interestingly, the sequence identity at the amino acid level is less than 10 %, but the 
positions of the residues that are conserved, reside at equivalent positions found in 
previous 14- 3- 3:phosphopeptide structures, that make contact with bound peptide 
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[138]. Indeed mutations of these residues within SMG7 reduced binding, as observed 
in previous 14 -3 -3 interaction studies [16] (and see above). 
The only crystal structure of 14 -3 -3 in complex with another protein, is one of 
the first proteins found to interact with 14 -3 -3, arylalkylamine N- acetyltransferase 
(AANAT) [18]. This study used a truncated form of AANAT, lacking the last amino 
6 amino acids (due to problems with crystallisation) phosphorylated on T31 by PKA 
[18]. This structure showed the actual region of AANAT, the area around pT31, 
binding to 14 -3 -3 in a similar conformation to the crystallised peptide studies of 
Rittinger et al [ 16], with the cis- proline at +2 twisting the interacting loop out of 14- 
3-3 (see figure 1.5). Superimposing the two 14 -3 -3 structures revealed a very slight 
change in 14 -3 -3 structure - about 2A wider and raising the floor of 14 -3 -3 by 1.51, 
indicating the rigidity of 14 -3 -3 [18]. Indeed it is this rigidity that led to the theory of 
14 -3 -3 acting as a `molecular anvil' by Mike Yaffe [139] - actively forcing bound 
proteins into a particular conformation. The solution of the co- crystal structure 
accompanied with previous structural and biochemical knowledge of AANAT [ 123, 
140, 141 ] revealed that extensive contacts keep AANAT in an active conformation, 
by restricting movement of the active loop, leaving the active site readily available for 
substrate binding. The result of which is that on 14 -3 -3 binding to AANAT, the Km 
for serotonin is lowered substantially [123]. Further studies revealed that 14 -3 -3 can 
bind another site on AANAT (containing pS205) and 14 -3 -3 binding to both 
phosphorylated sites (pT31 /pS205) lowers the Km for arylalkylamine 30 fold compared 
to unphosphorylated AANAT [19]. 14 -3 -3 binding to phosphorylated 5205, with T31 
mutated to A, increased the Km for arylalkylamine 40 fold to 1.2mM [19], indicating a 
key regulatory mechanism and showing dual binding is required for maximal activity. 
Binding to 14 -3 -3 may also protect AANAT from dephosphorylation and/or 
degradation, prolonging the activation state [19]. 
14 -3 -3 a is quite distinct from other isoforms and the recent elucidation of the 
14 -3 -3 a structure has revealed residues whose positions and properties explain 
explicit homo -dimer formation of 14 -3 -3 a and distinct binding partner selection [11]. 
14 -3 -3 a has two extra amino acids between helices a -C and a -D (identified in figure 
1.6) creating a more disordered loop and subsequently a helix one turn shorter than in 
Also A Phe -Cys substitution at residue 25 alters salt bridge formation such that 
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Figure 1.5 Crystal structure of 14 -3 -3 with AANAT. 
Ribbon model of the crystal structure of 14 -3 -3 complexed to AANAT, from co- 
ordinates l IB l .pdb, rendered using Pymol. Only one 14 -3 -3 monomer (green) and 
one AANAT (light blue) are shown. Red residues indicate the binding pocket, yellow 
the interacting region, pT32 in purple. The orange molecule is COT (CoA- S- Acetyl 
tryptamine). 
Figure 1.6 14 -3 -3 a complexed with phosphopeptide. 
Residues recently identified as phosphorylation sites [ 142] are coloured red, residues 
found to mediate 14 -3 -3 a isoform selectivity (cyan), dark blue indicates an extra 
amino acid compared to all other 14 -3 -3 isoforms, pink indicates S185. The peptide is 
in yellow, pSer in purple. From 1WYT.pdb [11]. 
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there are four stabilising interactions in the homodimer interface that could not occur 
in heterodimers. Additionally S5 and E80, both unique to a are juxtaposed, but in 
other isoforms, E80 would be adjacent to D or E, forming a highly unstable 
interaction [11]. Another intriguing observation is that, in 14 -3 -3 a, mutation of three 
residues near the C- terminus (M202, D204, and H206) that are only variant in a, to I, 
E, D residues in all other isoforms, gives a the ability to bind cdc25, similar to all 
other 14 -3 -3 isoforms [11] and figure 1.6. These data highlight the fact that although 
the basic pocket may bind phosphorylated ligands, other contacts along the binding 
groove play an important part in mediating interacitons. 
Apparent from the 15 crystal structures of 14 -3 -3 obtained so far (RCSB 
database, http://www.rcsb.org/pdb/, August 2005) has been the lack of good quality 
data to ascertain the structure of the extreme C- terminus (structure to S233 is the 
furthest achieved yet (1QJB)). This is due to the disordered nature of this region and 
it has been proposed to function as a regulatory `pseudo- substrate', binding within the 
14 -3 -3 amphipathic groove itself, therefore blocking interaction with ligands [131]. 
The authors of one of the first crystal structures noted that it could be modelled to fit 
quite comfortably within the groove [131], however this has not been observed in any 
crystal structures. Studies involving a combination of time -resolved fluorescence, 
FRET and molecular modelling have shown two intriguing features of this region. 
First, that when 14 -3 -3 is unbound in solution, this loop does in fact bind in the 
binding groove [143] and secondly that on phosphorylation of S233, this region 
adopts an extended conformation, protruding further into the binding groove [144]. 
These data are in agreement with previous results, as discussed in 1.2.6.3 and [145, 
146], that have shown phosphorylation of residue 233 modulates binding. 
It is worth noting where the conserved residues reside in the context of tertiary 
structure. Figure 1.7 shows the structure of 14 -3 -3 using the identical colourings as 
the sequence alignment in figure 1.2, except with divergent residues in green. It is 
evident that the invariant residues are located in the binding groove of the protein and 
divergent residues on the outer surface, perhaps explaining how 14 -3 -3 isoforms can 
often bind the same protein and also functionally replace each other. For example, 14- 
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3 -3 T can replace 14 -3 -3 as an essential cofactor for the ADP -ribosylation activity of 
exoenzyme S [147] and yeast strains devoid of 14 -3 -3 genes (BMH1 and BMH2) can 
be rescued with genes from Arabidopsis [148, 149]. Also, deletion of both BMH1/ 
BMH2 in yeast is lethal, whereas mutation of either isoform produces a viable 
phenotype [148], implying a degree of functional redundancy. Other examples of 
redundancy have been found in genetic analysis of mutants in Drosophila. One study 
showed 14 -3 -3 c with a degree of redundancy, between c and in the formation of 
photoreceptors [150]. 
There also exists preferential expression of isoforms, for example 14 -3 -3 Ç 
(Leonardo in Drosophila) [151], indicating the requirement of that particular isoform. 





® = Total conservation 
= Conserved substitution 
= Variable residues 
Figure 1.7 Sequence conservation on 14 -3 -3 
Surface rendering of the 14 -3 -3 structure from 1QJB, created using PyMol, from 
www.pymol.org. Residues are coloured according to level of conservation as 
explained in the key. Generally, the most conserved residues are in the central 
binding groove, with most divergent residues on the opposite side. 
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1.2.6. Regulation of interactions 
Generally 14 -3 -3 ligands need to be phosphorylated to allow interaction, 
allowing binding to be controlled by the action of appropriate kinases and 
phosphatases. Many kinases have a consensus similar to either of the Mode 1 or mode 
2 14 -3 -3 binding motif, see table 1.2 below, for some examples of kinases that have 
been shown experimentally to phosphorylate within a motif and induce 14 -3 -3 
binding. The similarity of the 14 -3 -3 binding consensus to the consensus for PKA, 
PKB and PKC (basic at n -3 or 4), suggest the co- evolution of these signalling systems 
[15]. 
Table 1.2 Known kinases that phosphorylate 14 -3 -3 motifs 
Kinase Consensus motif 14 -3 -3 ligand Reference 
PICA RXS/T, RR/KXS/T AANAT [19, 123] 
PKB (Akt) RXRXXS FKHR [98] 
PKC RXS, RXXS, RXXSXR Integrin CD18 [ 152] 
PKD (PKCµ) LXRX ( M/L/K/E/Q/A) S XXXX Par -lb [114] 
P21-activated PK (PAK) KRXS, RRXS Bad [153] 
MAPKAPK1 RXRXXpS/T p27Kipl [ 154] 
MAPKAPK2 PX _2S/TP Cdc25B /C [50] 
CamKI I Hyd-XR/KXXS/TXX Phosducin [70] 
CK2 S/TaaAaAa *AaAa KIF1C [38] 
References for kinases' motif consensus: PKA [155], PKB [156-158], PKC [159], PKD [160], PAK 
[161], MAPKAPK1 aka Ras -activated PK (RSK1) [156, 157], MAPKAPK2 [162], CamK II [162]. 
Underlined S/T indicates target residues to be phosphorylated. Aa are acidic residues, Aa* particularly 
strong if phosphoserine or phosphotyrosine [163]. 
However, often the kinases responsible are not known and given the 
increasing diversity of the 14 -3 -3 binding motif, many other kinases may well 
phosphorylate within and create 14 -3 -3 binding motifs. As alluded to earlier, 
phosphorylation of 14 -3 -3 directly also has an affect on ligand binding, discussed 
further below. 
1.2.6.1. Phosphorylation of 14-3-3 
It has long been postulated that phosphorylation of residues within the 
dimerisation domain (S59, S64, see figures 1.1, 1.4) would disrupt dimer formation 
and this in turn could affect the ability of 14 -3 -3 to bind target ligands [164]. The first 
report of a kinase capable of phosphorylating S58, on intact 14 -3 -3, was termed 
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Sphingosine dependent kinase (SDK1) as phosphorylation occurred only in the 
presence of sphingosine [164]. This kinase was later identified as a truncated form of 
PKCS [ 165, 166]. The group of Woodcock then showed that phosphorylation of 14 -3- 
3 by SDK1 /truncated form of PKCE on S58 negatively affects dimer formation [167], 
but did not affect 14 -3 -3 binding to phosphorylated ligands. This contrasts with 
findings from the laboratory of Guri Tzvion, who found dimer mutants of 14 -3 -3 
could bind bona -fide ligands (Raf -1 and Fas -16) independently of phosphorylation 
status [168]. PKB /Akt has also been shown to phosphorylate S58 [169]. Curiously, in 
that study, the authors found that dimerisation was not affected. 
Phosphorylation of S185 on 14 -3 -3 increased the inhibition of PKC two fold 
[7], however the mechanism of this inhibition is not clear, presumably a slight 
structural change in 14 -3 -3 allows a different orientation of binding to PKC. The 
kinase responsible for phosphorylation of S185 was identified during the course of 
these studies, when the group of Gotoh discovered INK can phosphorylate S185 on 
14 -3 -3 t and a (numbering used in paper is S184 for (, 186 for a; but they are 
comparable residues, see figure 1.2) in response to cell stress (Actinomycin 
treatment) [170]. Phosphorylation of S185 leads to the dissociation of Bax, causing 
translocation to the mitochondrion, leading to apoptosis by cytochrome C release. 
Phosphorylation of S185 also negatively regulates the interaction with Foxo3a [171]. 
Phosphorylation of 14 -3 -3 on S185, also causes release of Bad, the combination of 
which antagonizes Akt mediated signalling [171]. 
Phosphorylation of 14 -3 -3 Ç on S233 by Casein kinase 1 negatively affects the 
interaction with Raf -1 [145, 172]. As mentioned above, the residue S233 lies in the 
flexible, unstructured region of 14 -3 -3, the phosphorylation of which causes a 
conformational change, negatively affecting binding to ligands. 
A recent paper showed that 14 -3 -3 a from cultured spontaneously 
immortalized granulosa cells (SIGCs) is phosphorylated on seven residues and the 
phosphorylation level was reduced after treatment with Progesterone [142]. The 
significance of this has yet to be determined, but two of these residues lie between 
alpha helices (aA -aB, aC;aD, see figure 1.6, red residues), similar to 5185, and may 
well affect binding to ligands. The only other reported phosphorylation of 14 -3 -3 
causing a negative affect on interaction is tyrosine phosphorylation on Y127 in the 
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maize isoform, OF14 -6. Phosphorylation reduces the ability to associate with the 
peptide from plant H +- ATPase [173]. 
1.2.7. I soforms and Dimers. 
1.2.7.1. Binding specificity and affinity 
Discerning potentially different binding affinities between isoforms for a 
particular ligand is experimentally challenging. For example, due to the potential for 
14 -3 -3 to form heterodimers, experiments have to been conducted using in vitro 
assays, as 14 -3 -3 can be produced as pure homodimers, thus allowing one isoform at 
a time to be examined. Work involving screening of oriented peptide libraries used to 
identify optimal motifs identified different isoforms had different affinities for certain 
peptides [15]. These data were confirmed for the '1 isoform with Biacore experiments 
involving passing 14 -3 -3 (termed the ligand in these studies) over an immobilised 
peptide [15]) and solution assays, where 14 -3 -3 was pre -bound to peptides, before 
passing over the Biacore sensor (with bound peptide). From this work, it is clear that 
there is a distinct preference for any particular isoform, over a given sequence. 
However, further complication arises from the fact that one 14 -3 -3 dimer could bind 
two peptides, as discussed in section 1.2.3.2 [15]. This may explain tight binding to 
proteins with two 14 -3 -3 binding sites, for example, Foxo [98, 174, 175], Raf -1 [14, 
176] and AANAT [123]. There are also examples of particular isoforms interacting 
with ligands, with different affinities. For example yeast two hybrid studies on the 
Zinc finger protein A20 found that out of the several 14 -3 -3 isoforms that bound, 14- 
3-3 ri bound the most, with £ less and ß, the least [ 177] and see table 1.3. The dual 
specificity phosphatase CDC25B has been reported to bind 14 -3 -3 ß, and q more 
strongly than s and T [178]. Further experiments suggest that CDC25 has one binding 
site available to all isoforms, but a high affinity site for and r1 [178]. See table 1.3, 
below, for a summary of some isoform specific interactions with 14 -3 -3. This would 
go some way as to explain how 14 -3 -3s may regulate such diverse cellular functions 
if different isoforms had different functions, but many of these studies have identified 
the particular isoform through identification by a screen (e.g. yeast two -hybrid), or 
simply not tested other isoforms. However the structural studies on 14 -3 -3 u, show 
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unambiguous evidence of how this isoform is able to have such specific binding 
properties [11] and so it is likely other isoforms will have similar regulatory binding 
mechanisms. 




































C, [3/, not y 
Ç, 3, E, ri, not a and r 
13, E, Ç 
E and Ç, not others 
rI, y, not E or T, Ç slight 
T 
In vivo /in vitro Ref 
in vivo [177] 
in vitro [57, 58] 
in vitro, [i in vivo [59] 
in vitro, in vivo [93] 
in vitro, y in vivo [35] 
in vivo [17] 
a [ 179] 
11, ß, T, E slight, in vitro [50, 178] 
all, excepta in vivo [51, 52] 
C, E in vitro [ 180] 
ß, y, E, T, Ç slight, nota in vitro, in vivo [81] 
Ti in vitro [181] 
E in vitro [62] 







E, not S or T 
13, E, y; T, g slight), not a 
T, E, , ((3 slight) 
T, y, E,R,31 
ß, 
r),T 
Interactions indicated as in vitro include pull down assays, baculovirus 
in vitro [104] 
in vitro, in vivo [182] 
in vitro [105] 
in vitro, in vivo [ 116] 
in vitro, in vivo [43] 
in vitro [183, 184] 
in vitro [45, 185] 
system, or yeast two hybrid 
systems. In vivo interactions were demonstrated by co- transfection or single transfection of the 14 -3 -3 
ligand protein and use of isoform specific antibodies. When only one isoform is indicated, that isoform 
was generally selected from a screen (e.g. yeast two hybrid) or proteomic study (identification by ms). 
Other isoforms are listed as strongest interaction first. Not all 14 -3 -3 isoforms are necessarily tested for 
interaction. Abbreviations: A20, zinc finger protein; CamKII, Calcium and calmodulin- dependent 
dependent kinase kinase; CDK11, cyclin dependent kinase 11; CLIC4, Chloride intracellular channel 
protein; GR, glucocorticoid receptor; IGF -1, Insulin growth factor 1 receptor; NFAT3, Nuclear factor 
of activated T -cells 3; PMCA4, plasma membrane calcium pump; PKC, protein kinase C. 
1.2.7.2. Heterodimerisation 
The picture is further complicated by the ability of 14 -3 -3 to preferentially 
form heterodimers in vivo [186]. 14 -3 -3s produced in bacterial systems will form 
homodimers, even if there is a preference for a heterodimer, simply because it is 
energetically more favourable to form a dimer than monomer. Analysis of 14 -3 -3 in 
cells shows that many heterodimers exist. Studies in our laboratory using stably 
transfected PC 12 cell lines, found that the gamma isoform formed homo and hetero- 
Chapter 1 - Introduction 24 
dimers, whereas epsilon formed solely heterodimers, with no homodimers detected 
[186]. A summary of the findings is shown in table 1.4, below. 
Table 1.4 Summary of heterodimerisation of 14 -3 -3s 
Possible combinations from studies involving 14 -3 -3y and E 
Monomer 1 13 Y 11 i a E 
Monomer 2 E Y E E E E 13 
E Y 
11 11 
Data from [186]. 
Reading across the table (left to right), 14 -3 -3 isoforms are listed, with 
isoform of the possible conjoining monomer listed vertically. As y and E could form 
dimers with other isoforms, the reciprocal is listed in this table. Absolute preference 
of heterodimer is difficult and not attempted due to different titres of antibodies and 
large number of 14 -3 -3 isoforms present in the cells [186]. BMH1 and BMH2, The 
two 14 -3 -3 isoforms from Saccharomyces cerevisiae were also examined and were 
found as predominantly heterodimers. Another curious finding was the increase of 
14 -3 y:rl occurring hours after NGF treatment, an affect not 
seen for E:y heterodimers. 
Previous work by the group of Muslin showed stable transfection of a binding 
mutant of 14 -3 -3 rl formed a heterodimer with native in NIH3T3 cells [137]. The 
overall effect of transfected binding mutants into cells in culture was to sensitise them 
to radiation, in contrast to the protective role of normal, wild type 14 -3 -3. 
The ability of 14 -3 -3 to bind in an isoform -specific manner, and the ability to 
form heterodimers, suggests two roles: Heterodimers may offer a role of adaptor 
protein, bringing two different molecules together, whereas the homodimer may be 
more of a chaperone role that can sequester bound protein to a particular location, for 
example the cytoplasm. Examples of 14 -3 -3 exhibiting an `adaptor function' however 
has been seen only rarely: BCR kinase with Raf -1 kinase [ 187], Raf -1 and A20 [ 177] 
and Raf -1 and PKC [43]. 
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Heterodimers have also been observed in plants, where GFP fusions formed 
heterodimers with endogenous 14 -3 -3 in Arabidopsis cells [188]. Isoform specific 
localisation was also observed for many isoforms. 
1.2.7.3. 14 -3 -3 location and distribution 
Spatial and temporal regulation may offer an explanation as to how such a 
ubiquitous protein is able to have such specific effects on so many different 
molecules. For example, tissue specific expression or increased expression/repression 
of 14 -3 -3 at specific times, during the cell cycle or development, could modulate the 
activity of a number of proteins, helping shape the required outcome. 
14 -3 -3 is largely found in the cytoplasm, but is also found associated with the 
plasma membrane [183], the Golgi apparatus and in the nucleus [189]. There are 
several examples of 14 -3 -3 sequestering target proteins to the cytoplasm. For 
example, studies on the transcription factor for cell senescence, Daf -16 in C. elegans 
and FOX() (FKHR) in mammalian cells, found that after phosphorylation by 
PKB /Akt, 14 -3 -3 sequesters the transcription factor in the cytoplasm, inhibiting 
transcription [98, 190]. A similar role is performed by 14 -3 -3 for the cell cycle 
regulator Cdc25 [ 191 ] and the cyclin dependent kinase (CDK) inhibitor p27(Kip 1) 
[105, 154]. The tyrosine kinase c -Abl is phosphorylated by an unknown kinase, 
causing 14 -3 -3 sequestration of c -Abl to the cytoplasm [77]. DNA damage then 
causes JNK phosphorylation of 14 -3 -3, releasing c -Abl to the nucleus, inducing 
apoptosis [77]. 14 -3 -3 not only induces nuclear exclusion, although rare, there is one 
example is nuclear targeting of telomerase, by masking the nuclear export sequence 
(NES) for CRM1 (also known as exportin) [192]. Another regulatory role recently 
discovered for 14 -3 -3 is involvement in the quality control of various receptors, 
including potassium channels and acetylcholine receptors. In the case of the 
potassium channel, HCNK3, dibasic motifs located on the receptors are bound by 
COPI (coatamer I)- coated vesicles, forming a retrograde transport system for the 
HCNK3 channel back to the ER [64]. Although separated by some distance in linear 
amino acid sequence, 14 -3 -3 binds with mutual exclusivity [to the HCNK3 channel], 
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displacing the COPI vesicle, allowing the HCNK3 channel to escape the ER and 
locate to the cell membrane [64]. 
14 -3 -3 y has been found as the major isoform at the Golgi apparatus [189]. 14- 
3 -3 is also present at the Golgi and is shown to be a substrate for the Ste20 kinase 
YSK1 [193], the consequence of which is not known. 
Due to the high level of 14 -3 -3 found in the brain [2], the expression of 
individual isoforms has been the subject of many studies in particular in response to 
neurological disorders. For example analysis of 14 -3 -3 isoform expression within the 
prefrontal cortex has revealed differing levels at the DNA transcript level -14-3-313 
and 14 -3 -3 y are expressed at higher levels than rl and Ç [194]. Examination of the 
same tissue from patients with Schizophrenia found that14 -3 -3 rl was the only 
isoform that was significantly down regulated ([194] and references therein). The 
exact reason for this downregulation is unknown, but the authors do point out that the 
14 -3 -3 p gene is found within an area of chromosome 22 (22q12-q13) that is known 
to be mutated in the 5' UTR region in schizophrenics [194]. Specific 14 -3 -3 isoforms 
are also found in the cerebral spinal fluid (CSF) of patients with CJD (Creutzfeldt- 
Jakob disease) and is used a clinical marker for the presence of this disease [195]. The 
location of 14 -3 -3 isoforms within a murine (murine scrapie) model of CJD changes 
after infection with scrapie [196, 197]. Combined, these results suggest that 14 -3 -3 
may play a role in the pathogenesis of CJD. However a mouse knockout of 14 -3 -3 y 
(found in greatest abundance in CJD CSF [196]) had no difference in response to 
inoculation with infectious prion protein [198]. However, 14 -3 -3 isoform redundancy 
may have played a role. 
Many investigations involving 14 -3 -3 isoform specific localisation or 
increased /decreased expression have been centred on 14 -3 -3 a (also known as 
stratafin). 14 -3 -3 a has been shown to be up regulated in a number of cell lines and 
tumours and a number other investigations (discussed above) have suggested 14 -3 -3 
as having an anti -apoptotic role. Despite these antiapoptotic roles, 14 -3 -3 a in various 
cancers is commonly downregulated or silenced by promoter methylation [199, 200]. 
However this seemingly paradoxical situation remains controversial, as a recent 
proteomic study by the group of Julio Celis, found that 14 -3 -3 a promoter 
methylation is a sporadic event in primary breast cancers [201]. The proteomic results 
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were corroborated using specific 14 -3 -3 a antibodies for immunohistochemical 
analysis. There was also no increase in DeltaNp63, a dominant -negative 
transcriptional regulator of 14 -3 -3 a and also no increase in the E3 ubiquitin ligase 
that targets 14 -3 -3 a for destruction [201]. 
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1.3. Breakpoint Cluster Region Kinase (BCR) 
The term breakpoint cluster region (bcr) refers to an area of 5.8kb on 
chromosome 22 that by a reciprocal translocation event with the c -abl gene, from 
chromosome 9 produces the chimera bcr -abl (figure 1.8). It is this reciprocal 
translocation event that creates an aberrant chromosome called the Philadelphia 
chromosome (ph') that is the hallmark of chronic myelogenous leukaemia (CML) - 
found in over 90% of patients with CML [202]. CML is characterised by an abnormal 
build up of haematopoietic cells in the bone marrow and elevated peripheral white 
blood cell counts [203]. BCR -ABL proteins can vary in size, depending on the 
breakpoint within Bcr. The resultant fusion protein, containing different amounts of 
the bcr gene fused to abl gives rise to different clinical outcomes with ranging 
severity [204, 205]. For example, the protein fusion of 190KDa (p190BCRJABL) is a 
more potent transformer of fibroblast cells, compared to the longer, 210KDa 
(P Z 10BCxIABL ) fusion [ 205, 206] . As well as varying breakpoints, alternative splicing g 
of exons within both Bcr and c -Abl transcripts further increases the variety of BCR - 
ABL transcripts [207], the exact significance of this is yet to be elucidated. The 
normal product of c -Abl is intimately involved with regulation of cell death [208] and 
is usually tightly regulated by an N- terminal inhibitory region. When fused to Bcr, 
this inhibitory region is lost and the kinase is constitutively active [208]. This, 
combined with BCR -ABL being predominantly cytoplasmic [209] allows the BCR - 
ABL fusion to extensively phosphorylate cellular proteins, transforming cells and 
making them growth factor independent [210]. As an onco -protein BCR -ABL 
activates several signalling pathways, to achieve transformation of cells, highlighted 
in table 1.5. 
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Breakpoint 




















Figure 1.8 Chromosomal translocation of BCR 
The shortened chromosome, known as Philadelphia chromosome (Ph') is a hallmark 
of chronic myelogenous leukaemia (CML). Exchange of genetic material from 
chromosome 9 (where bcr resides) and chromosome 22 (where abl is found) forms 
bcr -abl transcripts of variable length. Most studies to date involving bcr have 
focussed on this chimeric gene and the abl gene alone, but rarely on bcr itself. 
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The formation of the BCR -ABL fusion protein is thought to occur during late 
S- phase, where the close proximity of each gene to the other has been highlighted by 
fluorescence in situ hybridisation (FISH) analysis [226]. The short distance is thought 
to afford the opportunity for reciprocal recombination [227]. 
The constitutively active tyrosine kinase activity of BCR -ABL, essential for 
the progression of CML [228], has been the focus of many studies to find an effective 
inhibitor, of which a compound known as Gleevec, Imatinib or STI571 (Novartis) has 
proved to be highly successful [229]. Structural studies have shown Gleevec to bind 
in the kinase domain of Abl and displace ATP, keeping the kinase in an inactive 
conformation [230, 231]. However, due to the highly selective nature of this kinase 
inhibitor, point mutations arise quickly following administration. For example one 
patient was found to have 19 point mutations in the BCR -ABL kinase domain [232, 
233]. Another approach to reduce the effect of overexpressed BCR -ABL, has been 
the development of siRNAs. They have been shown to decrease transcripts of BCR - 
ABL, but not BCR in primary cells from patients with CML [234], however the 
transition of siRNA based technology into a therapeutic agent can be an arduous task 
[235]. It is due to this clinical relevance that most research has focused on the 
chimeric BCR -ABL, with few studies on the normal cellular function of BCR. Whilst 
originally BCR -ABL fusion was thought to be found only in cases of CML, recent 
highly sensitive PCR techniques have found the presence of BCR -ABL transcripts in 
healthy individuals [236, 237]. Current opinion is that, in healthy individuals, the 
immune system is able to monitor cells producing these transcripts and stop 
proliferation. 
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1.3.1. BCR Domain organisation 
Although Bcr has homology to many proteins involved in cellular signalling, 
and has been shown to associate with well characterised proteins in cell signalling, it 
has no known physiological function [207]. Overexpression of Bcr itself inhibits cell 
proliferation [ 187] and it has been speculated that it can act as a negative regulator of 
BCR/ABL protein [238]. 
The normal Bcr gene gives rise to two major proteins that are 130kDa and a 
160kDa in size [239 -241] (most studies have centred on the 160kDa protein) and 
contain a number of domains, see figure 1.9. These include an oligomerisation 
domain [242], an atypical S/T kinase domain [147, 187, 243], SH2- binding domain 
[214], guanine nucleotide exchange factor (GEF) domain [244, 245]. and a GTPase 
activity (GAP) domain [246]. Residues 1 -294 of the kinase domain were originally 
identified (by a series of GST- truncation mutants of BCR) as incorporating the 14 -3 -3 
binding domain [ 147]. However, with longer exposure, binding can be seen with the 
other mutants corresponding to regions towards the C- terminus - indicating more 
then one binding site. There is also PH and C2 domains, identified by homology, that 
may help targeting of BCR to the membrane. The fact that BCR has demonstrable 
GEF and GAP activities suggests a dual role in G- protein signalling events. 
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Figure 1.9 Schematic of BCR kinase 
'SH2 domain that through phosphorylated tyrosine binds Grb- 2[247]. 
2SH2 domains essential for oncogenic activation of BCR -ABL, it is unusual in that 
phosphorylated serine and tyrosine residues are used within this SH2 motif, as 
opposed to phosphorylated tyrosine. The structure of the oligomerisation domain has 
been solved [248], defining how the observed tetramer of BCR [243] occurs. Possible 
14 -3 -3 binding motifs are indicated with filled circles, as identified in [249], `297' 
indicates amino acids 0 -297 identified in [147] that were shown to bind most 14 -3 -3. 
The domain marked PH has homology to Cdc24, Dbl, Vav (all GEFs) [244, 245], this 
domain also binds to XPB protein [250, 251]. PH (pleckstrin homology) and C2 
(Ca2 +- dependent phospholipid binding) domains may regulate BCR association with 
the membrane. RhoGAP has demonstrated GTPase activity toward p2lrac [246]. A 
PDZ domain mediates interact with AF6 [2.52], PDZK1 and Mint3 [253]. 
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The oligomerisation domain of BCR consists of a heptad repeat of 
hydrophobic residues that allow BCR to purify as a >600kDa oligomer [243] and also 
form heterotetramers with BCR/ABL in K562 cells [254]. Structural studies into the 
BCR oligomerisation domain (using amino acids 1 -72) have revealed that two N- 
shaped monomers form a dimer, through formation of an antiparallel coiled coil 
between alpha helices and domain swapping [255], followed by stacking of the two 
dimers to form a tetramer [248]. BCR -ABL also self oligomerizes through this 
domain in vivo in 293 cells [256]. Mutations within this region not only disrupt the 
oligomerisation [256], but also reduce the tyrosine kinase activity of BCR -ABL 
[242], reduce the ability to associate with the cytoskeleton [242], reduce its fibroblast 
transformation potential and increase its sensitivity to STI571 [257]. It has been 
suggested that the sole function of the BCR oligomerization domain is to reduce 
autoinhibition of BCR -ABL (by disrupting the SH3 domain of ABL binding) by 
causing intermolecular autophosphorylation [256]. 
The kinase domain of BCR has short segments homologous to other protein 
kinases, such as the GxxxxGK motif and GxGxxG with downstream lysine [243, 
258]. However, when originally characterised as having kinase activity [240] BCR 
had so little in common with other kinases that the possibility remained that a co- 
associating kinase activity was responsible for the activity observed. This was ruled 
out four years later, with work including an in -gel kinase assay [243], but the 
possibility that a kinase could associate with BCR in vivo remains a possibility. The 
group of Witte et al also showed that mutating the cysteine residue Cys322 to Lys 
reduced both the auto and trans -phosphorylation activity of BCR and proposed that it 
was similar to pyruvate kinase in having essential cysteine residues in the nucleotide 
binding domain [243]. The possibility remains that removing essential cysteine 
residues could interfere with binding partners of BCR and therefore the subsequent 
phosphorylation. 
One of the three Src homology 2 (SH2) binding domains of BCR (when 
phosphorylated on T177) allows it to bind to GRB -2, linking it to the Ras pathway 
[214]. The SH2 domains are discussed further below. 
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The central region of BCR is complex with homology to the three different 
Guanine exchange factors (GEFs). BCR has homology to the haematopoietically 
expressed VAV proto- oncogene and the mouse homologue of CDC25 Ras activator 
[244, 259], but has no demonstrated activity similar to these proteins. There is also 
homology to the oncogene Dbl, a protein capable of catalysing the guanine nucleotide 
exchange on Rho and CDC42 from GDP to GTP (a GEF) [245, 260, 261]. This Dbl- 
homologous region of BCR has been shown in vitro to stimulate GTP binding to 
CDC42, RhoA, Rac 1 and Rac2 [262]. This RhoGEF domain has also been shown to 
activate NF -KB through stimulation of endogenous p38MAPK in COS -7 cells [263]. 
The authors also identified autoinhibitory flanking regions either side of the DH /PH 
domain that reduced NF -KB activation in vitro and in vivo [263]. 
Interestingly full length BCR had GAP activity for CDC42, Rac 1 and Rac2, 
suggesting that BCR could act simultaneously with Rho proteins to coordinate 
cellular signalling [262]. Indeed the C- terminal of BCR has GAP activity for p21', 
see below. This region is also the site of the interaction with Xeroderma 
pigmentosum group B protein (XPB), which reduces the ATPase and helicase activity 
of XPB [250]. 
BCR interacts with the proto -oncogene c -myc through residues 871 -910, 
between the DBL domain and the C2 domain [264]. Next to the DB /PH domain of 
BCR, is the C2 domain (911 -1036) that has no known function, but C2 domains 
found in many other proteins bind phospholipids in a calcium dependent manner 
[265]. 
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1.3.2. Regulation 
BCR can associate with the proto -oncogene Fes, forming a stable complex in 
co- transfected Sf -9 cells [266]. BCR is also phosphorylated by Fes tyrosine kinase on 
Y177, Y246 and at least one of a cluster of tyrosine residues: Y276, Y279, Y283 [267]. A 
complete list of known phosphorylation sites on BCR is highlighted in table 1.6. 
Phosphorylation of Y177 by the Fes kinase inactivates the trans -phosphorylation 
activity of BCR toward 14 -3 -3 [267]. When Y177 is mutated to phenylalanine this 
abolishes GRB -2 binding and abrogates BCR -ABL induced Ras activation [214, 
268]. 
BCR is also a substrate for BCR -ABL, being phosphorylated on Y177, Y283 
and Y36° in vitro [269]. These studies found that Y177F and Y283F mutations had wild 
type kinase activities, whereas Y360F had markedly reduced kinase activity, indicating 
Y360 as an essential regulatory site. The authors also found that BCR purified from 
cells expressing BCR -ABL, in conditions to preserve tyrosine phosphorylation had 
reduced kinase activity [269]. In vitro tyrosine phosphorylation within residues 162- 
413 of BCR by Fes kinase, however, has been shown to decrease the association with 
14 -3 -3, in contrast to increased binding to Grb -2, PLCy, 85kDa PI3K subunit and Abl 
[270]. This is an interesting observation, as 14 -3 -3 binding to BCR has been shown to 
be a phospho -dependent interaction in vitro [44]. In that study potato acid 
phosphatase was used to déphosphorylate BCR, which reduced 14 -3 -3 binding [267]. 
Whether or not 14 -3 -3 has to bind BCR with high affinity in order to become a 
substrate remains to be investigated. 
Recently five additional phosphorylation sites (T310, 5459, S463, Y591and Y644) 
have been found on BCR, in a study designed to follow changes in tyrosine 
phosphorylation of BCR -ABL on treatment with the inhibitor Gleevec (STI -571) 
[271]. Of these residues, T31° was identified as a potential 14 -3 -3- binding site and 
within a PKA consensus using the protein motif scanning facility (at 
http: / /www.scansite.mit.edu) [271, 272]. The phosphorylation level of all these 
residues decreased on exposure to the inhibitor [271], with tyrosine phosphorylation 
on BCR being effected more rapidly than serine /threonine phosphorylation. This is 
due, most likely, to the inhibition of the Abl portion of the BCR -ABI kinase. 
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BCR has a region in the extreme C- terminus typical of PDZ binding ligands 
(S- T -E -V, figure 1.2) that can bind to the PDZ domain (PSD -95 /discs large /ZO -1) of 
AF -6 (a ras- interacting PDZ- domain containing protein of cell junctions) at the 
plasma membrane in epithelial cells [252]. Furthermore, a complex of these proteins: 
BCR, AF -6 and Ras at the cellular junction down -regulates Ras -mediated signalling 
and cell proliferation [252]. AF -6 is also a substrate for BCR, becoming 
phosphorylated on T893, which increases the interaction [252]. 
Recently, BCR has been shown to specifically interact with Mint3 (Munc 18- 
Interacting Protein) [253], a predominantly Golgi- localised protein that is involved in 
protein processing and vesicular trafficking in the distal secretory pathway. Rho 
GTPases are involved in vesicular trafficking [275] and they could be affected by the 
GAP and GEF activities of BCR through association with Mint3, therefore exerting 
an effect on the secretory pathway. BCR phosphorylates the same site on 14 -3 -3 as 
CK1, and now we find that BCR, too, is involved in the secretory pathway (see 
discussion). 
BCR also associates with ERBIN (ERB2 Interacting protein) through its PDZ 
domain [276]. Interestingly, ERBIN is also known to bind to b- catenin in vivo [277], 
a protein that we have recently shown to bind 14 -3 -3 [278]. 
BCR has been reported to associate through 14 -3 -3 with all isoforms of Raf 
kinase (See table 1.1 and 1.3). Significantly in this study, -10 times more Raf was 
found in the membrane fraction, than in the cytosol [ 187], suggesting recruitment of 
Raf. However there have been many conflicting reports on the regulation of Raf and 
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the role of 14 -3 -3 recruitment to the cell membrane (see [279, 280] for review). One 
recent model is that 14 -3 -3 binds to the proposed high affinity site, S641, aiding 
dimerisation and activation of Raf, 14 -3 -3 can then bind to the low affinity site, S259, 
that functions to `lock' C -Raf in the cytosol, attenuating Raf activation [281]. 
1.3.3. Substrates 
BCR kinase can phosphorylate histone and casein in vitro [243], but the only 
known in vivo substrates are 14 -3 -3 [147] and AF -6 [252]. Reuther et al [147] showed 
that phosphorylation of 14 -3 -3 i by BCR (in vitro) occurred exlusively on serine 
residues and produced four spots on thin layer chromatography, suggesting four 
phosphorylation sites. This point is discussed in chapter 3. 
AF -6 is phosphorylated on T893 by BCR, as determined by site directed 
mutagenesis, that induces binding to AF -6, causing downregulation of Ras -mediated 
signalling, as mentioned above [252]. 
1.3.4. Localisation 
BCR is ubiquitously expressed, with highest levels in brain and 
haematopoietic cells [207]. Early studies found BCR to be cytoplasmic in uncycled 
mouse haematopoietic cells [209, 239]. Studies using the cell -cycle blocker 
aphidicolin, have identified BCR as largely cytoplasmic during interphase, 
associating with chromosomes during mitosis [282]. The association was also found 
with DNA and heterochromatin in quiescent cells, identified using immuno -gold and 
electron- microscopy [282]. 
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1.4. Casein Kinase 1 (CK1) 
The protein kinase `Casein kinase I' (now termed CK1) is named after the 
initial discovery that preparations of a kinase from calf muscle could phosphorylate 
purified casein in vitro [283]. It is worth noting that both CK1 and the similarly 
named, but structurally quite different, CKII (now CK2) protein kinase are not 
responsible for the physiological phosphorylation of casein in milk (this is achieved 
by membrane bound casein kinases in the Golgi apparatus) [284]. Among one of the 
first serine /threonine protein kinases to be characterised, CK1 has since been shown 
to consist of several isoforms with molecular weight ranging from Mr 23,000 to 
60,000. The primary structure consists of a large, conserved kinase domain and 
variable N and C terminal domains (see figure 1.10, 1.11). CK1 is also a dual 
specificity kinase, being shown to both autophosphorylate and transphosphorylate 
tyrosine residues both in vitro and in vivo [285 -287], although it is predominantly a 
S/T kinase. In higher eukaryotic organisms, the CKI family consists of seven 
isoforms in mammals, denoted: a, ß, yi, 2, 3, 8 ands (figure 1.11), four in 
Saccharomyces cerevisiae, denoted: HRR25, YCK1, 2,3 and five in 
Schizosaccharomyces pombe denoted Ckil, 2, 3, Hhpl and Hhp2 [288]. Alternative 
splicing can increase the number of isoforms, resulting in different biochemical 
properties. For example in CKla there exists potentially four splicing variants [289- 
291 ]. A study by Zhang et al into one of these variants found that a 28 amino acid 
insertion into the catalytic domain (denoted CK1aL) had distinct effects on the kinase 
activity when compared to CK1 a [291]. CK1 aL has increased catalytic turnover, 
compared to CK1a toward some substrates, but not others. In addition, they also 
found that CK1aL exists at 15% of the level of CKla in almost all mammalian 
tissues tested. The insert appears just before the `hinge' region of CK1, where 
substrate is recognised and could therefore accommodate larger or different shaped 
proteins [291] and see figure 1.10 for CK1 crystal structure indicating classical 
bilobal protein kinase structure. Shorter splice variants of CK1 a in goldfish are 
localised to the nucleus of oocytes and all four isoforms of CKla are expressed in a 
tissue dependent manner [292]. 
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1.4.1. Substrate specificity 
The wide tissue distribution, large number of isoforms and broad substrate 
consensus has produced a formidable list of substrates and binding partners that 
implicate CK1 in a range of diverse cellular processes. To date, at least 60 substrates 
for CK1 have been identified (table 1.7). However, some proteins identified as in 
vitro substrates have not been shown to be phosphorylated in vivo, for example 
glycogen synthase [293]. The first in vitro substrates to have the phosphorylation sites 
identified after phosphorylation by CK1, were on SV40 large T antigen [294] and 
glycogen synthase [295], reviewed in [284]. Subsequently, Peter Roach and 
colleagues discovered that prior phosphorylation of rabbit muscle glycogen synthase 
by PKA, in vitro, allowed CK1 to incorporate much more phosphate [into glycogen 
synthase] [296]. Refinement of these studies using peptides with varying distance 
between the phosphorylatable Ser /Thr residues and the pre phosphoprylated residue, 
determined an optimal distance of two residues N- terminal to the Ser /Thr to be 
phosphorylated by CK1 to give the form pS /pTX1_2S /T, where X is any amino acid 
[297]. These phosphorylatable ser /thr residues then became known as `priming' sites. 
Additionally, blocks of three or four Asp or Glu residues ending at the -3 position can 
increase a substrates propensity to be phosphorylated by CKI, giving the consensus 
D /E3.4XXS /T, but are still not as good as a phosphorylated serine /threonine at n -3 
[298, 299]. Knowledge of these substrate determinants has enabled rapid 
identification of many CK1 substrates, using computer -based searches of known 
phosphorylated proteins. In most studies, known canonical motifs recognised by CK1 
isoforms have been show to phosphorylate Ser /Thr residues in vitro and in vivo, 
however, a growing number of alternative, `atypical', motifs are being discovered, for 
example: ß- catenin [300] and see table 1.7 for a summary of all published CK1 
phosphorylation sites. ß- catenin has four acidic residues the `wrong side', at n +7 
downstream from phosphorylatable serine in an SLS motif ([300] and see table 1.7), 
but peptides used in that study mimicking the 3-catenin site are 15 -25 fold less 
efficient that the classical peptides following the pS /pTX1_2S /T consensus motif 
[300]. With this, it is becoming clear that a general consensus motif for CK1 substrate 
recognition may not be possible, making substrate speculation less predictable. The 
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use of tandem mass spectrometry can identify exactly which S/T is phosphorylated on 
the peptide and therefore help to discover if a priming phosphorylation is required. 
The first published report of tyrosine phosphorylation by CK1 was a 
preparation from erythrocytes that could phosphorylate synthetic 
polyglutamine /tyrosine peptides [285]. Subsequent studies showed the yeast CK1 
isoforms: HRR25p, Hhpl and Hhp2 and Xenopus CK 1 a capable of both trans- and 
auto -tyrosine phosphorylation, although again trans -phosphorylation was only on 
synthetic peptide substrates and had lower efficiency [286, 287]. 
Table 1.7 CM substrates and interacting proteins 
Protein Site(s) of phosphorylation* CK1 isoformj Reference 
cytoplasmic' 
Adenomatous polyposis 
coli protein (APC) 
Aminoacyl -tRNA 
synthetases 
Acetyl CoA carboxylase 
ß-Catenin 












Ser /Thr residues identified 
serine phosphorylated 
Stoichiometry suggests two sites 
APS45LSGKGNPEEEDVD - atypical, 
priming for GSK phosphorylation 
of T41, S37, S33 
DEEEDS 137QAEVL - classical¶ 
GRATQS189EPGEE - atypical* 
unidentified in this study 
ser /thr phosphorylated 
PEST1 domain (544 -560) by CK -la only 
PEST2 domain (843 -893) by CK -la and b* 
QAVSEKS513TKFQLS is not 
phosphorylated in vitro, but is in vivo, 
along with 551° and 5519 Possibly hierarchal. 
AADSFS6LNDALS12GSGN - S6 classical, 
S12 minor site 
TLS7VSS10LPGLE, hierarchal 
However NOT found in vivo 
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rat striate [310] 
xCK1, 97% 
similar to CK1E* [306] 
rabbit 
reticulocyte* [307] 





MDCK cells [311] 
rabbit liver* [296, 312] 
rabbit# [293] 
41 
Protein Site(s) of phosphorylationt CK1 isoform$ Reference 
cytoplasmic' 
Guanine- nucleotide- 
exchange factor (GEF) 
Inhibitor -2 (regulatory 
subunit for PP 1) 
Initiation factor 2B, 
eIF2B, (c- catalytic 
subunit) 
Initiation factors 3, 4B, 5 
Insulin receptor 1 
03-subunit) 
Tumour necrosis 
factor a (TNFa) p75 
mRNP particles 
Non -structural protein 
(NSP5) 
p40 tyrosine kinase 
PARKIN 
Period (mPerl) 
Protein kinase C (PKC) 
Ptdlns(4)P 5- kinase 
(PIP2- kinsae) 
Prolactin 













S464 likely major site in vivo 
unidentified in this study 
exclusively serine phosphorylated 
exclusively serine phosphorylated 
unidentified in this study 
RRREDIGPSDSAS67NDPL 





T902 S V S PATFP S PL V T915 P 
unidentified residues, but identical 
peptide pattern as autophosphorylated PKC 
unidentified in this study 
inhibits its activity 
DES161Q potentially, not definitive 
Identify linker region and MH1 domain 
identify predominantly Ser phosphorylated 
unidentified in this study 
KEYKSS43QS45NITTEVYEASS56FEEK, 
SA mutants show S42, 43, 45, 55, 56 are 
Phosphorylated*, within a PEST region. 
DNLTLWTSDT233QGDEA - atypical 
rabbit 
reticulocyte 




























CKi (S. pombe)* 
S. pombe# [328] 
rabbit retie.* [329] 
CK1c, with 
C- terminal A* [330] 
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a -and 13- tubulin 
Beta -site APP cleaving 
enzyme (BACE) 
Calsequestrin (CS) 
Connexin 43 (Cx43) 
prefers Thr to Ser, also co- purifies 
identify Ser /Thr phosphorylated 
EAYEMPS 129EEGYQDY 
TVEGAGS87IAAATG 
major site 5129, minor site on S87 




ANYS3 ) 4AEQNRM 
GQAGS325TIS328NS330HAQ* 
rat liver* [335, 336] 
erythrocyte prep. [337] 
CK18, with 
C- terminal A* 
HEK293, PC124 [338] 
CK18, C -term A* [339] 
COS -7# 
[340, 341] 
rat liver* [342] 
CK18, C -term. A* 
rat kidney cells# [343] 
Cytoskeletal, membrane and sarcoplasmic reticulum - associated proteins, including receptors 
Connexin 49 (Cx49) 
Erythrocyte band 3 
Filamin, vinculin 
Spectrin 
m l -muscarinic receptor 
m3- muscarinic receptor 




molecules (N -CAM) 
Neurochordins 
Polyamine transporter 
Protein (TPO 1) 
Presenelin 1, 2 
Rhodopsin 
Ror2 (receptor - 
tyrosine kinase) 
Smoothened (Smo) 
unidentified in this study 
HDTEAT42ATDYHT - major site 
YMAQS303RGELLH - minor site 
unidentified in this study 
Ser, on -COOH terminal 
unidentified in this study 
14 potential sites, in clusters 
Identify 3rd intracellular loop, 
Ser345- Leu463 
Ser /Thr phosphorylated 
unidentified in this study 
Ser /Thr phosphorylated 
serine phosphorylated 
GEGAKYTT52ATEGNGGA 
yeast, genetic deletion approach 
PEMEEDS327YDS330FGEPSY 
DDEAS334TTVSK 
identify S/T residues 
DLNSSET629NDISS 
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eye tissue, 




h erythrocytes# ¶ [347 -350] 
CK 1 a, from 





muscle* [356, 357] 






CK18, C-term. A* 
HEK293, HeLa# [363, 364] 
CK1y* [355, 365] 
CKl E* 
CK1E in H293# [366] 
dm embryonic 
43 
Cytoskeletal, membrane and sarcoplasmic reticulum - associated proteins, including receptors 
(Dm) 
Tau 
TGFß -Type II 











prior phosphorylation of S39 by PKA, 
CaMKII or GSK -3 can increase 
subsequent phosphorylation" 
predominantly Ser phosphorylated 
unidentified in this study 
GDDEES512ES514D 
S2 cells stably 
expressing HhN# 
CK1S, with 






CKIc, C- termA* [330, 373] 
rabbit skeletal 
muscle* [357] 
CK18, C -term A* 
CHO, HEK293# [374] 
nuclear2 
Cubitus interruptus 

















0° S'°5 S14o after 
phosphorylation of 5117 by PKA, 
PKC, CamK or CDC2 
unidentified in this study 
RPRTSS319NA S322TI S 325GRL 
phosphorylation of S319 by PKB 
needed for phosphorylation of S323, S325 
SEEEQSSSS228VKKDE" 
rat CK1 6, with 






CKIs, C-term A* [377] 
CK1S* 
HEK293, 
ES stem cells# 
CK1a* 
[98, 190] 
VKMES240EGGADDS247AEE (S CK2) [378] 
suggest S288 and 5293, no data shown CK1s, C -term 0* [377] 
SRR -1 region CK16, with 
CK18 and c co- associate C- terminalA* [379] 
`A- domain' phosphorylated, undefined. CK15, with 
`Z- domain' phosphorylated peptide: C- terminal 0* 
CK1a in BHK# [380] FT204LGS207PLT21 °5211 PGGS2I5PGGer 








I and II 
unidentified in this study 
ADSQHS 123TPPKK - hierarchal 
EATADS 120QHSTP - atypical 
QAPQSS67QSVHD - atypical 
MEES4QS6DIS9LE - classical (murine) ¶ 
PPLS 15QES 18FS20D - hierarchal (human) ¶ 
WLDQDS 240V S242DQFS246V EFE 
QDKEESVES383SLPLNAI[check again!] 
RNA Pol II better substrate than RNA 


















Fibrinogen serine phosphorylated rat liver* [390, 391] 
Virally encoded proteins 
respiratory syncytial 




This phosphorylation has no effect on 
transcriptional activity 
Ser identified 
rat CK16, with 
C- terminal A* 
HEp -2 cells# [392] 
Calf thymus [391] 
I Largely cytoplasmic 
2 Able to transit to the nucleus /largely nuclear, but can also be found in the cytoplasm. 
*shown to occur in vitro 
#shown to occur in vivo 
shown to occur both in vitro and in vivo 
1 The phosphorylated serine is underlined, with the type of consensus motif indicated. 
Residues shown to be phosphorylated by PKA /PKC /'priming kinase' are indicated S/T and 
potential /suspected priming residues indicated SIT. 
The CK1 isoform used is indicated. The tissue sources for biochemical purifications of CK1, where 
known, are stated - these studies are predominantly early, purely biochemical work, before molecular 
cloning of CK1, and could thus contain multiple CK1 isoforms. 
The study identified these phospho -peptides by ms /mutation analysis of blocks of potential CK I 
sites only. 
Only two of the underlined residues are shown to be phosphorylated. 
! ! note the SLI, but note the amino acids n +7 downstream 
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1.4.2. Structure 
Crystal structures of CK1 have identified potential binding sites for substrate 
for phosphorylated substrate recognition, and potential autophosphorylation sites 
from the binding of tungstate /sulphate ions, see figure 1.10, from [393, 394]. The 
crystal structure of a truncated CK16 by Longenecker et al [394], using molecular 
replacement of the crystal structure of Ckil from Xu et al [393], identify three 
possible autophosphorylation sites: Y161, T166, S179 also indicated in figure 1.10, in 
orange type. 
These crystal structures are based on truncation mutants of CK16, lacking C- 
terminal residues for solubility reasons [393, 394]. CK16 has the last 97 C- terminal 
amino acids deleted, terminating at H317, with diffraction data accurate only to L298 
[394]. Ckil was deleted to N298, deleting the last 148 amino acids [393]. Whilst 
yielding very useful information on the catalytic nature of CK1, these structures 
exclude residues implicated in further autophosphorylation and subsequent auto - 
inhibition (see figure 1.11) [395, 396]. Limited proteolysis and site - directed 
mutagenesis of CK1 S and s, in mammalian cell lines and in vitro studies have been 
shown to increase the trans -phosphorylation activity of CK1 by ten -fold for CK16 
[395] and eight -fold for CK1c [396]. Indeed, many recombinant enzyme preparations 
used in studies listed in table 1.6 have used a truncated CK16 for in vitro studies - on 
order to have an active kinase. These findings are concordant with the fact that CK1a 
(examined here) lacks a C- terminus similar to CK1S, s and is constitutively active. A 
naturally occurring Ser -*Asn mutation at the autophosphorylation site S408 in the C- 
terminus of CK1 c from patients with sleep disorders has increased kinase activity 
compared to wild type [397]. It has been speculated that dimerisation of CK1 may 
also play a role in CK1 regulation, as crystal structures of CK1 determined by 
Longenecker et al appeared as dimers [398]. However, this may be an artefact of the 
crystalisation procedure. 








Figure 1.10 Crystal Structure of CK1 
Purple residues are possibly involved in phospho -substrate binding, orange residues 
indicate potential autophosphorylation sites; Mgt+ ATP is shown in yellow. 
Sulphate ions are shown in pink, blue indicates phosphorylation site Ser 242 (CKla 
numbering, equivalent to Ser 239 in this crystal structure). Structure rendered using 
PyMol from 1CSN.pdb. 
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1.4.3. Regulation of CK1 
CK1 is largely second messenger independent [284] and there have been few 
examples of the enzymatic activity being directly affected by another entity. For 
example, CK1 has been shown to be inhibited by phosphatidylinositol 4,5- 
bisphosphate (PIP2) in solution [399]. This inhibition is increased with a PIP2:protein 
mixture, suggesting other factors than PIP2 alone is /are involved [399]. The CK1 
homologue, dmCKl, from Drosophila has been shown to be activated and relocated 
from a predominantly cytoplasmic to nuclear location, in response to gamma 
irradiation [400]. The change in kinase activity was most likely due to 
phosphorylation of the C- terminus, as phosphatase treatment re- activated the kinase 
[400], in a mechanism similar to CK1 s and S described above. Other reports of CK1 
levels being elevated include insulin stimulation [401] and viral transformation [402], 
but more detailed investigations into the nature of these effects have not been 
reported. 
As described above, a major way in which CK1 recognises substrates is by 
prior or hierarchal phosphorylation. This can indirectly lead to regulation of CK1, by 
the activation or inhibition of other kinases (that are in turn regulated by their 
respective second messengers). Hierarchal phosphorylation has been shown to occur 
in several proteins, including the Adenomatous polyposis coli protein, the 
transmembrane protein smoothened, transcriptions factors such as FOXO 1 a (formerly 
FKHR), Cubitus interuptus (Ci -55), and p53, (see table 1.7). The result of these 
multiple phosphorylations can have a dramatic effect. For example, in the case of 
FOXOla, phosphorylation of 5319 by PKB creates a consensus for CK1, which 
increases phosphorylation of S322, which creates a consensus for S325. The result of 
this phosphorylation, including S329 (phosphorylated by DYRK1A) leads to the 
subsequent exclusion of FOXO 1 a from the nucleus [98, 190]. Indeed a newly 
discovered inhibitor of CK1, called D4476 (used in this study), has been shown to 
reduce the rate of nuclear exclusion of FOXOI a in HEK293 cells [403]. 


























Figure 1.11 Schematic Representation of mammalian CKT Tsoforms 
The conserved kinase domain is shown in grey, the variable N- and C- terminal 
regions are shown in blue and purple, respectively. Kinesin homology domains are 
show in turquoise and nuclear localisation sequences in green. Additionally, 
phosphorylation sites, where known, are represented with a white circled `P' and 
autophosphorylation sites by yellow filled circles. Regions known to undergo 
autophosphorylation that contain residues that have not been determined specifically 
are indicated by red filled circles, with amino acids either side of phosphorylatable 
residues indicated. References: phosphorylation sites on CKla, this study; CK15, 
Y'61 T'66 
S "9 [394]; CK16 C- terminal phosphorylation [395]; CK1c, [396]. 
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1.4.4. Sequence conservation between CK1 isoforms 
CK1 belongs to a large, evolutionary conserved family of protein kinases. 
Alignment of CK1 isoforms reveals highest conservation in the kinase domain, with 
highly divergent residues found at the N- and C- domains (see [288] for review). It is 
likely the highly divergent residues outwith the kinase domain provide substrate 
specifity for CK1 isoforms. Figure 1.12 shows an alignment of 16 CK1 isoforms from 
6 different organisms, over the region examined in this study (residues 213 -247). This 
reveals a high level of conservation; totally conserved residues are in red, with 
conserved substitutions in yellow. Interestingly (and relevant to the findings in this 
thesis), non -phosphorylatable residues comparable to position 218, in CKIa, are only 
found in two isoforms (in this alignment), whereas non -phosphorylatable residues are 
found in six isoforms at position 242. This difference in potential 14 -3 -3 interaction 
sites may provide a further level of regulation by reducing association with particular 
isoforms. 
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CK1 Gamma 2 (Rat) 
CK1 Gamma 3 (Rat) 
CK1 Gamma 1 (Rat) 
CK1 alpha (Rabbit) 
CK1 Beta (Cow) 
CK1 Delta (Rat) 
CK1 Epsilon (Rat) 
Hrr25 (S. cerevísiae) 
Hhp1 (S. pombe) 
Hhp2 (S. pombe) 
Yck1 (S. cerevisiae) 
Yck2 (S. cerevisiae) 
Cki3 (S. pombe) 
Cki1 (S. pombe) 
Cki2 (S. pombe) 




D ' gIGDTriR 
ERYQ IGDT RATPIE 
' 
YFLRGSLPWQGL D ERYQKIGDT RSTPIE 
YFNRTSLPWQGL .A QKYEKISEK MSTPVE 
YFNRGSLPWQGL AA QKCEKISEM MTTPVD 
YFNLGSLFWQGL AA 'QKYERISE MSTPIE 
YFNLGSLPWQGL A 'QKYERISE MSTPIE 
YFCKGSLPWQGL T QKYDRIME LNVSVET 
YFCRGSLPWQGL T QKYEKIME ISTPTE 
YFCRGSLPWQGLQD QKYQ'IRDT IGTPLE 
YFLRGHLPWQGLKAP QKYE IGE RSTNVYD 
YFLRGQLPWQGL P QKYEKÌGE RLTNVYD 
YFLRGSLPWQGL QKYE IGE Q TPLKE 
YFLRGSLPWQGL AA QKYERIGE QSTPLRE 
YFLRGSLPWQGL A HKYE ISE QSTSISE 
YFLRGSLPWQGZK P , . v , I MT , 
C-FNRTS(P)LPWQGLKA 
Figure 1.12 Sequence alignment around proposed interaction region 
Alignment of higher Eukaryotic CKT isoforms, showing amino acids around the 
proposed binding region - the flexible loop region, as identified by crystal structure. 
The peptide used in this study is shown underneath the aligned sequences. The Cys 
was introduced to allow convenient coupling to agarose heads, via ST-T groups. 
Residues 218 and 242 are indicated with arrows, CK1 a used in this study is 
underlined. 
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1.4.5. Function 
Studies on the saccharomyces cerevisiae CK1 isoforms, Hrr25, Yck1, Yck2 
and Yck3, have revealed a number of common functional themes involving CK1, 
including cytokinesis, membrane trafficking, cell division and DNA repair [288]. All 
isoforms apart from Hrr25 have an isoprenylation sequence that locates the kinase to 
the membrane. The function of mammalian isoforms is less clear, but recent work has 
identified some common themes. For instance, the mammalian CK16 and E isoforms 
are involved in the regulation of apoptosis through phosphorylation of key 
components of this process. The human p53 tumour suppressor is phosphorylated on 
multiple residues in both the N- and C- terminal domains (reviewed in [404- 408]). At 
the N- terminus of p53, CK1S /E phosphorylates S9 and S18 - after prior 
phosphorylation of S6 and S15 respectively. ATM kinase (ataxia telangiectasia 
mutated) has been shown to phosphorylate S15 [409] in response to DNA damage by 
the radiomimetic drug neocarzinostatin. S15 is also phosphorylated by ATR (ataxia - 
telangiectasia- and Rad3- related) in response to UV radiation [410]. Phosphorylation 
of S18 and /or S20 is thought to disrupt binding to MDM2, thereby potentially reducing 
the destruction/inhibition of p53 [405]. Interestingly, ionising radiation of MCF -7 
breast carcinoma cells promoted dephosphorylation of S376 (of p53), creating a 14 -3 -3 
consensus around S378, inducing 14 -3 -3 association and increasing p53 affinity 
toward DNA [21]. The level of complexity increased recently with the report that 
CK16 can phosphorylate key sites on MDM2 (S240, S242, S246, and S383) both in vitro 
and in vivo, that regulate p53 turnover [388]. 
CK1 can also phosphorylate inhibitors of PP1 - DARPP-32 (dopamine- and 
cAMP -regulated phosphoprotein of 32 kDa) and the regulatory subunit of PP 1 c, 
inhibitor -2, see table 1.7. Whilst phosphorylation of inhibitor -2 by CK1 increases its 
potency as an inhibitor of the phosphatase [315], phosphorylation of DARPP -32 does 
not [310]. Phosphorylation of DARPP -32 on S137 protects dephosphorylation of T34 
(phosphorylated by PKA/PKG) by calcineurin (PP2B), thus leaving DARPP -32 an 
efficient inhibitor of PPl [411]. DARPP -32 phosphorylated by CK1 is 
dephosphorylated efficiently by PP2Ac and PP2C, but not by PP 1 c or calcineurin, 
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leading to a proposed `phosphatase cascade' to re- activate PP1c after PKA- induced 
inhibition [412]. 
1.4.6. Localisation 
A focus of study in CK1 biology has been its location within the cell at 
various points of the cell cycle. CKIa has been shown to associate with cytosolic 
vesicular structures and the nucleus /centrosome throughout interphase, then associate 
with the spindle apparatus /kinetochore fibres during mitosis [413]. It is worth noting 
that CK1 has a kinesin homology domain, conserved throughout all known CK1 
isoforms (highlighted in figure 1.10). The kinesin motor proteins are associated with 
microtubules and are involved in cytokinesis; roles where CK1 has been impicated 
[288]. To further implicate CK1 in cell -cycle control, antibodies to CKIa injected 
into mouse oocytes, prevented progression to the first cleavage [414]. It follows that 
spatial organisation of CK1 would be an essential part of regulation, as alluded to by 
Gross and Anderson [288]. Concomitant with this idea, CK1 has recently been 
identified by yeast two- hybrid screen, using ` kinase dead' CK16 as bait, to interact 
with CG- NAP /AKAP450 [415] (also now known as AKAP350 [416]) in mammalian 
cells [415]. This is particularly interesting as CG- NAP /AKAP450 primarily localises 
to the centrosome [417, 418] and also has an established role of recruiting signalling 
molecules to the centrosome. This finding may explain why CK16 and s have been 
found localised to centrosomes in the past [339]. CK1 has also been found in 
membrane preparations [399]. 
CK1 can associate with a number of proteins, although this does not always 
seem to affect the kinase activity [419, 420]. Work in our laboratory has identified a 
number of brain proteins that associated with CKIa by affinity chromatography and 
co- immunoprecipitation [421]. These include RCC 1, High mobility group proteins 1 
and 2 (HMGland HMG2), Erf, Centaurin a -1, synaptotagmin IX and CPI -17 [421]. 
We have further characterised the interaction of centaurin -a and CPI -17 [419, 422]. 
Centaurin -a was shown to associate with a loop region within the kinase domain of 
CK1, using a peptide corresponding to the residues 214 -226 [419], a region proposed 
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to function as an interaction site [393], and conserved across all CK1 isoforms. 
However centaurin -a was not a CK1 substrate and had no effect on CK1 activity 
[419]. CK1 a has recently been reported to associate with the scaffold protein axin and 
like centaurin -a, binding did not reduce kinase activity [420]. 
A new binding motif for CK1 has recently been identified in the transcription 
factor NF -AT1 as FSILF [379]. The authors report that proteins from the Wnt, 
Hedgehog, and circadian -rhythm pathways contain the general motif FXXXF, that 
could be identified as a CK1 binding motif [379]. 
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1.4.7. Centaurin-a1 
Centaurin -a1 is a soluble 46 kDa phosphatidylinositol- (3,4,5) -inositol (PIPS) 
and inositol (1,3,4,5) tetrakisphosphate (IP4) binding protein that was originally 
identified in a screen of brain proteins using an IP4 analog immobilised on a resin 
support [423]. Also known as p421P4, centaurin -a1 was identified in our laboratory in 
a complex with CK1 purified from porcine brain [419]. Centaurin -a1 contains a zinc 
finger domain and two plecstrin homology (PH) domains that have been shown to 
bind PIPS and are required for targeting of centaurin to the membrane on PI3K 
stimulation [424, 425]. Centaurin -a1 is ubiquitously expressed, with highest 
expression levels in the brain [423]. Association of centaurin -a1 has been observed 
with vesicular presynaptic structures [426] and cell membranes [419]. Our laboratory 
further identified that CKIa and CK1c can associate with centaurin -a1 [419]. The 
interaction between centaurin -a1 and CK1 was further examined and is discussed in 
chapter 4. 
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1.5. AIMS 
The aim of this study was to investigate two 14 -3 -3 kinases, BCR and CK1. 
BCR has been shown to both associate with and phosphorylate certain 14 -3 -3 
isoforms, but the phosphorylation sites were undetermined. To understand the 
physiological significance of the phosphorylation site(s) on 14 -3 -3, in vitro kinase 
assays were performed using all 14 -3 -3 isoforms as substrate, followed by Ser -Ala 
mutants of 14 -3 -3. This approach identified residue 233 as the site of phosphorylation 
on 14 -3 -3 t and Ç. In vitro and in vivo binding experiments revealed that BCR can 
interact with all 14 -3 -3 isoforms, but to varying degrees. 
Our laboratory has shown that CK1 a phosphorylates 14 -3 -3 ( in vitro and in 
vivo. However the interaction of the two had not been fully addressed. Regulation of 
CK1 activity is largely ill defined; primarily regulation is through being `phosphate 
directed', or location dependent. 14 -3 -3 has been shown to modulate many enzymes, 
both by direct inhibition/activation and spatial directing. Therefore experiments were 
designed to investigate if CK1 could bind 14 -3 -3 and if so, identify any isoform 
specificity. An established site of interaction on CK1 for other proteins was 
confiinied as the site of interaction for 14 -3 -3, although crucially binding was 
dependent on phosphorylation. Phosphorylation sites on CK1 essential for 14 -3 -3 
association in vivo were identified by mutagenesis as S218 and S242. 
Dephosphorylation of S218 negatively affected interaction with 14 -3 -3, but increased 
association with Centaurin -al. 
These findings open up a possible regulatory mechanism for regulation of 
CK1 involving 14 -3 -3. 
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CHAPTER 2 
Materials and methods 
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2. Materials and methods 
Throughout the following section, the manufacturer of all chemicals, reagents and 
services are given in parenthesis. Where no mention is made, the reagent was from 
Sigma -Aldrich. All reagents were of analytical grade. 
2.1. Molecular biology 
2.1.1. Agarose gel electrophoresis of DNA 
Agarose gels of 1% were routinely used, dissolved in a 1 x solution of TAE buffer 
containing 40mM Tris -HC1, pH8.0, 20mM Acetic acid, and 1mM EDTA. The DNA was 
prepared using a 6x loading dye (detailed in table 2.8) to a final concentration of lx, then 
subjected to 50V DC until separated. To visualise the DNA, Ethidium bromide (EtBr) 
was included in both the gel and the buffer at a concentration of 0.5µg /ml, followed by 
transillumination using ultraviolet light. Interchelation of the DNA fragments with EtBr 
compared to standards run in parallel revealed the approximate sizes. Markers used were 
from Roche - VII for large fragments (BCR) and Roche XIV for smaller fragments, see 
appendix for an example of the sizes produced. 
2.1.2. Production of competent Eschericia coli. 
All DNA manipulations were carried out in Escherichia coli strain JM 109 or DH5a. 
JM109 cells were made competent by modification of the Hanahan method [427] and 
DH5a by modification of the method by Inoue et al [428]. The Hanahan method involves 
growing a 100m1 culture of JM 109 in antibiotic free media to an OD600 of 0.5. After 
centrifugation at 4,000g, 5min, 4 °C, the cell were re- suspended in 30m1 sterile 100mM 
RbC1, 50mM MnC12, 30mM Potassium acetate, 10mM CaC12, 15% glycerol, pH 5.8 and 
kept at 4 °C for 90 min. After further centrifugation at 4,000g, 5 min, 4 °C, the cells were 
re- suspended in 4ml of sterile, ice cold 10mM MOPS, 10mM RbC1, 75mM CaC12, 15% 
glycerol, pH 6.8, snap frozen and stored at -70 °C in 200µ1 aliquots. Briefly, DH5a cells 
were streaked onto LB -agar plates (no antibiotic) and incubated at 37 °C overnight. Ten 
colonies were introduced into 250m1 of SOB medium in a 2 litre flask and grown at 18 °C 
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until the absorbance at 600nm reached 0.6.The flask was cooled by incubation on ice for 
10 min, then centrifuged at 5000g for 10 min. The supernatant was removed and the 
pellet re- suspended in 80m1 of transformation buffer see table 2.8. The cell suspension 
was centrifuged as before and re- suspended in 20m1 of TB with DMSO at 7% final 
concentration. After further 10min incubation in an ice bath, the cells were dispensed into 
250111 aliquots and snap frozen in liquid nitrogen. 
2.1.3. Preparation of plasmid DNA 
Plasmid DNA from transformed E. coli cultures was either ethanol precipitated or 
purified using the QIAGEN DNA purification system. 
2.1.3.1. Small scale, `Mini- preps' of plasmid DNA 
Small scale preparations of DNA were used at various sub -cloning stages. Briefly 
5ml of overnight culture (with selective antibiotic) was spun down and the pellet re- 
dissolved in 250µ1 buffer P 1. Then addition of 2500 of an alkaline solution, P2, in order 
to lyse the cells was added for 5 min, with gentle mixing. This was neutralised with 
buffer 350µ1 N3 buffer. The cell debris, now a white precipitate was removed by 
centrifugation and the DNA recovered by binding to the QlAprep membrane. DNA was 
eluted into 50111 water or TE (10mM Tris -HC1, pH 8.5). 
2.1.3.2. Large scale, `Maxi- preps' of Plasmid DNA 
The Quiagen kit for purifying larger amounts of DNA was used to recover amounts 
of DNA necessary for transfection. The manufacturer's instructions were followed and 
briefly outlined here. Overnight cultures (200m1) of E. coli culture LB were centrifuges 
and the pellet resuspended in 10m1 buffer P 1. Buffer P2 (10m1) was then added to lyse 
the cells. After 5 min, 10 ml of neutralizing buffer N3 was added and left to stand for 10 
min at room temp. The lysate was clarified by using the Quiagen filter, the flow through 
was then passed through the Quiagen resin column, eluted and precipitated isopropanol. 
The DNA was washed with 70% ethanol, air -dried and dissolved in nuclease free water 
or TE (10mM Tris -HC1, pH 8.5). 
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2.2. DNA Manipulation 
2.2.1. Prokaryotic vector manipulations - 14 -3 -3 
The cDNAs for all 14 -3 -3 isoforms were from various sources. All isoforms were 
produced as GST fusions with the exception of 14 -3 -3 s that was produced as an MBP 
fusion. 
2.2.1.1. 14 -3 -3 3 isoform cloning 
14 -3 -3 ß, is an IMAGE clone (4843961/gí14060448), and was subcloned from the 
supplied vector (pOTB7) by PCR with two oligonulcleotides: 5' 
GATCGAATTCATGACAATGGATAAAAGTGAGCTGGTA and 3' 
GATCGTCGACTTAGTTCTCTCCCTCCCCAG, creating an EcoR1 and a Sall 
restriction site respectively (underlined). The PCR reaction was set up as in the following 
table: 
2.2.1.2. Polymerase chain reaction 
Table 2.1 nolvmerase chain reaciton 
Plasmid DNA 25, 50, 751,tg 
Primer 1 with a EcoR1 site (40pmol) 
Primer 2 with a Sall site (40pmol) 
DNA Polymerase buffer (10X) 
dNTPs (each at l OmM) 
nuclease free water 
Pfu DNA Polymerase (1U) 





39.5, 39, 38.511l 
10 
total 5Oµ1 
The program that yielded one product of high purity was 1 cycle of 95 °C, 2 min; 30 
cycles of 95 °C for 30 sec, 66 °C for 45 sec, 72 °C for 10 min; final cycle of 72 °C for 10 
min. 
2.2.1.3. Restriction enzyme digestion 
The PCR product was inserted into pGEX -4T1 (Amersham), by ligating under the 
following conditions: 10 vector, to 30 insert and a second reaction of 1µl vector and 60 
insert, 10 (1U) of DNA ligase, 10 10x DNA ligase buffer (see table 2.8) and nuclease 
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free water to 10µl. The reaction was left overnight at 20 °C. This created an N- terminal 
GST fusion protein with a thrombin cleavage site between the GST moiety and 14 -3 -3. 
2.2.1.4. 14 -3 -3 cs cloning 
14 -3 -3 6 was a gift from Henrik Leffers, provided in the vector pGPT -delta 6. The 
insert was produced as a PCR fragment using the oligonucleotides 5' 
GATCGAATTCATGGAGAGAGCCAGTCTGATC and 3' 
GATCGTCGACTCAGCTCTGGGGCTCCT creating an EcoR1 site and Sall site 
respectively (underlined). Essentially the same PCR reaction was used as for 14 -3 -3 13. 
The PCR product was digested with EcoR1 and Sall, cleaned up and ligated into cut 
pGEX -4T1 vector, creating an N- terminal GST fusion. 
2.2.1.5. 14 -3 -3 ri, y and T cloning 
14 -3 -3 ri and 14 -3 -3 y were a gift from Henrik Leffers. The 14 -3 -3 rl and 14 -3 -3 y 
clones were provided as N- terminal GST- fusions in the vector pGEX -2T (Amersham). 
14 -3 -3 Ç was from a human T -cell cDNA library and has been produced as an N- terminal 
GST fusion in the pGEX -2T vector [172, 429]. 14 -3 -3 c was produced as an N- terminal 
MBP fusion, from a rat cDNA (accession m84416) [10]. 14 -3 -3 T was from a human 
source and was produced as an N- terminal GST fusion. All cDNAs were checked by 
sequencing both strands by Cytomyx, Cambridge, UK or in house on an Applied 
Biosystems 3730 DNA analyser running Big Dye v3.1 and analysed using the programs 
ChromasProTM and GeneJockeyTM 
2.2.2. Eukaryotic vector manipulations 
2.2.2.1. Breakpoint Cluster Region (BCR) cloning 
A vector containing the bcr sequence was a kind gift from Owen Witte. To create a 
GST- fusion of BCR, the coding sequence for bcr was amplified by polymerase chain 
reaction (PCR) using two oligionucleotides 5' 
GATCGCGGCCGCGCGCCATGGTGGACCCGGTGGGCTT and 3' 
GATCGAATTCGACTTCGGTGGAGAACAGGATGCTCTGTCT creating the 
restriction sites Notl and EcoR1 respectively and underlined, ligated into the pEBG -2T 
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GST vector for mammalian expression (kind gift from Dario Allesi, School of life 
sciences, University of Dundee) creating an N- terminally fused bcr construct. A C- 
terminally FLAG tagged fusion of ber was created with two oligionucleotides: 
(5' GATCGAATTCATGGTGGACCCGGTGGGCTTCG and 3' 
GATCGCGGCCGCTTAGACTTCGGTGGAGAACAGGATGCTCTGTCT) were used 
to produce ber cDNA, containing the restriction sites EcoR1 and Notl for ligation into the 
pCMV -4A vector (Stratagene), producing a C- terminal fusion with the FLAG tag. 
2.2.2.2. Casein Kinase 1 (CK1) cloning 
The cDNA corresponding to casein kinase la from rabbit skeletal muscle (from Peter 
Roach) was cloned into pcDNA 3, using oligonucleotides to create an N- terminal HA tag 
was created by Thierry Dubois [430]. Site -directed mutagenesis of this clone was used to 
create ser -ala mutations within possible 14 -3 -3 binding sites. 
2.2.3. 
2.2.4. Site -directed mutagenesis of CK1 a 
To obtain point mutations of CK1 a to observe binding requirements to 14 -3 -3, slight 
modification of the QuickchangeTM site directed mutagenesis protocol (Stratagene) was 
used. The sense primer used for the S218A mutant was 5' GA TAT GTT TTG ATG TAT 
TTT AAT AGA ACC AGC CTG CCG TGG CAA GGA CTA AAG GCT GCA ACA 3' 
and the antisense primer used was 5' GA TAT GTT TTG ATG TAT TTT AAT AGA 
ACC GCC CTG CCA TGG CAA GGA CTA AAG GCT GCA ACA 3' this created a 
unique, translationaly silent restriction site: Ncol, italic, bold. The changed residues are 
underlined. The template used for this was an HA -CKIa in pcDNA3 plasmid. The ultra 
high fidelity enzyme PfuUltraTM was used (in place of the standard polymerase) for the 
PCR creation of mutant template. 
2.2.4.1. Polymerase chain reaction 
1µ1 pcDNA3 -HA -CKIa plasmid (2, 5, andlOng), 50 10x Pfu Ultra high fidelity 
reaction buffer, 1111 dNTPs (25mM each dNTP), 1.5µ1 sense primer, 1.50 anti -sense 
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primer, 38.6111 water, 1111 Pfu Ultra high fidelity DNA polymerase to a total volume of 
50µ1 were added together in that order. 
Temperature cycling for the PCR consisted of denaturation at 95 °C for 2 min, 
annealing temperature of 68 °C for 30sec, extension temperature of 72 °C for 13min 
(2min /Kb) for 1 cycle, followed by 30 cycles of 95 °C for 30sec, 68 °C for 45sec and 72 °C 
for 13min, with a final 10min of 72 °C. The PCR product was treated with Dpnl, an 
enzyme that digests specifically methylated and hemimethylated DNA [431], in this case 
the parental DNA. The product was checked by agarose gel electrophoresis, before being 
transformed into XL -blue supercompetent cells (Stratagene). Mini -preps of at least 8 
individual colonies were prepared and treated with Ncol to screen for DNAs containing 
the new and unique restriction site. 
The same procedure was used for creation of a S242A mutant and S218A/S242A 
double mutant of CK I a , using the following primers: sense primer 5' ATA CGA AAG 
ATT AGC GAA AAG AAG ATG GCC ACT CCT GTT GAA GTT TTA T and 
antisense primer: 5'CCT TAC ATA AAA CTT CAA CAC GAG TGG CCA TCT TCT 
TTT CGC TAA TCT TCT CGT AT 3'. The underlined base indicates the mutated base. 
For the S242A mutant, the pcDNA3 -CKl a w/t plasmid was used, for the double mutant, 
the pcDNA3 -CKla S218A plasmid was used. Again, all cDNAs were checked by 
sequencing both strands in house or by Cytomyx, Cambridge, UK. 
2.2.4.2. Site Directed Mutagenesis of 14 -3 -3 
The 14 -3 -3 ( -myc mutants S233A, S233D and 14 -3 -3 i mutant T233A were created 
in pcDNA3 vectors by Thierry Dubois using site directed mutagenesis [172] and 
unpublished. 
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BIOCHEMICAL TECHNIQUES 
2.3. Protein assay 
Protein concentration was routinely measured using the Bradford method 
[432]. A concentrated dye (Bio -Rad) was diluted 1:4 with water, to give a lx 
solution. Samples were made up to 50µ1 with water and then 4 volumes (200µ1) lx 
dye was added and allowed to incubate for 5 min at room temperature. The 
absorbance was measured at 595 nm and compared to a standard curve assay, 
constructed with known amounts of BSA. 
2.4. Sodium -dodecyl sulphate polyacrylamide electrophoresis (SDS - 
PAGE) 
Table 2.2 Buffers and solutions for SDS -PAGE 





29:1 acrylamide :N,N'- ethylenebisacrylamide* 




Resolving gel 8 -18% (w /v) 29:1 acrylamide :N,N'- ethylenebisacrylamide 
(8 -18 %) 0.375M Tris -Hcl (pH8.8) 
0.1% SDS 
0.1% Ammonium persulphate 
0.1% TEMED 
Tri -glycine running 0.2M Glycine 
buffer 25mM Tris 
0.1% (w /v) SDS 
3x SDS loading 0.15M Tris -Hcl (pH6.8) 
buffer 30% Glycerol 
(Laemmli buffer) 9% SDS 
15% ß- mercaptoethanol 
0.007% Bromophenol blue 
Coomassie blue stain 10% (v /v) Glacial acetic acid 
50% (v /v) Methanol 
0.2% (w /v) Coomasie brilliant blue (G250/R250) 
Destain 10% (v /v) Glacial acetic acid 
30% (v /v) Methanol 
*referred to as acrylamide in text 
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Proteins were routinely separated by size under denaturing conditions by 
polyacrylamide gel electrophoresis, using Tris -glycine gels of varying density of 
acrylamide, according to the method of Laemmli [433]. Samples were made to lx final 
concentration in Laemmli buffer, boiled briefly before storage and /or separation. Samples 
were applied to a two -phase SDS -PAGE gel consisting of the stacking gel (5% 
acrylamide, pH 6.8), followed by the resolving gel (8 -18% acrylamide and pH 8.8). A 
vertical slab -gel apparatus from Sigma was used, with the cathode at the top, and anode 
bottom. For the first, stacking gel phase, a voltage of 100V was applied (typically 20 
min), followed by an increase to 150V, variable current for the resolving gel. An 8% gel 
was used for large proteins, e.g. BCR (160kDa), 10% for 60- 100kDa, 12.5% for 30- 
60kDa (14 -3 -3), 15% for 10 -30kDa and 18% for small peptides (gel recipe from 
Sambrook [434]). Generally pre- stained protein markers from New England Biolabs were 
used, with a range of 6.5kDa to 175kDa. Separated proteins were visualised with either 
staining by coomassie /GelCode® or transferred to nitrocellulose membrane for analysis 
by western blotting. 
2.4.1. 
2.4.2. Western blotting 
Table 2.3 Transfer buffer 
TBS -Tween 20mM Tris -HC1, pH 7.6 
(TBS -T) 137mM NaCl 
0.1% Tween -20 




After separation by SDS -PAGE, proteins were transferred from the gel to 
nitrocellulose membranes in the presence of transfer buffer at constant current of 0.2A for 
90 min. The membranes were routinely blocked using 5% skimmed milk solution made 
up using TBS -Tween for 1 h shaking at room temperature. This was followed by 
incubation with the primary antibody for 1 -2 hours at room temperature, or 4 °C 
overnight, in 5% milk solution. After four 10 min washes in TBS -Tween the membrane 
was incubated with secondary antibody conjugated to horse radish peroxidase in 5% milk 
solution for 1 hour with shaking. After a final wash regime of four to six washes, the 
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membrane was incubated with the enhanced chemiluminescence (ECL) system 
(Amersham Pharmacia, UK) for five minutes. Immediately after this incubation, the 
membrane was dried and exposed to autoradiographic film (Kodak) for various time 
intervals from 10 sec to 60 min. For the use of phospho -specific antibodies, the above 
procedure was repeated exactly as above, except a 1% BSA in TBS -Tween solution was 
used to reduce cross -reaction with phospho casein present in milk. 
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Table 2.4 Antibodies used for western blotting and immunoprecipitations 



















14 -3 -3ß 2042 Ac- TMDKSELVC AA/HM rabbit poly 1:3000 
14 -3 -3y 1005 Ac- VDREQLVQKAC AA/HM rabbit poly 1:6000 
14 -3 -3e C -term 1116 CGEEQNKEALQDVEDENQ AA/HM rabbit poly I :3000 
14 -3 -3 1002 Ac- MDKNELVQKAC AA/HM rabbit poly 1:3000 
14 -3 -3i 2043 Ac- GDREQLLQRARC AA/HM rabbit poly 1:3000 
14 -3 -3e 789 Ac- MERSASLIQKAC AA/HM rabbit poly 1:3000 
14 -3 -32 197 Ac- MEKTELIQKAC AA /HM rabbit poly 1:3000 
14 -3 -3 PAN 1106 Whole protein, KCIP AA/HM rabbit poly 1:3000 
14 -3 -3 S233" T233L CTLWTSDTPQGDEAEAG AA /SC sheep poly 1:500 
14 -3 -3 S185P SPEKA EILNSPPEKAC AA /SC sheep poly 1:250 






c- terminus Santa 
Cruz 





n- terminus Santa 
Cruz 
goat poly 1:250 
CKIy CKIy c- terminus Santa goat poly 1:250 
(R -19) Cruz 
CK16 CKI6 c- terminus Santa goat Poly 1:250 
(R -19) Cruz 
HA- tagged 
protein 
HA -7 YPYDVPDYA Sigma mouse mono 1:2000 
Myc- tagged 
prtoein 
9E10 EQKLISEDL Sigma Mouse mono 1:1000 
FLAG -tagged 
protein 
M2 DYKDDDK Sigma Mouse mono 1:1000 
GST Anti- whole protein Sigma rabbit poly 1:1000 
GST 
Rabbit IgG Anti 
rabbit 
rabbit whole molecule IgG Bio -Rad goat poly 1:2000 
Mouse IgG Anti 
mouse 
mouse whole molecule IgG Chemicon goat poly 1:2000 
Goat IgG Anti 
goat 
goat whole molecule IgG Sigma donkey poly 1:2000 
Sheep IgG Anti 
sheep 
sheep whole molecule IgG Sigma donkey poly 1:2000 
Rat IgG Anti rat rat whole molecule IgG Amer- 
sham 
goat poly 1:1000 
Pharmacia 
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2.5. Generation of antiserum to phospho- 14 -3 -3 S185. 
2.5.1. Peptide coupling and Immunisation of the sheep 
Approximately lmg of the peptide EILNpS185PEKAC (for ` pSPEKA' antibody) was 
coupled to maleimide- activated Keyhole Limpet Hämocyanine (KLH) according to the 
manufacturers instructions (Pierce, Rockford, IL, USA) using the cysteine introduced at 
the C- terminus for this purpose. The coupled peptide was injected subcutaneously with 
Freund's complete adjuvant (FCA), an emulsion containing mycobacteria that generally 
produces a strong immunogenic response. Three subsequent booster injections were 
performed, approximately every month, using half as much KLH conjugated peptide and 
incomplete FCA, lacking mycobacteria. One litre of blood yielded 200 -400 ml serum and 
was stored at -20 °C until further use. The animal(s) were not exsanguinated after the 
immunisation procedure. Immunisation and serum recovery were performed according to 
Diagnostics Scotland's standard procedures. 
2.5.2. Peptide affinity purification of anti -phospho- 14 -3 -3 
2.5.2.1. Immobilising the peptide 
Table 2.5 binding buffer 
Binding buffer 50mM Tris -HC1 pH7.5 
5mM EDTA 
Blocking buffer 50mM Tris -HC1 pH7.5 
50mM Cysteine 
5mM EDTA 
The peptides to be used for purification of the antibody were immobilized using the 
Pierce Sulfolink® gel, essentially as according to the manufactures instructions. Briefly, 
one milligram each of the peptides used for the immunisation of the sheep, SPEKA and 
pSPEKA were dissolved at a concentration of lmg /ml in binding buffer and incubated 
with 1 ml (bed volume) of Sulfolink® coupling gel (Pierce, Rockford, IL) for 30 min, 
rotating at room temperature, followed by a further 15 min incubation at room 
temperature. After washing with binding buffer, the beads were blocked with a 50mM 
Cysteine solution for 30 min, rotating at room temperature. After extensive washing to 
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remove Cysteine, the columns were stored in binding buffer with the inclusion of 0.05% 
sodium azide. 
2.5.2.2. Binding and eluting the Antibody 
The serum was clarified by ultracentrifugation at 40,000 RPM (125,000g) in a 
Beckman Type 45Tí centrifuge at 4 °C for one hour and then filtered through a 0.45µm 
low protein binding (PVDF) membrane filter (Millipore, Bedford, MA). The supernatant 
was diluted ten times in binding buffer and then passed four times through the column 
containing bound unphosphorylated SPEKA peptide, at 4 °C, using gravity flow. The 
serum was then passed four times through the phosphorylated pSPEKA peptide column, 
again at 4 °C. Each column was washed with 20 column volumes of binding buffer, 
followed with elution using 10 ml of 200mM acetic acid. Each 1 ml fraction was eluted 
directly into 220µ1 of 1.5M Tris pH-10 to neutralise the solution, the pH was checked 
using pH indicator strips (BDH, UK) and corrected to pH 8, if not already and stored at 
4 °C. 
2.5.2.3. Testing the Antibody 
Serial dilutions of the dissolved SPEKA/pSPEKA peptides were spotted onto 
nitrocellulose membrane and blocked in 1% bovine serum albumin (BSA) in TBS -T for 
30 min, followed by three 5 min washes in TBS -T. The first three fractions were tested 
by incubating with blocked membrane containing either phospho- or unphospho- peptide 
to observe the specificity. Pre -incubations with either the dephospho- or unphospho- 
peptide were also performed by incubating approximately 2µg antibody, measured by 
Bradford, with 1µg peptide -a molar concentration several fold higher of peptide to 
antibody was used. To observe how the antibodies behaved with whole proteins, brain 
extracts (containing approx 50% phosphorylated 14 -3 -3) were subjected to SDS -PAGE 
alongside recombinant 14 -3 -3 ß and The gel was transferred to nitrocellulose 
membrane and cut into strips for testing each fraction. The best fractions were pooled and 
dialysed overnight at 4 °C in the following buffer: 20mM Tris -HCI (pH7.5), 150mM 
NaCl, 100µg /ml BSA (Added after autoclaving), 50% Glycerol (added after dialysis) and 
0.05% NaN3. 
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2.6. Purification of antibody to S233 site on 14 -3 -3 4 
Essentially the same protocol as outlined above was used, with the following 
exceptions. First, two peptides were synthesised corresponding to the S233 region of 14- 
3-3 ç; one with an N- terminal cysteine: CWTSDpT233QGDE and another with a C- 
terminal cysteine: WTSDpT233QGDEC. Each peptide was coupled to KLH, BSA or MAP 
(multiple antigenic peptides) matrix (Pierce) for injection at differing stages. Peptides 
coupled to KLH were introduced into the animal first, with subsequent injections coupled 
with BSA and /or MAP. The reason for this was to try to reduce the immunogenic 
response to the carrier (KLH, BSA, MAP) whilst maintaining the response to the peptide. 
However, testing of serum showed a very poor immunogenic response (data not shown). 
Subsequently, a longer peptide consisting of CTLWTSDpT233QGDEAEAG was used as 
an immunogen, in the hope of getting a stronger antigenic response. Two approaches 
were used to purify the antibody -one peptide column using an N- terminal cysteine 
CWTSDpT233QGDE and another with a C- terminal cysteine (WTSDpT233QGDEC). The 
serum was passed through columns containing these immobilised peptides, washed, 
eluted and tested as for the phospho -S 185 antibody. 
2.7. Cell culture 
COS -1 and HEK293 cells were routinely cultured in Dulbecos's modified Eagle's 
medium (DMEM, Invitrogen) supplemented with 10% Foetal bovine serum (Invitrogen) 
penicillin, streptomycin and L- glutamine at 1U /ml, 1µg /ml and 0.292mg /ml respectively, 
at 5% CO2 and 37 °C in a humidified incubator. 
2.7.1. HEK293 cells, COS -1, COS -7 cells 
On reaching 90 -100% confluence, the cells were trypsinized with 2m1 trypsin per 
175cm2 flask and split 1/5 for maintenance or plated out at varying densities for further 
treatment, for example transfection. Cell viability was routinely checked by using the 
trypan Blue exclusion test, whereby 2mls of an approximately 1 x 106 cells /ml suspension 
were incubated with 0.1m1 of 0.4% trypan blue stain for 5 minutes at room temperature. 
Exclusion of the dye was observed in a haemocytometer for counting viable cells. 
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2.7.2. Transfection of cells using electroporation 
Cells were grown in flasks until confluent, trypsinized and collected by 
centrifugation. After washing in DMEM, the cells were re- suspended in 10 mis of HeBS 
buffer (20mM HEPES pH 7.05, 137mM NaCI, 5mM KC1, 0.7mM Na2HPO4, 6mM D( +) 
glucose, filter sterilised) and counted in a haemocytometer. Approximately 2x106 cells in 
250µ1 HeBs with 5 -10µg DNA and 50µg herring sperm carrier DNA were added to an 
electroporation cuvette and electroporated using a BIO -RAD gene pulser set at 0.25V and 
125µF. After a recovery period of 10 minutes, 1 ml of DMEM was added to the cells 
before being incubated for 24 hours in DMEM with FBS at 37 °C, 5% CO2. 
2.7.3. Transfection of cells using Lipids 
A number of lipid:DNA complex forming reagents are available for transient 
transfections. Here Lipofectamine (Invitrogen), Metafectene (Cambio) and FuGene 
(Roche) reagents were trialled for transfection efficiency. Manufacturers instructions 
were generally followed, with plating of 2 -3x106 cells per 100mm plate were plated out 
24 hours before transfection, using antibiotic -free media and left until 80 -90% confluent. 
Ratios of DNA:lipid mix were -1:3, for example transfection using Lipofectamine 2000 
was achieved by mixing 8µg DNA with 24111 reagent in serum -free DMEM to allow 
DNA:lipid complexes to form. After 20 -30 minutes, this mixture was then added to the 
plates and left to incubate for 24 hours at 5% CO2, 37 °C. 
2.7.4. Transfection of cells by calcium phosphate precipitation 
A modified calcium phosphate precipitation method of was used to transiently 
transfect HEK 293 cells. All solutions were prepared in distilled water and sterile filtered 
through a 0.22µm pore syringe filters. Confluent cells were trypsinized as described 
above and 2-3x106 cells per 100mm plate were plated out 24 hours before transfection, 
using antibiotic -free media and left until 60 -90% confluent. For each 10 cm- diameter 
plate to be transfected, 10µg of DNA was made up to 0.45 ml with sterile distilled water 
in a sterile tube. In co- transfection experiments, each plasmid was added to the same 
tube. To this, 5011l of 2.5 M CaC12 -2H20 was added and the solution mixed by vortexing 
for 15 sec. 0.5 ml of transfection Buffer (50 mM HEPES-HC1 pH 6.96 (pH is critical in 
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this buffer), 280mM NaC1 and 1.5 mM Na2HPO4) was added and mixed thoroughly by 
vortexing for 60 sec. The resulting solution was left for 30 min at room temp to induce 
the precipitation of DNA /CaC12 complexes before pipetting the suspension drop -wise to 
the plate of cells. The cells were then incubated in a 37 °C, 2.5% CO2 incubator. After 16 
hr post -transfection, the media was replaced with fresh media and cells incubated at 37 °C 
in 5% CO2 for a further 8 -24 hours. 
2.7.5. 
2.7.6. Stimulation of 293 cells with dbcAMP 
24 hours after transfection, cells were serum starved by incubating in only DMEM for 
16 hours before application of dbcAMP. A stock solution of 100mM dbcAMP in sterile 
water was prepared immediately before the experiment. 40µ1 was added to 4mls DMEM 
for differing times; a timetable was constructed to ensure stimulation times were exact. 
For control experiment, 20µM PKAi -Myr peptide was incubated with the cells for 30 
minutes before dbcAMP addition. 
2.7.7. Lysis of mammalian cells 
Plates were washed twice with ice cold PBS and lysed on ice with 1ml of ice cold 
standard lysis buffer using a cell scraper. Standard lysis buffer contained 25mM Tris pH 
7.5, 137mM NaC1, .01% NP -40, 10% glycerol, 1mM EDTA, 1mM EGTA, 1mM DTT, 
20mM NaFm 20mM 13-glycerol phosphate, 20mM Sodium pyrosphosphate and a 
protease inhibitor cocktail from Roche. Changes to this combination were trialled and are 
detailed in chapter 3.1.3. The lysate was clarified by centrifugation at 16,000G for 30 min 
at 4 °C, addition of 500 washed Pansorbin A cells (Calbiochem) for 60 min, to remove 
endogenous IgG, then a further 30 min at 16,000G, 4 °C. 
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2.8. In vitro BCR kinase assay of 14 -3 -3 
2.8.1. In vitro kinase assay using 32P -ATP 
Glutathione Sepharose 4B (Amersham Pharmacia) beads were used to pull down the 
GST fusion of BCR from cell lysates of either COS -1 or HEK293 cells, transfected 24 
hours earlier, and lysed in standard lysis buffer. The cell lysates were clarified by 
centrifugation at 13,000 RPM for 30 minutes at 4 °C; then GSH beads added to the 
supernatant for 2 hours with constant rotation at 4 °C before washing three times with 
lysis buffer. The beads were then washed twice in kinase assay buffer (without ATP and 
DTT). After the last wash, the beads were re- suspended in a final volume of 25111 kinase 
assay buffer, with a final concentration of 50mM HEPES (pH 7.05) 10mM mM MgCl, 
201AM ATP and 20µM DTT. Between 2 -10µg of each 14 -3 -3 isoform was used for each 
assay. The reaction was carried out for 30min at 30 °C and stopped in Laemmli's buffer 
[433] prior to SDS PAGE. 
Essentially the same procedure was carried out for using the BCR -FLAG construct. 
The transfected cells were lysed and clarified as before, except that the clarified lysate 
was cleared of endogenous IgGs using protein AG beads before adding 4µg of anti -M2 
antibody and incubating with rotation 4 -16 hours. The antibody:BCR -FLAG complex 
was recovered using a mix of protein AG beads incubated with the lysate for 4 hours, 
before washing as before in preparation for the kinase assay. 
2.9. Casein kinase 1 inhibitors 
2.9.1. CKl-7 
CKI -7 (Shiegaku, Tokyo, Japan) was dissolved in dimethyl sulphoxide (DMSO) as a 
10mM stock. For pre- incubation experiments with CKI -7, BCR -FLAG 
immunoprecipitates were turned end over end during the last wash of the IP in kinase 
assay buffer including 1001,tM CKI -7 (minus ATP). Where stated, CKI -7 was added just 
prior to addition of the substrate (20- 1001AM). 
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2.9.2. D4476 
D4476 (gift from Rodolfo Marquez, School of Life sciences, The University of 
Dundee) inhibitor was dissolved in DMSO to a stock of 1mM and was used at 20µM in 
the final assay. This was added immediately prior to addition of the substrate. No pre - 
incubation with D4476 was required to observe an inhibitory effect. 2111 of DMSO was 
used as a vehicle control. Both inhibitor kinase assays were performed exactly as in 2.8.1. 
2.9.3. Phosphorylation of Centaurin -o1 by all classes of Protein kinase C 
Approximately 10µg centaurin -a1 (GST- removed with Thrombin) was incubated with 
lU each of PKCa, 11 and E. The PKC activator - a micelle mixture of Phosphatidylserine 
(PS) and diacylglycerol (DAG) was made immediately prior to the assay by mixing 30111 
PS and 8111 DAG together, reducing the volume by speedvac for 5 min until a glossy 
pellet formed. This was re- suspended in 50W 20mM HEPES, pH 7.05 and incubated in a 
water bath for 30 min. Each assay had the following: PKC kinase assay buffer (40mM 
HEPES pH7.4, 2mM EGTA, 20mM MgC12), 0.03mg /ml PS, 8µg /ml DAG (3.64l 
micelle mix),10011M ATP, 1011Ci (0.37MBq) [32P] -ATP, 114ig centaurin -a1 and lU PKC. 
PKCa had an additional 3mM CaC12 added. The reactions were made to 6O0, incubated 
at 30 °C for 30 min and stopped in Laemmli buffer. Each reaction was run on a 12% SDS- 
PAGE gel, an autoradiograph taken and the bands corresponding to centaurin -a1 cut out 
and digested with trypsin (see section 2.12). For the GST- centaurin- a1:CKla binding 
assay, intact GST-centaurin-ai was phosphorylated exactly as above. 
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2.10. Recombinant Protein Purification 
Table 2.6 Clones used for protein over -expression in E. coli 














Amp 37 °C 0.9 0.5mM 4h 
MBP 
(pMAL) 
David Jones Amp 37 °C 0.6 0.5mM 4h 




Amp 37 °C 0.9 0.5mM 4h 
GST- 14 -3 -3y 
(pGEX -2T) 
David Jones Amp 37 °C 0.9 0.5mM 4h 
GST- 14 -3 -3y 
(pGEX -2TK) 
Henrik Leffers Amp 37 °C 0.9 0.5mM 4h 
MBP-14-3-30 
(pMA1) 
David Jones Amp 37 °C 0.6 0.5mM 4h 
GST- 14 -3 -( 
(pGEX-4T1) . 
Thierry Dubois Amp 37 °C 0.9 0.5mM 4h 
GST- 14 -3 -3i 
(pGEX -2T) 
Henrik Leffers Amp 37 °C 0.9 0.5mM 4h 
GST- 14 -3 -311 
(pGEX -2TK) 
Henrik Leffers Amp 37 °C 0.9 0.5mM 4h 




Amp 37 °C 0.9 0.5mM 4h 
GST- 14 -3 -3T 
(pGEX -2T) 
David Jones Amp 37 °C 0.9 0.5mM 4h 
GST -centaurin -al 
(pGEX -4T 1) 
Kanamarlapudi 
Venkateswardu 
Amp 25 °C 0.6 0.5mM 4h 
GST- 14 -3 -3T S233A 
(pGEX -4T1) 
Thierry Dubois Amp 37 °C 0.9 0.5mM 4h 
GST- 14 -3 -3 S185A 
(pGEX -4T 1) 
Thierry Dubois Amp 37 °C 0.9 0.5mM 4h 
GST- 14 -3 -g S233A 
(pGEX-4T1) 
Thierry Dubois Amp 37 °C 0.9 0.5mM 4h 
GST- 14- 3- 3ÇS233D 
(pGEX-4T1) 
Thierry Dubois Amp 37 °C 0.9 0.5mM 4h 




Amp 30 °C 0.8 0.5mM 4h 
GST- 14 -3 -3 Dimer mutant 
(pGEX-4T1) 
Shaun Mackie Amp 25 °C 0.9 1mM 4h 
*MBP- 14 -3 -3c had added glucose at 2g /1 at all stages. 
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All GST- 14 -3 -3 fusion cDNAs were transformed into E. coli 
BL21(DE3)pLysS competent cells (Novagen), and selected on agarose plates 
containing 100µg /ml of the appropriate antibiotic. A 100m1 culture was grown 
overnight from one colony in LB supplemented with Ampicillin at 100µg /ml. A 1 /10 
dilution of the starter culture was made into the same medium and grown at the 
temperature indicated in table 2.6 until the OD reached 0.6 -0.9. The culture was then 
induced using isopropyl- beta -D- thiogalactopyanoside (IPTG, from ICN) at 0.5 -1mM 
for 3 -4h at 25 -37 °C, in a shaking incubator (220 RPM). The same procedure was 
used for the MBP- 14 -3 -3 c, but with the addition of glucose at 2g /litre at all stages. 
The purpose of including glucose was to prevent the build up maltose- degrading 
enzymes, so as not to degrade the amylose resin, used at a later stage, to recover the 
MBP -fusion. Cell pellets, re- suspended in lysis buffer (PBS, 1mM PMSF, 1mM 
EDTA, 1mM DTT, protease inhibitor tablet (Roche) and 0.1% Triton), were 
sonicated 6 times for 30s with an amplitude of 5 microns. The Triton X -100 
concentration was increased to 1 %, the cell suspensions were rotated for 30 min at 
4 °C and clarified by centrifugation at 16,000g for 30min. The supernatant was then 
passed through a 0.2211m filter and the GST fusion protein was recovered from the 
lysate using glutathione sepharose 4B beads (Amersham /Pharamcia) and the MBP - 
14 -3 -3 c recovered by amylose resin (New England Biolabs). The beads were washed 
extensively and the 14 -3 -3 cleaved from the GST moiety using 50U thrombin (Sigma 
T -7009) for each litre of original culture of GST fusion, or 50U factor Xa /litre for 
MBP14 -3 -3c. The protease was removed by passing the supernatant through a 
benzamidine sepharose column. Benzamidine sepharose beads were first equilibrated 
in benzamidine binding buffer (20mM Tris pH 7.4, 500mM NaCI) before the cleaved 
14 -3 -3 protein was then passed through the immobilised benzamidine column twice. 
The 14 -3 -3 was then concentrated and buffer -exchanged into PBS and protease 
inhibitors using a vivaspin 10K MWCO concentrator (Fisher), snap -frozen in liquid 
nitrogen and stored in small aliquots at -70 °C until use. 
Intact GST- 14 -3 -3 was eluted off the glutathione beads by incubating GST- 
14-3-3 bound beads with l0mis of GST elution buffer (50mM Tris pH7.4, 20mM 
glutathione) for 1 hour at 4 °C, with gentle agitation. The eluted protein was dialysed 
into PBS to remove bound glutathione, concentrated and stored as above. MBP -14 -3- 
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3 E could not be stored in this way if to be used for `bait' in future pull down 
experiments, due to the maltose binding with such affinity that it can not be dialysed 
off. For these purposes, the MBP- 14 -3 -3 E was prepared just before use and left on 
the amylose beads. For reciprocal binding experiments, MBP- 14 -3 -3e was eluted with 
maltose and treated as for the GST fusion proteins. 
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2.11. In Vitro Transcription Translation 
Table 2.7 Clones Used for IVTT 
6- catenin -FLAG (pCMV -4A) Shaun Mackie 
BCR -FLAG (pCMV -4A) This Study 
HA -CKIa (pcDNA3) Frank McKeon 
HA- CK1a17 -325 
HA -CKI a 164 -325 
HA- CK1a189 -325 
HA-CK1a217-325 
HA- CK1a233 -325 
HA- CK1a17 -287 
HA-CK1a164-287 
HA- CK1a189 -287 









One µg of each plasmid GST -Bcr, delta catenin, casein kinase la w /t, S218A, S242A, 
S218A/S242A were incubated with 4O111 of a T7 TNT coupled transcription/translation 
system (Promega Corp., Madison, WI). This rabbit reticulolysate master mixTM includes 
all amino acids, but lacks methionine. Added separately, 0.37 MBq of [35S]- methionine 
(Amersham) and nuclease -free water took the volume to 5O111. The 
transcription/translation reaction was allowed to proceed for 90 min, the lysate was then 
divided into two, incubated with either GST or GST- 14 -3 -3 and incubated for 15min at 
30 °C, then 30011l of NP -40 buffer containing 1511l GSH beads was added and this was 
left with gentle rotation for 1 hour. For phosphorylation stimulation /inhibition 
experiments, after the 90min transcription/translation period, the lysate was incubated for 
a further 30min with the inclusion of PKA and 100µM ATP or 5mM NaF. The beads 
were washed 5 times in NP -40 buffer and subjected to SDS -PAGE. After 
staining /destaining, the gel was incubated for 30min with Amplify solution (Amersham), 
effectively a scintillant, to enhance the signal. The gel was dried, and exposed to film at - 
70°C. 
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2.12. Protein digestion and mass spectrometry 
Proteins separated by SDS -PAGE were stained with either coomassie blue (R250) or 
the colloidal dye GelcodeTM (Pierce) to reveal bands. Individual bands were excised and 
treated according to the protocol of Aitken and Learmonth [435]. Briefly, gel pieces were 
incubated with three changes of 0.2M NH4HCO3 /50% acetonitrile at 30 °C for 30 min to 
remove SDS. The proteins were reduced by incubation with 20mM DTT /0.2M 
NH4HCO3 /50% acetonitrile at 30 °C for 1 hr. After several washes to remove DTT, the 
cysteine residues were alkylated by incubation in 50mM iodoacetamide (made fresh) for 
20 min. After further washing the band was cut into small (1 x 2mm) pieces and shrunk 
with the addition of 100% acetonitrile (gel piece turns opaque white) - the acetonitrile 
was then removed in a centrifugal evaporator. The gel pieces were then rehydrated with a 
trypsin solution on ice for 15 min on ice, then enough 0.2M NH4HCO3 was added to 
cover the pieces and incubated overnight at 30 °C. The peptides were collected in the 
supernatant, further extraction was achieved by sonication for 30 min at 35 °C, the 
supernatants collected and lyophilised in a centrifugal evaporator for 30 min. Peptides 
were stored at -20 °C until analysis by mass spectrometry. 
2.12.1. Image analysis - Densitometry using AIDA /ImageJ software 
Image analysis was performed predominantly on gels with coomassie stained 
proteins, or autoradiographs of radiolabelled proteins for accurate quantification of 
binding levels. Briefly, sections were drawn through each band to assess if the signal was 
too intense for analysis; only sharp peaks were analysed. The area under the peak was 
then calculated according to the software developers' instructions. 
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Table 2.8 Media and buffers used 
LB (Luria -Bertani) broth l Og tryptone, 5g yeast extract, lOg NaC1, distilled water to 1 
litre 
LB Agar l Og tryptone, 5g yeast extract, 10g NaC1, 12g agar, distilled 
water to 1 litre 
SOB 20g tryptone, 5g Yeast Extract, 2ml of 5M NaC1, 2.5ml of 1M 
KC1, 10m1 of 1M MgSO4, distilled water to 1 litre.Prior to use 
add: 10m1 of 1M MgC12 
SOC As SOB media, but with the addition of 20m1 of 1M glucose 
TE 10mM Tris -Hcl pH 7.5, 1mM EDTA 
NZY+ 10g cassamino acids (casein hydrolysate), 5g yeast extract, 5g 
NaC1, water to 1 litre. Prior to use add: 12.5m1 1M MgC12, 




10mM PIPES, 55mM MnC12 *, 15mM CaC12, 250mM KC1. 
The media was made to pH 6.7 with KOH, autoclaved, the 
filter- sterilised MnC12 was added 
TBS 25mM Tris, pH7.5, 137mM NaCl. 
DMEM Invitrogen #2169035 
DMEM 
reduced serum 
DMEM as above, but with 0.1% FBS 
FBS Foetal bovine serum, heat inactivated. Invitrogen #10108165 
Trypsin .05% EDTA Invitrogen #25300054 
ATP Preparation of 10mM stock: 2.5g of adenosine -5'- triphosphate 
MW 605g, dissolved in 400mis ice cold water, adding 
immediately small lumps of KOH to near pH 8.0, then a 
concentrated KOH solution to exactly pH 8.0 
Cell Culture lysis buffer 50mM Tris (pH 7.5), 10% glycerol, 137mM NaC1, 10mM VI- 
glycerol phosphate, 10mM NaF, 10mM NaVO4,1mM EDTA, 
1 mM dithiothreitol (DTT) and protease inhibitor cocktail 
tablet, EDTA -free (Roche) 
Kinase assay buffer 2x stock: 100mM HEPES pH7.0, 20mM MgC12, 2mM DTT *, 
4011M ATP *, 0.37MBq y- 32ATP *. *Added just before use. 
NP -40 20mM Tris pH 7.5, 100mM NaC1, 10% glycerol, 1mM DTT *, 
0.1% non -idet P40. *Added just before use. 
Laemmli Buffer 3x 
(loading dye) 
' 
For 40m1: 7.6ml Tris Hcl pH 6.8 1M, 12ml glycerol, 6ml ß- 
mercaptoethanol, 12ml 20% SD, 1.2ml 1% bromophenol blue, 
1.2ml water. 
*add just before use 
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CHAPTER 3. 
Identification of phosphorylation site 
on 14 -3 -3 by BCR kinase 
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3. Identification of phosphorylation site on 14 -3 -3 by 
BC t kinase. 
3.1 Introduction 
14 -3 -3 has been shown to be phosphorylated by the wild type BCR kinase and 
also the chimeric BCR -ABL kinase [147]. The authors ascertained the 
phosphorylation to be on serine /threonine residues and on 14 -3 -3 and i isoforms, in 
addition they showed that 14 -3 -3 zeta was 15 times a poorer substrate for BCR than 
tau. 14 -3 -3 -t, and ß have also been shown to associate with BCR kinase [147, 187]. 
14 -3 -3 binding to BCR may well be dependent on BCR phosphorylation [44]. Figure 
3.1 shows a schematic of kinases that phosphorylate BCR. 
To identify which 14 -3 -3 residue was phosphorylated by BCR kinase, BCR 
was produced in mammalian cells and incubated with all mammalian 14 -3 -3 isoforms 
in an in vitro kinase assay (Figure 3.4). In agreement with Reuther et al [ 147], only 
14 -3 -3 i, and to a lesser extent Ç, were phosphorylated. Alignment of all 14 -3 -3 
isoforms shows the only common and unique Ser /Thr to i and , is residue 233 (Thr 
in Ç, Ser in t). This site was previously identified in our laboratory as a 
phosphorylation site by CK1u [172], the phosphorylation of which reduces the 
interaction with Raf kinase [145]. Repeating the kinase assay using mutants of this 
site revealed that residue 233 of 14 -3 -3 zeta and tau are phosphorylated by BCR 
kinase (figure 3. 6, 3.7). As BCR phosphorylates the same site on 14 -3 -3 as CK1 a, 
experiments were performed to rule out the possibility of phosphorylation of S/T233 
by a contaminating endogenous CK1. 
To investigate the possibility that additional isoforms may also interact with 
BCR, three approaches were taken. Firstly BCR -FLAG was overexpressed in 293 
cells, GST- 14 -3 -3 fusion proteins were incubated with the lysate, glutathione beads 
added and the `pull downs' were subjected to SDS -PAGE and western blotted for 
anti -FLAG antibody (figure 3.17). Secondly, 293 cells were co- transfected with 14 -3- 
3 isoforms and BCR -FLAG, reciprocal immunoprecipitations carried out and binding 
levels ascertained by western blot (figure 3.18). Thirdly, BCR -FLAG was 
overexpressed in cells, immunoprecipitated and western blotted to detect interaction 
with endogenous 14 -3 -3 isoforms (figure 3.19). 
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During these investigations it was observed that a PKA -like associating kinase 
co- precipitated with M2 anti -FLAG antibody from cell lysates. 
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3.1.1. DNA manipulation and purification of recombinant proteins used for 
kinase assays and binding experiments. 
A clone of BCR from Owen Witte was introduced into the mammalian 
expression vector pEBG -2T resulting in an N- terminal GST fusion protein. A C- 
terminal FLAG tagged construct of BCR was also produced by PCR and inserted into 
the vector pCMV -4A (Stratagene). All recombinant 14 -3 -3 clones were produced as 
GST fusions, except 14 -3 -3 s that was produced as an MBP fusion. The 14 -3 -3 
proteins were cleaved using thrombin (GST constructs) or factor Xa (MBP) (see 
Materials and methods). 
GST- 14 -3 -3s could be conveniently stored in 30% glycerol at -70 °C for 
several months without aggregation or degradation (data not shown). The MBP -14 -3- 
3s construct used as `bait' in pull down experiments had to be used directly after 
purification from the bacterial lysate. This was due to the maltose binding so tightly 
to the MBP moiety such that it could not be dialysed off and so could not be re- 
captured on the amylose resin. GST- 14 -3 -3 s constructs had been tried before in our 
laboratory, but resulted in a series of truncations when analysed by SDS -PAGE [10]. 
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3.1.2. GST -BCR and BCR -FLAG transfection in cells 
Previous studies centred on BCR have used eukaryotic expression systems 
when studying full length BCR [204], or bacterial systems when truncation mutants 
of BCR were studied [243]. Correct folding and post translational modifications may 
well be required for such a large protein. To this end BCR was produced in 
mammalian cells and purified using immuno- precipitation or glutathione affinity pull - 
down followed by extensive washing. Different cell lines were tested for their ability 
to ectopically express BCR. COS -1, COS -7 and HEK293 cell lines were compared 
for their ability to produce BCR. Overall COS -7 cells gave the best yield, with COS -1 
and HEK293, producing less, in that order (figure 3.2 and data not shown). 
However, both GST -BCR and BCR -FLAG constructs were consistently 
difficult to express, with optimal conditions ascertained empirically. Indeed, in cases 
where other groups have over expressed BCR in HEK293 cells [252] they could only 
detect BCR by western blot. Briefly, HEK293 cells were most sensitive to plating 
density (no less than -80% or 1.8 -26 cells /l Ocm plate, at time of plating), splitting 
density during maintenance (no less than 1:4) and number of passages before 
significantly reduced transfection efficiency (no more than 15 -20 passages). Longer 
than 2 -3 minutes incubation with trypsin also reduced transfection efficiency. Several 
transfection approaches were tested - Cationic lipids (Lipofectamine 2000 ®, 
Metafectine®, Fugene ®), electroporation and calcium phosphate DNA precipitation 
(all detailed in Materials and methods). Lipofectamine and metafectine proved the 
most efficient, as judged by western blotting and monitoring of an empty GFP 
construct transfected in a parallel (data not shown). The COS -1 and -7 cells were 
more robust during routine culture and plating densities and responded better to 
calcium phosphate transfection than other strategies. 
BCR transfection in HEK293 cells produced lower levels of BCR compared 
to COS -1 and COS -7, but still sufficient to assess both kinase activity and 14 -3 -3 
binding without creating a false representation of binding interactions. As COS -1 
cells were more robust than HEK293 and gave greater levels of transfection, they 
were used for routine production of BCR to be used in kinase assays. 
Chapter 3 - BCR phosphorylation of 14 -3 -3 86 
BCR produced as a C- terminal FLAG fusion had greater activity than BCR as 
an N- terminal GST fusion (data not shown). Perhaps due to less steric hindrance near 
the kinase domain. Also, western blot analysis of GST -BCR pull downs revealed 
several cross -reacting bands (figure 3.2), perhaps truncated forms of BCR. In addition 
BCR -FLAG was useful for further studies involving binding experiments with GST- 
14-3-3. 















Glutathione pull down 
1% whole lysate 
HEK293 COS -1 
Figure 3.2 Expresion efficiency in COS -1 and HEK293 cell types. 
A, COS -1 cells were transfected with either control vector (lane 1) or a GST -BCR 
construct (lane 2). Glutathione beads were incubated with the cell lysates, washed and 
western blotted with anti -GST antibodies. B, HEK293 or COS -1 cells (indicated) 
were transfected with empty vector (pCMV -4A) or BCR -FLAG in pCMV -4A, lysed 
and anti -FLAG immunoprecipitates analysed by western blot using anti -FLAG 
antibodies. 
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3.1.3. Optimisation of BCR purification and phosphorylation of 14 -3 -3 by 
BCR. 
The source of active BCR for most previous studies has been from 
baculovirus infected insect cell systems (sn2, sf9 cells [44, 243]) or purified from cell 
types expressing BCR or BCR -ABL such as MDCK or K562 respectively. 
Composition of lysis buffers used varied in terms of ̀ phosphate protection' i.e. the 
inclusion of phosphatase inhibitors, perhaps because at that stage little was known 
about the intricate regulatory mechanism of BCR. Later studies have shown 
phosphorylation of Y360 reduces transphosphorylation activity of BCR purified from 
COS -1 cells [269]. However, previous reports have shown treatment of BCR with 
phosphatase reduced the interaction with 14 -3 -3 [44]. So with this in mind, 
experiments were performed to find optimal conditions where sufficient BCR could 
be produced in a form able to interact with and phosphorylate 14 -3 -3. Briefly four 
plates of HEK293 cells were transfected with equal amounts of BCR -FLAG DNA 
and each plate was lysed in four different lysis buffers. All buffers had the same basic 
composition of Tris, salt and detergent (see Materials and methods and table in figure 
3.3). The purpose of each buffer is detailed below: 
Buffer A - was designed to maintain optimum phosphorylation state 
Buffer B - as A, but containing DTT that may reduce the inhibitory activity of VO4 
and amount of BCR immunoprecipitated using IgG (by dissociating the light chain), 
but may improve purification/reduce contaminating proteins 
Buffer C to allow dephosphorylation 
Buffer D -a buffer similar to one used in an original investigation on BCR [436]. 
After lysis in the respective buffer, each lysate was clarified by centrifugation and the 
BCR -FLAG was immunoprecipitated with anti -FLAG antibody. After SDS -PAGE, 
one IP from each buffer was equilibrated in kinase assay buffer and incubated with 
14 -3 -3 i and [321P -ATP. 14 -3 -3 levels in each lysate remained constant, indicating no 
bias toward lysis efficiency of any buffer (figure 3.3B). Coomassie staining showed 
that lysing cells in buffer B allowed the most BCR to be immunoprecipitated and 
therefore, presumably, the highest level of phosphorylation. 
Buffer B was chosen for further experiments as it yielded the greatest amount 
of active BCR. 









A B C D 
4-BC R 
14 -3 -3T 
A B C D 
Autoradiograph Coomassie 
Buffer DTT NaF Na3VO4 ß-G-p EDTA PI 
A OmM 1 mM 1 mM 5mM 5mM yes 
B 1mM 1mM 1mM 1mM OmM yes 
C OmM OmM OmM OmM OmM yes 
p OmM OmM OmM OmM 5mM yes 
B 
30KDa - 
A B C D 





Figure 3.3 Optimisation of lysis buffer for BCR immunoprecipitation and 
14 -3 -3 t phosphorylation. Equal amounts of bcr -flag DNA were transfected into 
separate 10cm dishes containing HEK293 cells. After 24 hours, the cells were washed 
twice in PBS and lysed in buffers A -D containing: Tris (25mM), NaC1 (137mM), 
detergent (NP -40, OA% v /v), glycerol (10% v /v), and various other components as 
listed in the table. The BCR -FLAG was immunoprecipitated using anti -FLAG 
antibodies, washed extensively and incubated under kinase assay conditions with 51.1g 
of recombinant 14 -3 -3 i and [32P] -ATP. The reactions were separated by SDS -PAGE, 
coomassie stained, dried and exposed to film at -70 °C. The autoradiograph on the left 
shows that that buffer B allowed for the greatest 32P incorporation into 14 -3 -3 i 
compared to other lysis buffers. A coomassie load control is shown in the right hand 
panel. B shows a western blot of 1% of each lysate using a general anti- 14 -3 -3 
antibody indicating equal amounts of 14 -3 -3 present in each lysate. Buffers A -D are 
indicated. 
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3.1.4. BCR selectively phosphorylates 14 -3 -3 isoforms in vitro 
BCR -FLAG was used for all subsequent kinase assays, due to higher kinase 
activity. Typically 10µg BCR -FLAG DNA was transfected into HEK293 cells, using 
Lipofectamine or Calcium phosphate precipitation method (see Materials and 
methods for details). After 24 -36 hours the cells were lysed, incubated with Pansorbin 
cells, to remove endogenous proteins that may cross -react with protein A, and then 
clarified by centrifugation. The BCR -FLAG was immunoprecipitated with M2 anti - 
FLAG antibody conjugated to sepharose beads, washed in lysis buffer followed by 
equilibration in kinase assay buffer, then incubated with 14 -3 -3 isoforms in an in 
vitro kinase assay in the presence of [321P -ATP (figure 3.4). The kinase reactions were 
stopped in Laemmli sample buffer and subjected to SDS -PAGE. Between 2 and 51.1g 
of 14 -3 -3 were incubated in the kinase assay, as used in previous reports [147, 187]. 
Out of the seven 14 -3 -3 isoforms incubated with BCR kinase, only the 14 -3 -3 tau and 
zeta were phosphorylated (figure 3.4). Coomassie load control is shown underneath. 
The experiment was repeated at least twice for all isoforms assayed in parallel, for 
other isoforms such as r and , multiple assays were performed. 









Figure 3.4 BCR kinase phosphorylates only 14 -3 -3 tau and zeta 
All 14 -3 -3 isoforms were produced and purified as described in materials and 
methods. Equal amounts of recombinant 14 -3 -3 were incubated with BCR -FLAG 
immunoprecipitated from HEK293 cells, under kinase assay conditions. The IPs 
separated by SDS -PAGE, stained and the autoradiograph shown in the top panel. 
Coomassie staining shows approximately equal loading. 
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Figure 3.5 Comparison of the 14 -3 -3 isoforms around residue 233 
14 -3 -3 i and Ç share a residue capable of undergoing phosphorylation at reside 233. 
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3.1.5. BCR phosphorylates 14 -3 -3 tau and zeta on Ser /Thr 233 
Alignment of the mammalian 14 -3 -3 isoform sequences indicate that the only 
Ser /Thr residues common to r and Ç, but not present in the other isoforms, are S233 in 
14 -3 -3 T and T233 in 14 -3 -3( (see alignment above, figure 3.5). Using Ser /Thr -Ala 
mutants of these phosphorylation sites, kinase assays were performed as before. 
Figure 3.6 shows BCR -FLAG incubated with 14 -3 -3 T w/t and 14 -3 -3 t S233A. 
Levels of BCR kinase and recombinant 14 -3 -3 in the assay are approximately equal 
as judged by coomassie blue staining (right hand panel). Autophosphorylated BCR 
and phosphorylated 14 -3 -3 are indicated with arrows. Control immunoprecipitations 
with empty vector (indicated FLAG in figure 3.6) showing no phosphorylation of 14- 
3-3. It is clear that BCR kinase only phosphorylates wild type 14 -3 -3 i; the S233A 
mutant shows only a small amount of background phosphorylation, indicating S233 
as the phosphorylation site. 
14 -3 -3 ( and Ser -Ala mutants of the known phosphorylation sites S185 and 
S233 were next assayed with BCR (figure 3.7). Although phosphorylation of 14 -3 -3 
was low and 14 -3 -3 T wt very strong, there is a difference between 14 -3 -3 ( w/t and 
S233 mutant. There is no difference between w/t and S185A, indicating S233 is the 
site of phosphorylation by BCR. The coomassie stained gel is shown underneath, 
indicating equal protein loading. 
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Figure 3.6 A Ser -Ala mutation at residue 233 abolishes phosphorylation of 14 -3- 
3 'r in vitro. BCR -FLAG and FLAG vector control transfected cells were 
immunoprecipitated with anti -FLAG antibodies, washed and incubated with 
recombinant 14 -3 -3 T and r S233A. An autoradigraph on the left shows 
phosphorylation of 14 -3 -3 T wt, but not T S233A mutant. A coomassie load control is 
shown on the right. 
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Figure 3.7 A Thr -Ala mutation at residue 233 abolishes phosphorylation of 14 -3- 
3 in vitro. 
14 -3 -3 T and Ç isoforms and mutants were incubated with BCR kinase under kinase 
assay conditions (see Materials and methods). 14 -3 -3 i is clearly phosphorylated 
more than wt and Ç S185A. S233A mutant is not phosphorylated, indicating that 
233 is the site of phosphorylation. 
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3.1.6. Endogenous CK1 does not co- precipitate and phosphorylate 14 -3 -3 in 
BCR -FLAG immunoprecipitations. 
Serine 233 was previously identified in our laboratory as a phosphorylation 
site by CK1 a [ 172]. With the knowledge that CK1 a is active toward known substrates 
at very low concentrations (Thierry Dubois, personal observation), the possibility 
existed that endogenous CK1 was co- precipitating through endogenous 14 -3 -3 (in 
high abundance in cells) with BCR kinase and it was this endogenous CK1 that was 
phosphorylating 14 -3 -3 at the 233 site. Additionally, there is reported evidence of 14- 
3-3 acting as a `scaffold' between BCR and Raf [187]. Perhaps CK1 could replace 
Raf in this complex? 
To exclude this possibility, two approaches were taken. First, inhibitors of 
CK1 were used. One is an established CK1 inhibitor, CKI -7, of the isoquinoline 
sulfonamide family and the other a newly developed ATP -competitive CK1 inhibitor 
called D4476 (shown in figure 3.11 (from [403]) that was developed in Dundee after 
these studies had commenced. Secondly BCR was co- transfected into HEK293 cells 
with CK1a wild type and kinase dead mutant (D136Á) and then kinase assayed in 
vitro to see if phosphorylation on 14 -3 -3 T could be increased or decreased 
respectively by out -competing endogenous CK1. The idea being that the transfected 
kinase dead CK1 would then be `bridged' to BCR by endogenous 14 -3 -3. 
Figure 3.8 shows BCR incubated with 14 -3 -3 T as substrate, with the inclusion 
of CKI -7 or DMSO as a vehicle control. Positive (14 -3 -3 T wt) and negative (14 -3 -3i 
S233A) controls are shown in the two left hand lanes (both without CK1 inhibitor). 
Using CKI -7 at 1001AM did not reduce phosphorylation activity toward 14 -3 -3, 
indicating that CK1 is not present in the immunoprecipitation and phosphorylation of 
14 -3 -3 must be due to the BCR kinase. Subsequent experiments using the D4476 
inhibitor are shown in figure 3.10. 
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Figure 3.8 CM -7 has little effect on BCR phosphorylation of 14 -3 -3. 
BCR -FLAG was immunoprecipitated from HEK293 cells as described in Materials 
and methods. CKI -7 (501.1M) was added to the washed immunoprecipitates containing 
BCR immediately prior to addition of 5µg 14 -3 -3 T substrate and [32P] -ATP. 14 -3 -3 T 
S233A was used as a negative control, DMSO was added as a vehicle control. A 
coomassie load control is shown in the right hand panel. 
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3.1.7. Overexpression of BCR and CK1 
To further investigate the potential CK1:14- 3 -3:BCR association, BCR -FLAG 
and HA -CK1 a were transfected into HEK293 cells and BCR -FLAG was 
immunoprecipitated using the M2 a -FLAG antibody. HEK293 cells have plenty of 
endogenous 14 -3 -3, so triple transfections with 14 -3 -3 were not deemed necessary. 
Equal amounts of BCR, CKIa and empty vector DNA were transfected using 
Lipofectamine, the cells lysed after 24 hours and then incubated with M2 anti -FLAG 
antibody. Each washed immunoprecipitate was incubated with 51.ig of recombinant 
14 -3 -3 T with or without the CK1 inhibitor, CKI -7, under kinase assay conditions 
(figure 3.9). Control transfections using empty FLAG vector (pCMV -4A) only, 
empty FLAG vector with CK1 a wt or kinase dead mutant (lanes 1 -5) shows the 
specificity of the immunoprecipitation, with very little background phosphorylation 
(lanes 1 -5). Although equal amounts of DNA were present in all transfections it 
seemed co- transfecting CK1 with BCR substantially reduced the level of BCR 
expressed, as judged by coomassie stain (figure 3.9, bottom panel). The strength of 
the autoradiograph signal correlated with the amount of BCR seen by coomassie 
staining, compare lanes 6 -10, fig 3.9 (representative of several different assays). Lane 
6 of figure 3.9 shows typical phosphorylation of 14 -3 -3 i, however lane 7 shows a 
reduction in phosphorylation (due to less BCR being present) that is then drastically 
reduced by addition of CKI -7 (lane 8), possibly indicating that CK1 could be 
phosphorylating 14 -3 -3 T. Lanes 9 and 10 show transfection with a kinase dead 
mutant of CK1 that has been shown to be completely devoid of kinase activity [380]. 
These kinase assays responded to CKI -7 treatment with the same pattern as with the 
wild type CK1 (compare with lanes 4 and 5), indicating that the CKI -7 was inhibiting 
general, background, kinase activity. Interestingly CKI -7 reduces BCR 
autophosphorylation activity (lanes 8 and 10, figure 3.9); further suggesting that CKI - 
7 can reduce kinase activity non -specifically. It must be stressed that CKI -7 was used 
at a high concentration here (10011M) along with pre- incubation of the BCR IP with 
CKI -7 for one hour. This step was deemed necessary as preliminary experiments 
showed little effect on inhibition of CK1 at the concentrations published previously 
e.g. -9µM in [403, 437] and data not shown. As CKI -7 is an ATP -competitive 
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Figure 3.9 Co- expression of BCR and CK1a 
BCR -FLAG or empty vector (FLAG) were co- transfected with HA -CK1 and HA- 
CK1 kinase dead (KD) mutant, BCR immunoprecipitated from lysates using a -FLAG 
then incubated with/without CK1 inhibitor CKI -7 (100µM), in vitro with 5µg 14 -3 -3 
T and 511,Ci [32P] -ATP. Lanes 1 -5 are controls with empty vector (FLAG tag only) 
transfections, lanes 6 -10 show immunoprecipitated BCR. Presence or absence of CK1 
wt and KD are indicated. BCR levels of transfection can be seen in the coomassie gel 
and reflected in the autophosphorylation levels in the autoradiograph (top panel). 
Approximately equal loading of 14 -3 -3 is also indicated on the coomassie stain, BCR 
can be seen in the third panel, where the contrast has been increased compared to the 
middle panel. 
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inhibitor, concentrations this high may well affect kinases generally. However, CKI -7 
has been used at concentrations up to 504LM [438], although no mention of other 
kinases being affected are mentioned in this study. Although levels of BCR in co- 
transfection preparations are not equal to BCR transfected alone, if CK1 was capable 
of co- associating through 14 -3 -3 with BCR, expression of a kinase dead mutant 
would be expected to substantially reduce phosphorylation of 14 -3 -3. 
3.1.8. D4476 does not affect BCR kinase auto- or trans -phosphorylation 
activity. 
As previously mentioned, Hidaka and co- workers reported an IC50 of 8.5µM 
for CKI -7 [437] whilst by Rena et al reported a value of 611.M [403]. In experiments 
performed here CKI -7 reduced phosphorylation of 14 -3 -3 only at a high 
concentration and when pre- incubated for an hour before the kinase assay and at a 
high concentration (see figures 3.8 with 3.9). D4476 however has recently been 
shown to be highly specific for CK1 and has an IC50 of 0.311M at 100µM ATP [403]. 
Therefore the use of D4476 instead of CKI -7 could avoid the unwanted side effect of 
reducing BCR kinase activity. To this end, separately transfected CKIa and BCR 
immunoprecipitated from HEK293 cells were assayed for kinase activity in parallel 
as before, except with the addition of D4476 at 2011M (figure 3.10). The CK1 IPs 
were included to check the efficacy of the inhibitors. D4476 completely inhibited the 
ability of CKl a to phosphorylate 14 -3 -3z, whereas there was no effect on BCR. CKI - 
7 was used at 501.1M in this experiment and shows no effect on phosphorylation of 14- 
3-3 by the BCR immunoprecipitate. However partial reduction in phosphorylation of 
14 -3 -3 by CK1 was observed, indicating that the CKI -7 was functioning properly. 
DMSO alone actually increases phosphorylation compared to kinase assay buffer 
alone, for both BCR and CK1 -a phenomenon peculiar to DMSO, as occasionally 
observed previously [439]. 
These data demonstrate that CK1 was not the 14 -3 -3 kinase in BCR 
immunoprecipitates because no reduction in phosphorylation was observed on 
incubation with 14 -3 -3 r under kinase assay conditions, including the highly specific 
D4476 inhibitor or CKI -7 inhibitor - compare lanes 2, 3 and 4 in each panel, figure 
3.10 
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Figure 3.10 CK1 does not co- immunoprecipitate with BCR kinase. 
All assays contained 2µg 14 -3 -3T and 5iCi [3 P] -ATP. Lane 1, nothing indicates 
kinase buffer alone; lane 2, DMSO as vehicle control; lane3, CKI -7 in DMSO at a 
concentration of 501.1M and lane 4 contains 20µM D4476 in DMSO. Kinase reactions 
were stopped in Laemmli buffer, boiled and subjected to SDS -PAGE, coomassie 
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Figure 3.11 Structures of CK1 inhibitors used in this study (from [403] and 
[440]). CKI -7 is a well established CK1 inhibitor, whereas D4476 is a newly 
identified inhibitor, with an IC50 approximately ten times lower than CKI -7 [403]. 
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3.2. M2 FLAG antibody precipitates a cyclic A -like kinase: a 
cautionary tale 
During the course of the investigation, constructs of 14 -3 -3 11 and y in the 
pGEX -2TK vector (hereafter referred to as `2TKrC and `2TKy') were used that have 
the additional motif GSRRASV (a cyclic AMP -dependent kinase phosphorylation 
site) which remains attached to the recombinant protein, after thrombin cleavage of 
the GST moiety. The purpose of this is to label recombinant proteins in vitro using 
32P and recombinant cyclic A- kinase, allowing easy detection in binding experiments. 
This vector was not deliberately used for this purpose and was not seen as a potential 
problem. Specifically, immunoprecipitation with anti -FLAG antibodies has been 
widely used, shown to be highly specific [441 -443] and therefore unlikely to 
immunoprecipitate protein kinase A. However, M2 a -FLAG immunoprecipitates 
from BCR -FLAG or FLAG empty vector transfections that had been extensively 
washed and then incubated with 14 -3 -3 containing this extra site showed robust 
phosphorylation of 2TKr1 an 2TKy (figure 3.12, lanes 1, 2, 9 and 10). Curiously, 
BCR -FLAG phosphorylated `2TKy)' more than FLAG empty vector alone (compare 
lanes 1 and 2). This result suggests three possibilities: 
(1) BCR phosphorylates a motif similar to PKA and is phosphorylating GSRRASV 
(2) BCR phosphorylates a true site on 14 -3 -3i 
(3) PKA associates with BCR and is phosphorylating GSRRASV. 
14 -3 -3 T, tS233A mutant and 14 -3 -3 6 were assayed in parallel by way of control and 
showed predicted results (figure 3.12, lanes 3 -8). BCR did not phosphorylate 14 -3 -3 
r) or y when different constructs, devoid of GSRRASV, were used (see figure 3.4). 
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Figure 3.12 M2 FLAG antibody co- purifies with a PKA -like kinase 
BCR -FLAG and FLAG empty vector were transfected into COS -1 cells, 
immunoprecipitated, extensively washed in lysis buffer and incubated with 5µg 14 -3- 
3 protein. 14 -3 -3 rl and y have a slightly higher molecular weight than 14 -3 -3 i due to 
extra amino acids in the PKA phosphorylation site. Control kinase assays are shown 
in lanes 3 -8, with i wt as a positive control and í233A and a as a negative control. A 
coomassie load control of recombinant protein is shown in the lower panel. 
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Pre -conjugated M2 anti -FLAG beads were used to see if the contaminating 
kinase could be removed, but to no avail (data not shown). Kinase assays of the anti - 
FLAG beads used to pre -clear lysates with 14 -3 -3 showed an identical pattern (to 
figure 3.12) as transfected lysates and for this reason, non -transfected cells were used 
for further studies. A time course was carried out to establish some kinetic parameters 
and is shown in figure 3.13A. M2 anti -FLAG antibody and protein A:G beads were 
added to un- transfected COS -1 cell lysate, centrifuged briefly, washed and divided 
equally into seven Eppendorf tubes. Equal amounts of 14 -3 -3y in pGEX -2TK were 
added and incubated under kinase assay conditions (excess ATP) for the time 
indicated. Densitometry was performed on the autoradiogram and the values plotted 
against time, shown in figure 3.13B. The kinase is very resilient - being able to 
robustly phosphorylate 14 -3 -3 for three hours. 
Experiments to identify the phosphorylation site(s) were carried out, whereby 
14 -3 -3 y was phosphorylated, separated by SDS -PAGE and digested with trypsin. 
The resulting fragments were separated by HPLC and analysed by mass spectrometry 
and solid phase sequencing (by Dr Andy Cronshaw, EPIC, University of Edinburgh). 
The peptide corresponding to the radiolabelled peak had the sequence GSRRASV, 
identifying it as the only phosphorylation site (data not shown). 
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Figure 3.13A Time Course of 14 -3 -3 y phosphorylation. 
FLAG antibody and protein AG beads from COS -1 lysates were washed and 
incubated with 14 -3 -3y in the pGEX -2TK vector for the indicated times under kinase 
assay conditions. Reactions were stopped in Laemmli buffer, subjected to SDS- 
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Figure 3.13B Densitometry of 14 -3 -3 y phosphorylation. 
Each time point of the autoradiograph above was analysed by densitometry using 
AIDA (see Materials and methods). The values were plotted against time and show 
no reduction in kinase activity, even after three hours. 
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3.2.1. PKA co- precipitates with the M2 anti -FLAG antibody from cell lysates 
Having established that a PKA motif is phosphorylated by a -FLAG 
immunoprecipitates, further experiments were performed with the specific, natural 
inhibitor of cyclic -A kinase, PKAi - a natural inhibitor (this preparation from calf 
muscle). Empty vector and BCR -FLAG DNA was transfected into cells and 
immunoprecipitates prepared as before. Both immunoprecipitates were incubated 
with 2TKy, either with or without PKAi under kinase assay conditions and the 
autoradiograph is shown in figure 3.14. The PKA inhibitor eliminates 
phosphorylation of 2TKy, suggesting that PKA is the kinase present in the precipitate. 
The possibility remained that PKA could be phosphorylating14 -3 -3 T on 
residue 233. This was ruled out by two data: first, no phosphorylation was seen in the 
empty vector control lane, only in BCR lanes (figure 3.12, compare lanes 3 and 4). 
Secondly, BCR -FLAG was immunoprecipitated as before and incubated with 14 -3 -3 
T wt, either with an inhibitor of PKA (PKAi) or PBS (the PKAi solvent). There was 
no difference in phosphorylation of 14 -3 -3 T, on incubation with PKAi, see figure 
3.15 top panel. 
The only published contaminating, or co- associating protein with the a -FLAG 
antibody is with a rat Mgt + -dependent phosphatase [444]. Data from this study 
suggests that a PKA -like kinase can also associate with the M2 a -FLAG antibody. 














Figure 3.14 PKA co- precipitates with M2 -FLAG antibody. 
Immunoprecipitates from empty vector (FLAG) and BCR (BCR -FLAG) transfected 
COS -1 cell lysates were incubated with PKAi under kinase assay conditions for 30 
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Figure 3.15 co- precipitating PKA does not phosphorylate 14 -3 -3 
BCR -FLAG from COS -1 cells was immunoprecipitated as above and incubate with 
14 -3 -3 T wt under kinase assay conditions, with the inhibitor PKAi. A coomassie load 
control is shown in the lower panel. 
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3.2.2. Investigation of BCR:14 -3 -3 interaction using an in vitro transcription 
translation system (IVTT) 
To investigate the BCR:14 -3 -3 association, preliminary experiments utilised 
the IVTT system. BCR was produced in an in vitro transcription translation system 
containing 35S- methionine, the reactions made up to 0.5ml and incubated with GST- 
14 -3 -3 (figure 3.16). As a positive control, Delta -catenin was used as it is a similar 
size to BCR and has been shown to associate with 14 -3 -3 in vitro in our laboratory 
[445]. Even with a very long exposure, no BCR was seen to associate with 14 -3 -3 in 
this system. This could point to the association being phosphorylation dependent as 
the necessary kinase maybe absent from the reticulolysate, or present in such low 
abundance that a sufficient level of BCR phosphorylation was not achieved - 
therefore the interaction was not seen. As this result proved negative, no further 14 -3- 
3 isoforms were tested for association with BCR using this system. 
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Figure 3.16 In Vitro Transcription Translation (IVTT) of BCR -FLAG followed 
by pull down with GST- 14 -3 -3 
The IVTT product was incubated with GST or GST -Zeta for 4 hours at 4 °C. For a 
positive control, Delta -catenin was also transcribed and incubated with the GST /GST- 
zeta. BCR -FLAG is apparent as the higher band, 6- catenin as the slightly lower band 
(compare lanes 1, 2 and 6). 
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3.2.3. GST- 14 -3 -3 pull down of BCR 
Three isoforms of 14 -3 -3 have been shown to interact with BCR [147, 187]. 
To investigate if other isoforms can associate, in vitro binding assays were 
performed. To allow for potential post translational modifications, BCR -FLAG was 
over -expressed in HEK 293 cells and lysed in buffer containing high concentrations 
of phosphatase inhibitors. The lysate was then clarified by centrifugation, divided 
equally and incubated with equal amounts of recombinant GST- 14 -3 -3 isoforms. The 
GST- 14 -3 -3 was recovered by using GSH beads (Amersham) and after extensive 
washing, the pull downs were subjected to SDS -PAGE followed by western blotting 
with anti- FLAG antibodies (figure 3.17). As equal amounts of BCR -FLAG 
transfected lysates were incubated with equal amounts of GST- 14 -3 -3 and the 
western blots performed at the same time, it is clear that 14 -3 -3 ri and y `pull down' 
more BCR than the other isoforms. It is therefore reasonable to suggest that BCR has 
higher affinity for 14 -3 -3 11 and y in this in vitro binding experiment. 
Phosphorylation of 14 -3 -3 on S233 has been shown to negatively regulate 
interaction with Raf [145]. A mutant of 14 -3 -3 , in which Ser233 was mutated to an 
Asp with the hope of mimicking the phosphorylated residue was also incubated with 
BCR -FLAG lysate (figure 3.17, lane 9). However, no reduction in binding was seen, 
indeed a slight increase is apparent. This is due to the fact sometimes the simple 
introduction of a carboxyl group does not have the same effect as a phosphate group, 
as, for example, Raf -1 S259D mutation [279]. 
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Figure 3.17 BCR interacts with all 14 -3 -3 isoforms in vitro. 
HEK 293 cells were transfected with BCR -FLAG, lysed and incubated with the 
indicated GST- 14 -3 -3 isoform. A loading control for 14 -3 -3 stained with Ponceau S 
is shown in the lower panel. The T233D construct was also assayed, lane 9. An 
equivalent amount of 1% of the BCR -FLAG lysate that used for each incubation is 
shown in lane 1. A GST -only incubation is shown in lane 2. 
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3.2.4. Co- expression of BCR and 14 -3 -3 isoforms in HEK293 cells. 
Having shown that 14 -3 -3 can pull down BCR from a cell lysate, the 14-3 - 
3:BCR interaction was next investigated in vivo. BCR -FLAG and 14 -3 -3 Ç, rl, y (myc 
tagged) and 14 -3 -3 -i (HA tagged) constructs were co- transfected into HEK 293 cells. 
The 14 -3 -3 was immunoprecipitated with anti -myc or anti -HA antibodies, extensively 
washed and after SDS -PAGE was western blotted with anti -FLAG antibodies to 
detect BCR association with 14 -3 -3. Figure 3.18 shows all 14 -3 -3 isoforms 
transfected were able to associate with BCR. Because transfection of 14 -3 -3 
alongside BCR seemed to produce varying levels of both 14 -3 -3 and BCR in the 
lysate (compare panels A and B in figure 3.18) interpretation of the data to ascertain 
preferential binding is difficult. Also 14 -3 -3 i was in a different vector and so will be 
discussed separately (dotted box in figure 3.18). Overall 14 -3 -3 y seems to bind more 
tightly to BCR than 14 -3 -3 rl and as BCR levels are less in the a- myc- 14 -3 -3 ti and 
immunoprecipitations (panel C, lanes 1, 2, 4). Panel B shows levels of BCR present 
in the lysate. Although there is less BCR -FLAG in lanes 1 and 2, compared to lane 4, 
there is significantly more 14 -3 -3 available for binding BCR (panel A, lanes 1 and 2), 
further indicating that y associates with BCR with higher affinity. As 14 -3 -3 i is in a 
different vector and subsequently a different antibody used (a -HA) direct 
comparisons can't be drawn. However a clear association can be seen, comparing 
lanes 3 in all three panels in figure 3.18. As the levels of 14 -3 -3 i and ß in the cell 
lysates seem more equal, 14 -3 -3 i may be binding less tightly than 14 -3 -3y. Perhaps, 
as 14 -3 -3 i is a substrate for BCR and as 14 -3 -3 y is not, BCR phosphorylation may 
reduce the association with 14 -3 -3 i, an observation observed for 14 -3 -3 :Raf 
interaction on the equivalent residue after CK1 phosphorylation [172]. 14 -3 -3 y on 
the other hand being non -phosphorylatable may therefore be able to associate without 
disruption. There is a difference between 14 -3 -3 and rl association with BCR - there 
is much more 14 -3 -3 rl in the lysate than Ç, yet r7 still pulls down less BCR, perhaps 
due to Ç and r) binding a different subset of endogenous proteins with different 
affinities. The data shown in Fig. 3.18 agree with the in vitro binding studies (figure 
3.17) using recombinant 14 -3 -3 to capture BCR. As well as verifying that the 
isoforms Ç and r, as shown previously, bind BCR [ 147, 187] the data shown here 
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indicate that the y and 11 isoforms can also associate with BCR in vivo, perhaps 
highlighting a binding preference for 14 -3 -3 y. 
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Figure 3.18 Co- transfection of BCR -FLAG with 14 -3 -3 isoforms. 
101,tg of each DNA was transfected into HEK293 cells using Lipofectamine 2000 and 
after 24 hours the 14 -3 -3 was immunoprecipitated using the indicated antibody. 1% 
of each lysate was examined by western blot using a -myc, a -HA or a -FLAG 
antibodies (panels A and B).Western blotting using antibodies to FLAG was used to 
reveal the association of BCR in the immunoprecipitates (panel C). The dotted box 
indicates the a -HA immunoprecipitate, for separate analysis from the a -myc IPs. 
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3.2.5. Endogenous 14 -3 -3 association with BCR. 
Having shown that all recombinant 14 -3 -3 isoforms examined can pull down 
BCR in vitro and that co- transfection experiments of 14 -3 -3 with BCR show 
association in vivo, experiments were performed to observe what endogenous 14 -3 -3 
isoforms associate with BCR. To this end, BCR -FLAG from transfected cells was 
immunoprecipitated and western blotted for endogenous 14 -3 -3 using isoform- 
specific antibodies (see Materials and methods). This showed that 14 -3 -3 ß, 
y, E, Ç and T associate with BCR -FLAG (Figure 3.19). 14 -3 -3 T is expressed at low 
levels in 293 cells; nevertheless interaction with this isoform can be seen. The 14 -3 -3 
6 isoform is only expressed at high levels in epithelial cells and is present at such low 
levels in the 293 cell line that no interaction could be detected. To demonstrate that 
14 -3 -3 isoforms do not bind non -specifically to the IgG:resin, an 
immunoprecipitation with control IgG was carried out, followed by a western blot 
with an antibody that recognises all 14 -3 -3 isoforms (PAN). This highlighted the 
specificity of immunoprecipitation, as no 14 -3 -3 was seen (figure 4.19, lower panel, 
far left lane). Equal amounts of BCR in each immunoprecipitation are indicated by 
anti -FLAG western (middle panel, figure 3.19). 
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Figure 3.19 BCR interacts with all 14 -3 -3 isoforms in 293 cells. 
293 cells were transfected with BCR -FLAG, the lysates pooled and divided into 
seven aliquots for immunoprecipitation with anti -FLAG antibody. 1% of the input 
lysate was western blotted with anti- 14 -3 -3 antibodies to verify levels of endogenous 
14 -3 -3 proteins (top panel). The input lysate (1 %) was also western blotted with anti - 
FLAG antibody (middle panel) to check that BCR -FLAG was expressed and present 
at an equal level in each IP. The BCR -FLAG was immunoprecipitated with a -FLAG 
M2 antibody and each a -FLAG IP was western blotted with antibodies specific for a 
14 -3 -3 isoform as indicated (bottom panel). 
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CONCLUSION 
The two normal genes, bcr and abl, are ubiquitously expressed in normal 
tissues [207, 208] and their precise role is poorly defined, but aberrant fusion of the 
two leads to CML as discussed in chapter 1. By exploring the interaction of the 
normal bcr protein with 14 -3 -3, data presented here shows an increased repertoire of 
14 -3 -3 isoforms able to interact with the BCR kinase. Also identified was 14 -3 -3 
residue 233 as the site of phosphorylation on the and T isoforms. This is the same 
14 -3 -3 residue that is phosphorylated by CKla [172]. Although 14 -3 -3 r), y and E 
were found to associate with BCR they do not appear to be substrates for the kinase. 
However, the association of 14 -3 -3 with BCR may cause a change in sub -cellular 
location and/or modulate activity of BCR. There is a rational explanation why 
phosphorylation at Ser233 in this isoform led to the observation by Reuther et al 
[ 147] of four phosphopeptide spots on thin layer electrophoresis (TLE). From our 
own extensive protein sequence analysis ([446] and unpublished) we have shown that 
tryptic cleavage of 14 -3 -3 isoforms produces the following two C- terminal peptides: 
223( R)DNLTLWTSDS233AGEECDAAEGAEN245 and 
213( K) DSTLIMQLLRDNLTLWTSDS233AGEECDAAEGAEN245 This is due to 
partial cleavage at arginine223 (underlined). Combined with the unique cysteine 
residue (underlined) in the tau isoform which may undergoe partial oxidation to 
cysteic acid under normal conditions of trypsin digestion, phosphorylation at residue 
233 would yield two radiolabelled phosphopeptides, multiplied by two due to the 
partially oxidised cysteine residues (which have a more acidic mobility) producing a 
total of four spots on TLE. 
Several steps were taken to rule out endogenous CK1 phosphorylation of 14- 
3-3 on residue 233. A kinase dead mutant of CK1 and two CK1 inhibitors were used 
and the results showed that phosphorylation of 14 -3 -3 on S233 was solely by BCR. 
The inhibitors used were CKI -7 (an established CK1 inhibitor) and the other a novel 
CK1 inhibitor known as D4476 with a ten fold greater IC50. Also shown here is 
evidence that BCR does not phosphorylate S185 on 14 -3 -3 any less than wild type, 
a residue shown recently to be phosphorylated by JNK [170]. The finding that residue 
233 on 14 -3 -3 is phosphorylated by BCR is important, as phosphorylation of this 
Chapter 3 - BCR phosphorylation of 14 -3 -3 116 
residue can negatively affect interaction with other signalling molecules [145, 172]. 
In addition the association of a contaminating kinase, most likely PKA, is reported for 
the M2 anti -FLAG antibody. The contaminating kinase is most likely PKA based on 
two pieces of evidence. First, the amino acid sequence of the substrate is known and 
is a specific PKA phosphorylation motif and, secondly native PKA inhibitor 
completely wiped out the kinase activity. PKA associating with BCR or, through the 
M2 antibody (used throughout the study), was also ruled out as the kinase 
phosphorylating 14 -3 -3. 
Chapter 3 - BCR phosphorylation of 14 -3 -3 117 
CHAPTER 4 
CK1a association with 14 -3 -3. 
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4. CKI o association with 14 -3 -3 
4.1. Introduction 
Previous studies investigating CK1 signalling complexes have revealed a 
number of interacting proteins with a wide range of functions and localisations 
(reviewed in [288, 408]. Work in our laboratory found that CK1 co- purified with a 
number of proteins including the phosphatidylinositol 3,4,5- trisphosphate- binding 
proteins centaurin -a and -al in brain ([419] and see figure 4.1). The site of interaction 
on CKIa with centaurin -a and -al was further identified as a loop region contained 
within the kinase domain comprising residues 217 -233 [419]. The original mass 
spectrometry data that identified CKia from the co- purifying protein complex 
showed no indication of phosphorylated CK1 a. This was despite identifying the 
tryptic peptide containing residue S218 in the original data. From crystallographic 
studies [393, 394], the loop region has been postulated to be a site of interaction with 
other proteins (see section 1.11). Based on this observation and having identified 
several other proteins associated with CK1 (figure 4.2), a synthetic peptide was 
produced corresponding to this region and was shown to bind a number of proteins 
from brain including: Actin, importin -al, importin -ß, PP2Ac, centaurin a -1 and 
HMG1 [421]. However, 14 -3 -3 was not identified during those investigations. This 
region of CK1 contains a possible 14 -3 -3 binding motif, if residue S218 were 
phosphorylated (RTpS218LP). The aim of this study was to examine the possibility 
that 14 -3 -3 could interact with this sequence, if phosphorylated within this potential 
14 -3 -3 binding motif. To this end, a similar peptide was synthesised, with the 
exception of having a phosphorylated S218 residue and an additional N- terminal 
cysteine: C213FNRTpS218LPWQGLKA226. The cysteine was introduced to allow 
binding to affinity material. This peptide is shown in this chapter (section 4.2) to bind 
all 14 -3 -3 isoforms in a phospho- dependent manner whereas dephosphorylation of 
the peptide actually increased its ability to bind Centaurin -al. Similar to many 14 -3 -3 
binding motifs, this sequence contains a reasonable consensus motif for PKA or PKC. 
To this end, the phosphatase inhibitor, NaF, and /or purified PKA catalytic subunit 
was added to CKl a produced in an IVTT system and binding assays were performed 
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using GST- 14 -3 -3 (. Binding was shown to increase on treatment with PKA/NaF, 
indicating a phospho- dependent binding mechanism. 
Various CKl a truncation mutants (designed to examine the region around 
5218 in the interaction) were expressed in an IVTT system and the results suggested 
that S218 is not the only site essential for 14- 3- 3:CKla association. On further 
inspection of the CKla sequence, however, another possible 14 -3 -3 mode 1 binding 
site is present - at S242. The presence of this site might explain why a CKI a 
truncation mutant lacking S218, but containing S242 could still bind 14 -3 -3. In 
addition, the crystal structure of CK1 reveals that S242 would be accessible for 
binding (see figure 4.13). To address this possibility, site directed mutagenesis was 
performed to create both single and double Ser -Ala mutations of residues S218 and 
S242. 
First, experiments designed to see if endogenous 14 -3 -3 could associate with 
CKIa in mammalian cells revealed that 14-3-31-land 14 -3 -3 y associated more 
strongly than other isoforms. Therefore for future binding experiments using cell 
culture, the association of endogenous 14-3-311 and y with CKIa was examined. To 
try to increase the amount of phosphorylated CKIa present in the cell, HEK293 and 
COS -7 cells transfected with HA -CKIa in the presence of db -cAMP to (either 
directly or indirectly) stimulate phosphorylation of sites 5218 and S242. This 
produced a transient increase in binding to 14 -3 -3 
In HEK293 cells, the CKl a mutant S218A had slightly reduced ability to 
associate with 14 -3 -3, whereas mutation of S242A reduced the binding almost 
completely. The double mutation completely abolished binding, indicating that S242 
is part of the major binding site. This could be due to different binding affinities of 
14 -3 -3 for these sites or different levels of kinase activity and/or kinase selectivity 
toward these sites. A further possibility is that the S242 interaction is behaving like a 
`gatekeeper', binding 14 -3 -3 first, then allowing S218 (with presumably lower 
affinity) to bind into the other binding pocket of the 14 -3 -3 dimer, according to the 
`gatekeeper hypothesis' [139]. 
Analysis of the crystal structures of 14 -3 -3 and CK1 using the molecular 
docking program `DOT' and `ZDOCK' through a web -based interface called ClusPro 
(http: / /nrc.bu.edu /cluster /) [447] revealed potential insights into the interaction. 
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Further analysis by Paul Taylor, Edinburgh University, suggested CK1 a could only 
bind one site at any one time, due to steric hindrance. While computer -aided 
modelling cannot rule out the possibility of CK1 a binding into each binding pocket of 
the 14 -3 -3 dimer, major conformational changes would have to occur. 
The identification of binding partners for CKIa that may affect sub -cellular 
location is important, as CK1 a has few other modes of regulation (see chapter 1.4). 
The complex with centaurin -a1 is of particular interest as centaurin -a1 is 
predominantly localised at the plasma membrane and so may target CK1 to 
substrates. A summary of interactions examined in this chapter are shown in figure 
4.2. 




11- Centaurin al 
11- Synaptotagmin IX - CKIa 
I- HMG1 /2 
41- CPI -17 
Figure 4.1 Centaurin -al co- purifies with CK1a from pig brain. 
Other signalling molecules were also discovered, as indicated by arrows. 
Identification was by mass spectrometry, from Dubois et al, from excision of the 
coomassie stained [419]. 








Figure 4.2 CK1 binding partners investigated in this study. 
CK1 associates with 14 -3 -3 in a phospho- dependent manner. Centaurin -a1 is 
phosphorylated by PKC on residues S87 and T276. 
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4.2. Results and Discussion 
4.2.1. DNA manipulation and purification of recombinant proteins 
A construct of CK1a was obtained from Peter Roach, and cloned into 
pcDNA3 by Thierry Dubois. Mutants of HA -CK1a were produced according to the 
Stratagene Quickchange protocol as described in Materials and methods. All 
recombinant 14 -3 -3 isoforms were produced as GST- fusions, except epsilon that was 
produced as a maltose binding protein (MBP) fusion, see Materials and methods 
section 2.10, and cleaved with thrombin or factor Xa - see appendix Al for SDS- 
PAGE /coomassie staining to assess purification). CK1E was from David Virsup and 
was cloned into pS752 by Thierry Dubois [419]. 
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4.2.2. Peptide synthesis and clean up of the synthetic peptide by HPLC and 
coupling of peptide to Sulfolink column. 
The synthetic peptide C214FNRTpS218LPWQGLKA226 has a high propensity to 
form inter -peptide disulphide bonds and so was delivered with the inclusion of a large 
amount of DTT. See Materials and methods for details on synthesis. In order to 
successfully couple the peptide to Sulfolink beads (Pierce) the DTT was removed by 
reverse phase HPLC. The peptide was loaded onto a Vydac `low TFA' column and a 
gradient of 0% to 100% acetonitrile resulted in the peptide eluting after 26 minutes 
(see figure 4.3). The fractions were immediately neutralized with Tris base and then 
incubated with equilibrated Sulfolink beads (see Materials and methods) at a ratio of 
approximately 1 mg peptide per 1 ml beads. The amount of peptide bound was 
assessed by the use of 5,5'- Dithio- bis(2- Nitrobenzoic acid) (DTNB or Ellman's 
reagent). A binding efficiency of -90% was calculated (data not shown). A sample of 
this peptide was checked for integrity using mass spectrometry by Rob Wakefield, 
University of Edinburgh (data not shown). 
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Figure 4.3 HPLC purification of the CK1 peptide corresponding to residues 
C- 14FNRTpS218LPWQGLKA226. 
A Vydac C18 `low TFA' column was equilibrated with a shallow gradient from 
methanol to water, then lmg CK1 peptide (in 5001_11 water) was injected onto the 
column, followed by 10 minutes of water. Then a gradient of 100% water to 100% 
acetonitrile, both with the addition of 0.01% trifluoroacetic acid (TFA) was applied, 
see Materials and methods for exact details. DTT and other impurities washing 
through can be seen eluting at time points 2, 7 and 13 minutes. A sample of the eluant 
at 26min was analysed by mass spectrometry and confirmed to be the 
phosphopeptide. This fraction was used for the study. 
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4.2.3. A phospho peptide corresponding to residues 214 -226 of CK1a binds 
all 14 -3 -3 isoforms. 
To investigate whether the peptide corresponding to the proposed `docking 
loop' of CK1 could bind 14 -3 -3, equal amounts of peptide -coupled beads 
(20µg /14nmol peptide) were aliquoted into Eppendorf tubes and made up to 0.5ml 
in binding buffer (see Materials and methods). After incubation with each 
recombinant 14 -3 -3 isoform (151.1,g) and extensive washing, the bound 14 -3 -3 was 
analysed by SDS -PAGE and coomassie blue staining (figure 4.4). This shows that all 
14 -3 -3s associate with the peptide, albeit to different extents. Comparing lanes 1 from 
all panels, 14 -3 -3 y, i , and then ß appear to bind most, then i, and s all bind to a 
similar extent, with a binding to a much lesser extent. Treatment of the beads with k 
phosphatase (PPase) almost eliminated binding to 14 -3 -3 (lanes 2). Control 
experiments with incubation of the PPase with the inhibitor VO4 (lanes 4) indicate 
that the interaction is phospho- dependent and the effect was not due to PPase 
masking the binding of the peptide to 14 -3 -3, for example. Lane 3 shows that adding 
the phosphatase inhibitor VO4 alone does not affect the interaction. Surface plots of 
each panel, indicating intensity of each band (created using ImageJ) were created to 
aid visualisation of the gels. It is worth noting that even if overall binding levels are 
low (s and a) an identical pattern of binding is observed, after the inclusion of 
phosphatase inhibitor (Na3VO4). Two repeat experiments were conducted, the bands 
were measured by densitometry and the results are summarised in figure 4.5. This 
shows the intensity of 14 -3 -3 bands from phosphatase untreated and treated phospho- 
peptide beads for each isoform. Although the fairly large error bars in figure 4.5 
should be noted, the overall binding capacity changed consistently with phosphatase 
treatment. Confidence that the interaction is phospho -specific can be drawn from the 
finding that binding of all 14 -3 -3 isoforms altered in a similar way. It is also worth 
noting that the phosphopeptide coupled beads used in these binding experiments were 
dephosphorylated in a large batch and then divided equally for incubation with 14 -3- 
3. As all 14 -3 -3 isoforms were incubated with identically treated beads, an accurate 
comparison can be drawn between binding assays. 
Figure 4.5B shows the change in 14 -3 -3 binding, after dephosphorylation of 
the beads, taking the amount of 14 -3 -3 bound to phosphorylated beads as 100 %. The 
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difference to dephosphorylated beads was then calculated to show the difference 
dephosphorylation makes to each isoform. This shows that dephosphorylation of 
S218 reduces the binding by a relatively similar amount for five of the 14 -3 -3 
isoforms. The binding pattern of 14 -3 -3 and I1 are more distinct, with 
dephosphorylation of Ç creating the biggest change in binding, in other words Ç binds 
more specifically to the phospho peptide, than the dephospho peptide. On the other 
hand, the change in 11 binding shows relatively less discrepancy toward binding 
dephosphorylated S218 peptide. 
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Figure 4.4 A phospho -peptide corresponding to residues 213 -226 of CK1a 
associates with all 14 -3 -3 isoforms in a phospho- dependent manner. 
Sulfolink® beads conjugated to 201,1g peptide corresponding to residues 214 -226 (C- 
FNRTSPLPWQGLKA) of CKla, were incubated with all 14 -3 -3 isoforms (panels 1- 
7) washed three times and subjected to SDS -PAGE followed by coomassie blue 
staining. Lane 1: shows untreated beads; lane 2: beads treated with lambda 
phosphatase (PPase); lane 3: control whereby beads were incubated with the 
phosphatase inhibitor sodium orthovanadate (Na3VO4); lane 4: control with 
phosphatase inhibitor (Na3VO4) and phosphatase together; lane 5: indicates the 
amount of 14 -3 -3 incubated with the peptide beads (input). Surface plots of each 
panel are shown on the right hand side (performed using ImageJ, from 
http: / /rsb.info.nih.gov /ij /). 
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Figure 4.5 Densitometry analysis of CK1 phospho peptide binding to 14 -3 -3 
A, ImageJ software was used to measure the density of bands corresponding to 14 -3- 
3 and the standard deviation plotted using Sigmaplot. Values shown are the 
percentage of the intensities of 14 -3 -3 captured compared to the intensity of 14 -3 -3 
applied to the beads. B, percentage change in 14 -3 -3 binding after dephosphorylation 
of the pS218 peptide, taken from data in A. The amount of 14 -3 -3 captured by 
phosphorylated beads was taken to 100 %, with the amount captured by 
dephosphorylated beads, multiplied by the same factor, to show comparative binding 
differences between 14 -3 -3 isoforms. 
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4.2.4. The CK1 a phosphopeptide binds centaurin -a1, only when 
dephosphorylated. 
We have previously shown that Centaurin -a1 associates directly through the 
domain, shown here to interact with 14 -3 -3, using a non -phosphorylated peptide 
[419]. To determine if phosphorylation of S218, within this region, could affect this 
interaction, GST and GST- Centaurin were incubated with approximately 14nmol 
phospho -peptide coupled to beads and an equal amount of dephosphorylated peptide - 
beads. The incubation times and dephosphorylation conditions were identical to those 
in the previous experiment (4.2.3). The amount of GST- Centaurin -a1 bound was 
assessed by SDS -PAGE and coomassie staining (Figure 4.6). Interestingly GST- 
Centaurin-a1 showed very little association with the phospho -peptide, but 
significantly increased association was seen after dephosphorylation of the peptide 
(compare lanes 2 and 3, left panel). The GST control shows no association with the 
peptide -beads (right panel, lanes 2 and 3). 
This result extends previous findings that centaurin -a1 associates with CK1 
region 214 -226 [419] and furthermore reveals that phosphorylation of S218 
negatively affects the interaction. 
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Figure 4.6 Centaurin interacts with region corresponding to CK1 214 -226 only if 
dephosphorylated 
Sulfolink® beads conjugated to 20µg peptide corresponding to residues 214 -226 (C- 
FNRTSPLPWQGLKA) of CKIa, were incubated with GST- centaurin -a1, washed 
three times and subjected to SDS -PAGE followed by coomassie blue staining. The 
left panel in lane 1 shows a representative amount of GST- centaurin -a1 that was 
incubated with the peptide- beads; lane 2 shows untreated (phospho- peptide) beads 
and lane 3 shows beads containing dephosphorylated peptide. Right Panel shows the 
same conditions, except that GST was incubated with the peptide beads. 
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4.2.5. CK1 expressed by IVTT associates with 14 -3 -3, increasing with NaF 
treatment. 
After observing that 14 -3 -3 can associate with a region of CKl a in a phospho- 
dependent manner, intact CK1a w/t was produced as a 35S- labelled in vitro, 
transcription, translation (IVTT) product and incubated with GST- 14 -3 -3. 
Additionally, attempts were made to increase the phosphorylation state of CK1 a by 
kinase(s) present within the reticulocyte lysate, by incubating the lysate with 
phosphatase inhibitor. To this end, the IVTT reaction was made up to 1mM NaF after 
the 90 minutes needed to produce CKIa and incubated for a further 30 min. A control 
reaction was also incubated for an extra 30 min, with 4p1 water added (the NaF 
solvent). A sample of the reaction both with and without NaF treatment is shown in 
lanes 1 and 2 of figure 4.7. Figure 4.7 shows HA -CK1 a w/t incubated with GST -14- 
3 -3 and GST as a control. After incubation with NaF, 2 -3 times more CKla 
associated with 14 -3 -3 than a control incubation without NaF (compare lane 4 with 6, 
left panel). Densitometry was used to quantify the increase (figure 4.7, lower panel). 
A coomassie stain on the right shows that equal amounts of GST and GST- 14 -3 -3 
were incubated with the IVTT reaction. A similar experiment was carried out in 
which recombinant PKA was added to the assay after IVTT synthesis, along with 
NaF, however no additional increase was seen (data not shown). These results 
suggest that a basal level of interaction is possible between 14 -3 -3 and CK1 a, which 
may be phosphorylation dependent. Certainly conditions to preserve phosphorylated 
residues further increases the affinity of CKl a toward 14 -3 -3 . 
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Figure 4.7 14 -3 -3 binds CK1a in a phospho- dependent manner. 
Phosphatase inhibitor (NaF) treatment of CK1a produced in an IVTT system 
increases its ability to bind 14 -3 -3. CK1a was produced in the reticulolysate for 90 
minutes, then incubated with NaF for an additional 30 minutes at 30 °C. Lanes 1 and 2 
show 2% of the lysate used for the untreated and phosphatase inhibitor treated (NaF) 
IVTT reactions. Lanes 3 and 5 show GST controls; lanes 4 and 6 show GST- 14 -3 -3 Ç 
associating with HA -CK1a. Densitometry analysis of three binding experiments 
shows a consistent increase in binding with phosphatase inhibitor treatment. 
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4.2.6. All CK1 a truncation mutants associate with 14 -3 -3. 
To further investigate whether residues 214 -226 of CK1 are involved in 
binding to 14 -3 -3, truncation mutants of CKl a were produced by IVTT (35S- labelled) 
and incubated with GST or GST- 14 -3 -3 (as in figure 4.7). The truncation mutants 
were designed to eliminate the region around S218 and a schematic is shown in figure 
4.8A, indicating predicted molecular weights. Two percent of the IVTT reaction was 
analysed by SDS -PAGE (figure 4.8B) to assess the expression level of each mutant. 
Mutants 4 and 5 yielded much smaller amounts compared to the other truncation 
mutants, but could be detected after a longer exposure (indicated in separate panel). 
After incubation with GST- 14 -3 -3, mutant m5 (233 -325) that does not have the 
region 214 -226 was, unexpectedly, still able to bind 14 -3 -3 (figure 4.8.C, lane 12, 
asterisked). Figure 4.9 shows the coomassie gel indicating equal loading of GST and 
GST- 14 -3 -3 protein with the IVTT reactions. 
This is in contrast to previous findings for centaurin -a, a1:CK1 interaction 
[419]. One explanation is another possible 14 -3 -3 binding site in this region, 
consisting of KKMpS242TP where pS242 would be phosphorylated for 14 -3 -3 
binding. From the tertiary structure, S242 appears to be more structurally constrained 
in comparison to S218 (figure 4.12.) and hence had not been considered in initial 
investigations. However, residue S242 would still be accessible for both 
phosphorylation and 14 -3 -3 binding, see figure 4.12. 
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Figure 4.8 14 -3 -3 associates with all truncation mutants of CK1a. 
A, schematic of truncation mutants; B, autoradiograph of 2% 35S- labelled IVTT 
reaction; C, autoradiograph of a GST pull down from the reticulocyte lysate, using 
10µg GST or lOug GST- 14 -3 -3 , as in figure 4.7., separated by 15% SDS -PAGE. 
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Figure 4.9 Coomassie stain of figure 4.9, showing equal loading of GST and 
GST- 14 -3 -3 ;. 
This figure refers to the autoradiograph in figure 4.8. 
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4.2.7. CK1a associates predominantly with 14 -3 -3 11 and y in un- stimulated 
HEK 293 cells. 
To analyse the possible 14- 3 -3:CK1 interaction in vivo, a screen of CKla 
binding affinity to the five 14 -3 -3 isoforms present in abundance in HEK293 cells 
was performed. HEK293 cells were transfected with 101ig HA -CKla wt for 24 hours 
in the presence of serum and lysed in buffer containing high concentrations of 
phosphatase inhibitors (see Materials and methods). The HA -CKla was then 
immunoprecipitated using HA antibody- conjugated agarose beads (Roche) for three 
hours at 4 °C, washed three times in lysis buffer, re- suspended in Laemmli buffer, 
subjected to SDS -PAGE and transferred to nitrocellulose membrane. The use of pre - 
conjugated anti -HA beads allowed clear detection of 14 -3 -3, as using protein AG 
Sepharose produced unsatisfactory high levels of cross reaction with the secondary 
antibody (data not shown). The membranes were then probed with anti- 14 -3 -3 
antibodies (figure 4.10A), stripped and re- probed with anti -HA to check similar levels 
of CKla were present in each binding assay (4.10B). A control IP is shown in lanes 2 
in which a non -HA- immune IgG was incubated in the cell lysate. 
This established that, in unstimulated cells, native endogenous 14 -3 -3 rl and y 
gave the strongest signal. Although it is not possible to discern quantitatively the 
binding affinity for the ri and y isoforms, due to the differing titres of the antibodies 
(discussed in chapter 1.2.7), there is still a clear difference between the isoforms. It is 
interesting to note that these two 14 -3 -3 isoforms identified here as associating to a 
greater degree in vivo, are the same isoforms as in the phospho S218 peptide:14 -3 -3 
binding experiments (figure 4.4). 
Interestingly, these two isoforms (14 -3 -3 rl and y) have recently been 
identified as being able to bind CaMKK, whereas 14 -3 -3 and E were not [35] and in 
so doing, protect it from dephosphorylation in HEK293 cells. The sequence similarity 
between these two isoforms, at the amino acid level, could explain the similar binding 
characteristics (see section 1.1.2) and [448]. 
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Figure 4.10 14 -3 -3 isoforms bind CKla in vivo. 
A, Unstimulated HEK293 cells were transfected with HA -CK1 a and 
immunoprecipitated with anti -HA- conjugated beads. After extensive washing in lysis 
buffer, the immunoprecipitates were subjected to SDS PAGE and western blotted 
with antibodies specific to 14 -3 -3 isoforms. Left hand lanes show a non -immune IgG 
control and right lanes show the a -HA IP. B, Equal amounts of CK1 were present for 
assessment of 14 -3 -3 immunoprecipitations. Re -probe of figure 4.10A with anti -HA 
antibody, showing in lanes 1: 1% of the lysate in unstimulated HEK293 cells 
transfected with HA -CK1, lanes 2 anti -HA- conjugated agarose beads and in lanes 3 
immunoprecipitated HA -CK1 using anti -HA- conjugated agarose beads. 
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4.2.8. 14 -3 -3 isoforms associate with CK1 a in vitro 
To confirm the 14 -3 -3 isoform specificity of the 14- 3- 3:CKla interaction, a 
reciprocal experiment was performed, whereby recombinant 14 -3 -3 was added to 
lysates from cells transfected with HA-CKla. Recombinant GST and GST- 14 -3 -3 
protein were incubated with the cell lysate, pulled down and western blotted for 
CKla using a -HA antibodies. The results are very similar to the CKla 
immunoprecipitations shown in figure 4.10, with GST- 14 -3 -3 i1 and y pulling down 
the most CKla, followed by f3 and Ç (figure 4.11). A GST control lane is shown in the 
far left hand lane and, in the far right hand lane, 1% of the lysate that was incubated 
with each 14 -3 -3 isoform. Densitometry analysis of the blot was performed to 
determine binding levels between 14 -3 -3 isoforms. The amount of CKla pulled down 
by each 14 -3 -3 isoform was compared to the amount of CKI present in 1% of the 
lysate. This is the amount of HA-CKla available for binding and values for 14 -3 -3 
isoform binding are plotted as a percentage of this (figure 4.11C). It is clear that 14 -3- 
3 ri interacts substantially more strongly than other isoforms, followed by y, ß, i, 
and u does not interact at all. Equal amounts of recombinant protein were added as 
judged by ponceau staining (figure 4.11, panel B). 
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Figure 4.11 14 -3 -3 isoforms associate with CK1 in vitro. 
A, COS -1 cells were transfected with HA -CKIa, the lysates were then clarified 
before addition of 101_tg recombinant GST- 14 -3 -3. Each sample was rotated at 4 °C for 
1 hour before addition of glutathione beads. After two hours, each pull down was 
washed 3 times in lysis buffer before separation by SDS -PAGE. The gel was 
transferred and western blotted with a -HA. B, Ponceau staining shows equal loading 
of recombinant 14 -3 -3 isoforms. C, Densitometry analysis of the blot in A, shows 14- 
3-3 associating with CK1 to varying degrees. 
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4.2.9. Activation of PKA causes increased association of 14 -3 -3 with CK1a in 
HEK 293 cells. 
The 14 -3 -3 binding motif R(S)X1,2pSX(P) is, in general, a good consensus for 
a number of kinases including PKA, Ca2 +- calmodulin kinase II and PKC (see chapter 
1.2.5 and table 1.2). Indeed, using the Scansite facility (at http: / /scansite.mit.edu) to 
analyse the CKIa amino acid sequence revealed a PKA or PKC phosphorylation site 
around the possible 14 -3 -3 binding motif at S242. Also, by examining the sequence 
around residue 218, there is also another possible phosphorylation site for PKA/PKC, 
although not detected by Scansite (see figure 4.12, sequence). From the manually 
curated database of phosphorylation sites phospho base at EMBL 
(http: / /phospho.elm.eu.org /) it is clear that more than 50% of PI<A substrates have a 
consensus similar to that found around the 5218 site on CK1 i.e. just one basic 
residue at n -1. 
It is clear from the CK1 crystal structure that both serine residues would be 
accessible to kinase(s) and therefore available for 14 -3 -3 binding (figure 4.12). 
To determine if PKA could phosphorylate CK 1 a on either of these residues 
and thus induce association with 14 -3 -3, HA -CKla was transfected into cells and 
PKA then activated with the addition of dibutyryl -cAMP. A time dependent increase 
in 14 -3 -3 binding could be seen with addition of db -cAMP (figure 4.13); with 
maximal binding seen after 10 minutes. Loading controls are shown in the lower 
panels of figure 4.13, indicating equal amounts of 14 -3 -3 rl and ß -actin present in the 
lysate and equal amounts of CKla being present in each IP (bottom panel). A repeat 
of this experiment with shorter time points showed maximal binding at an even 
earlier time point of 5 minutes (data not shown). This time scale broadly agrees with 
the group of Roger Tsien who were able to observe PKA activation by Forskolin or 
db -cAMP in real time using FRET and a specially created construct containing 14 -3- 
3 fused to a flexible loop region containing a perfect PKA phosphorylation site within 
a 14 -3 -3 binding motif [449]. Binding of 14 -3 -3 to CKl a decreased, even below the 
level of original binding, after 60 minutes, possibly due to indirect activation of 
phosphatases and or translocation of CK1 after 14 -3 -3 binding. 
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Figure 4.12 Proposed interaction region within CK1a. 
The upper red coloured strand shows the flexible, unstructured region of CK1 
proposed by Xu et al [393] (who first solved this structure) to act as an interaction 
loop with other proteins on account of its flexible nature. S218 is shown in yellow, 
with the proposed 14 -3 -3 binding region in red. The loop could also theoretically 
function as an autoinhibitor of CK1, binding into the ATP binding region just above 
(and shown in figure 1.9.), but this remains a postulation [393]. The lower region in 
blue indicates the second proposed 14 -3 -3 binding region around S242 (in orange). 
The two lysine residues, indicated, start to form part of the alpha helix, potentially 
making a poorer binding site. However, the pSLP residues would be easily accessible 
for binding. Created with Pymol, using coordinates from 1 CK l .pdb in the 
Brookhaven database. 
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Figure 4.13 Stimulation of PKA in 293 cells causes increased association of 
endogenous 14 -3 -3 with CKla w /t. 
HEK293 cells, transfected with CKla were serum starved for 18 hours, then 
stimulated with dibutyryl cAMP (db -cAMP) for the indicated times. Lanes land 2 are 
control lanes with no CKla, with and without db -cAMP. A small amount of 14 -3 -3 
was detected in these control lanes, indicating that the effect of PKA stimulation may 
not be reproducible. Lane 3 shows unstimulated cells transfected with CKla as a 
control; lanes 4, 5 and 6 show increasing time with db -cAMP. 1% of the lysate was 
western blotted for a -ß -actin and a- 14 -3 -3 n. The immunoprecipitated HA-CKla blot 
was striped and re- probed with a -HA after blotting with a- 14 -3 -3 11 (lower panels). 
Ten minutes stimulation of PKA induced the greatest amount of 14- 3- 3:CKla 
association, thereafter the association reduced. A Repeat experiment showed a similar 
result. 
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4.2.10. Phosphorylation dependent binding of 14 -3 -3 ri to CK1a 
Site directed mutagenesis was then carried out to produce S218A, S242A and 
a S218A/S242A double mutant of CKIa, to reveal if these residues are essential for 
association with 14 -3 -3. Having established that PKA activation increases the 
association with 14 -3 -3 and CKIa in 293 cells, subsequent binding experiments 
involving mutants of CK1 were carried out using cells stimulated with db -CAMP. 
HA -CKIa wt and SA mutants were transfected into HEK293 cells, stimulated with 
db -cAMP, lysed and the washed anti -HA immunoprecipitates analysed by western 
blot for the presence of endogenous 14 -3 -3 (figure 4.14). The S218A mutation 
caused a slight reduction in 14 -3 -3 binding compared to wild type CKIa, whereas 
S242A and double 218/242 mutation reduced 14 -3 -3 binding almost entirely (figure 
4.14, top panel). A 1% sample of the lysate was western blotted for 14 -3 -3 and the IP 
blot stripped and re- probed with anti -HA antibodies (lower panels) to check protein 
loading. As the double S218A/S242A mutation had the same affect as the single 
S242A mutation, two possibilities are apparent. One is that 5242 is the major site of 
14 -3 -3 phospho- dependent interaction and the other is that a SA mutation at this 
position changes the local structure, or conformation of CK1, in such a way as to 
decrease the binding affinity. The fact that S218A decreases the binding substantially, 
but not completely, suggests it does play a role in 14 -3 -3 binding. A possible scenario 
could be that each 14 -3 -3 monomer of the 14 -3 -3 dimer could bind a phosphorylated 
residue of S218 and 5242 simultaneously, after phosphorylation by PKA/PKC or 
other kinase. Such `bidentate' binding has previously been observed for molecules 
such as Raf, BAD, and Cbl [ 15, 17], this concept is explored later (section 4.2.18 - 
CK1:14 -3 -3 modelling). 
Although treatment of cells with db -cAMP has been well documented in the 
literature to increase PKA activity, it cannot be concluded that activating PKA will 
directly induce phosphorylation at the residues 218 and 242. Indeed it would also not 
prove that it is the physiological kinase, but would open up possibilities for future 
studies into the regulation of CK1:14 -3 -3 association. Further experiments treating 
cells with the PKA inhibitor peptide (myristoylated for entry into cells) showed a 
reduction in binding (figure 4.15). There remains the possibility that PKA could 
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activate another kinase by phosphorylation, or inactivate a phosphatase (by 
phosphorylation of a phosphatase inhibitor, e.g. DARPP -32), thus leading to 
increased phosphorylation of CK1. 
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Figure 4.14 Residues S218 and S242 of CK1a are required for 14 -3 -3 association. 
Transfected HEK293 cells with point mutations of HA -CKl a were serum starved, 
then stimulated with db -cAMP for 10 minutes. The cells were lysed and HA -CKIa 
immunoprecipitated with anti -HA antibodies (clone HA -7 conjugated to agarose 
beads). The lysates were extensively washed and western blotted with anti 14 -3 -3 
antibodies. Control blots showing 14 -3 -3 levels and equal amounts of CKla in each 
IP are shown in the lower two panels. Lane 1 shows empty vector control; lane 2, 
wild type CK1a; lane 3, CKIa S218A; lane 4, CK1a S242A; lane 5, CK1a 
218A/S242A. The blots are representative of three separate experiments. 
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4.2.11. Inhibition of PKA reduces CK1a:14 -3 -3 association 
After establishing that PKA stimulation of cells increases 14 -3 -3 association 
with CK1 a, experiments were performed to investigate if the interaction could be 
disrupted by inhibiting PKA activity. PKA activity was `knocked down' by use of a 
myristoylated PKA inhibitor peptide: Myr -GRTGRRNAI (Myr -PKAi) and the 
consequent 14 -3 -3 association with CK1 a observed by western blotting. This peptide 
corresponds to the inhibitor region of protein kinase A inhibitor, with a myristoylated 
N- terminus to allow entry into cells. For these studies the reciprocal experiment was 
perfoinied whereby HEK293 cells were co- transfected with 14 -3 -3 and CKIa, then 
14 -3 -3 immunoprecipitated, followed by analysis of CK1 a by western blot. Panel A 
in figure 4.15 shows that stimulation of PKA with db -cAMP in this experiment 
caused a negligible increase in CKIa association (compare lanes 1 and 2, panel A). 
However, pre- incubation with 2011M of the peptide: Myr - GRTGRRNAI (Myr -PKAi) 
for 30 minutes reduced the CK1:14 -3 -3 interaction even below that of unstimulated 
cells (panel A, compare lanes 1 and 3). Control lanes are shown on the right hand side 
of the panels, with no CK1 present, but identical stimulations (lanes 4 -6). Control 
panels B and C show equal amounts of 14 -3 -3 and CK1 in each treatment, apart from 
lane 3. Lane 3 has lower levels of 14 -3 -3, but it also has lower CK l a. Inhibition of 
PKA would be expected to interfere with many cell signalling processes and so may 
be causing either reduced transfection efficiency, degradation of both proteins or 
change of location, resulting in lower levels of 14 -3 -3 and CK1. The overall binding 
level of CK1 in this experiment was low, perhaps due to high passage number of the 
HEK 293 cells. Experiments using HeLa cells provided increased transfection 
efficiency of CK1 and 14 -3 -3; but did not show a difference' in binding between the 
Ser -Ala mutants (data not shown). Although this may be because the amount of 14 -3- 
3 immunoprecipitated is so high, it may mask the phosphorylation -dependent 
binding. Also 14 -3 -3 was used that does not bind as tightly as other isoforms. The 
reason 14 -3 -3 was chosen was to potentially continue to investigate the role 
phosphorylation of on Thr 233 and interaction with CK1. 
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Figure 4.15 Incubation of an inhibitor of PKA reduces association of CKla with 
14 -3 -3 4. 
HA -CK1 a and 14 -3 -3 -myc constructs were co- transfected into HEK293 cells as 
indicated above panel A. Lanes 3 and 6 were incubated with 2011M Myr -PKAi for 30 
min before addition of 1mM db -cAMP (lanes 2, 3, 5 and 6) for 30 min. After lysis, 
14 -3 -3 was immunoprecipitated using pre- conjugated anti -myc -agarose beads, 
washed, separated by SDS -PAGE and western blotted using anti -HA antibody (panel 
A). Panels B and C show 1% of lysate blotted for a -HA and a -myc. 
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4.2.12. 14 -3 -3 binding mutant 
A mutant of 14 -3 -3 - R56A, R60A was designed to remove the phosphate 
requirement for ligand binding, but which unlike the charge reversal mutant K49E, as 
used by Fu et al [ 134] might not exclude all interaction (see chapter 1). The R5660A 
mutant has been used by the group of Muslin, who found that it decreased the 
interaction with phospho -ERK [137]. Work in our laboratory also found this 14 -3 -3 
mutant to abrogate interaction with 6- catenin [450]. Casein kinase la was produced 
by IVTT and further incubated with NaF to increase phosphorylation status of the 
CKIa, as described in 4.2.6. After removing 2p1 (5 %) of the lysate, the remaining 
34L1 was made up to 2O0111 binding buffer, divided in two and incubated with either 
GST or GST- 14 -3 -3 Ç. A parallel incubation was performed, substituting wild type 
GST- 14 -3 -3 , for GST- 14 -3 -3 Ç R5660A (figure 4.16). 
Surprisingly, mutation of these residues made no difference in the ability of 
14 -3 -3 to associate with CKIa. It is likely that only a small fraction of CKla would 
be phosphorylated in the reticulocyte, providing a small amount of phospho -CKl a 
available to associate through the classical phospho -peptide binding pocket in 14 -3 -3. 
It is therefore possible that intact CKIa associates with 14 -3 -3 not solely in a 
phosphorylation dependent manner, and a low affinity interaction with 
unphosphorylated CK1 is obscuring the effect of the binding mutant in figure 4.16. 
To test the possibility that unphosphorylated CK1 interacts with 14 -3 -3 with 
relatively low affinity, while phosphorylated CK1 interacts at higher affinity, repeat 
experiments were performed using 10- and 50 -fold less 14 -3 -3 wt to capture CK1 a 
from the IVTT lysate, in an attempt to selectively capture phosphorylated CK1 a. 
However, using less 14 -3 -3 showed an identical amount of CKIa being captured as in 
figure 4.16A (shown in figure 4.16B). 
Mutational analysis of 14 -3 -3 or y isoform would be ideal, as perhaps with 
a larger binding capacity, it would be more sensitive to mutations in the 14 -3 -3 
binding groove. Perhaps some 14 -3 -3 isoforms have a binding preference for 
phosphorylated proteins and others are not as selective. Compare ri with , in binding 
single, phosphorylated peptide S218, for example (figure 4.4). Also it would be 
interesting to see the effect of the K49E mutation on 14- 3 -3:CK1 binding. 
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Figure 4.16 Mutation of R5660A has no effect on CK1a association with 14 -3 -3 Ç 
A, HA-CKla was produced by IVTT, using 35S, with extra incubation with 5mM 
NaF and incubated with 10µg GST- 14 -3 -3 Ç wt or GST- 14 -3 -3 Ç R5660A protein. 
The GST- 14 -3 -3 was then captured with the addition of GSH beads. After washing 5 
times with lml NP -40 binding buffer, the bound CKla was separated by SDS -PAGE, 
stained /destained, dried and exposed to film. Top left panel shows a representative 
5% of the lysate incubated with each of the GST- 14 -3 -3s. The top right panel shows 
equal amounts of CKla binding to both the wt and R5660A 14 -3 -3s. A coomassie 
load control is shown underneath. B, Repeat experiment using 1µg and 0.2µg, as 
indicated, of GST- 14 -3 -3 to pull down CKla. Coomassie could not detect the 0.2µg 
14 -3 -3 loaded. 
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4.2.13. Inhibition of CK1 binding to 14 -3 -3 using 14 -3 -3 antagonists 
Results from the previous section suggest that CK1u may interact with 14 -3 -3 
through regions different from the amphipathic groove and thus through contact of 
residues different from R56 and R60. Mutation of R56 and R60 to alanine, may not 
preclude binding to all molecules, indeed the work of Fu et al have shown that a 
range of both charge reversal and neutral mutations within the amphipathic groove 
can have a dramatically different outcome on interactions with the same protein [ 134, 
135] (and see figures 1.2, 1.3 and 1.4 for location of residues involved in ligand 
contact). 
In order to firmly establish if CKla binds in the 14 -3 -3 groove, two 
established antagonists of 14 -3 -3 binding were used in an attempt to disrupt the 
interaction. One is a 14mer peptide corresponding to the region of Raf kinase 
incorporating pSer259, with a reported binding affinity to 14 -3 -3 of 120nM [451]. 
The other is a hybrid of two R18 peptides, known as Difopein (Dimeric fourteen three 
three peptide inhibitor) originally described in [30] and produced as a GST fusion for 
thrombin cleavage by Carolyn Brechin, The University of Edinburgh. The R18 
peptide was derived from a phage display screen and has a kD of 7 -9 nM [29]. 
Combination of two R18 peptides is likely to have a synergistic effect on 14 -3 -3 
binding, as a peptide with a tandem phosphorylated 14 -3 -3 motif decreased the kD 
from 730 to -20nM (30 fold) [15]. The 14 -3 -3 `inhibitors', R18 and difopein, were 
incubated with CKla (produced by IVTT, using 35S) and 14 -3 -3 wt, R5660A or 
14 -3 -3 ri wt at a 10 fold molar excess. Glutathione beads were used to capture the 
GST- 14 -3 -3, after a two hour binding period and after four washes in NP -40 buffer, 
the CK1 was visualised by SDS -PAGE, coomassie staining and autoradiography (see 
figure 4.17). The IVTT lysate used to produce CKla was also incubated with the 
phosphatase inhibitor NaF to attempt to increase the level of phospho-CK 1 a. 
Figure 4.17 (lanes 3 and 4) demonstrates that 14 -3 -3 c wt and R5660A 
mutant bind in a fashion very similar to that shown in figure 4.16, but in comparison, 
14 -3 -3 ri binds with higher affinity (see lane 5). This is in agreement with previous 
findings outlined in this chapter, from data using peptide binding experiments (figure 
4.4), in vitro assays using intact CKla (4.11) and in vivo binding assays from 
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transfected cells (4.10). Inclusion of the Raf peptide curiously increased the binding 
of 14 -3 -3 wt and R5660A to CKla (compare lane 3 and 4 to lane 6 and 7), but 
reduced the interaction with ri wt to background levels (compare lane 5, to lane 8). 
Parallel incubation using the difopein peptide, again, had a similar effect on 14 -3 -3 
wt and R5660A binding (lanes 9, 10); but almost completely removed 14-3-31 
interaction with CK 1 a (lane 11). 
These data indicate that CK1 a binds to 14 -3 -3 ì through the amphipathic 
groove, but this experiment, in itself, does not confirm it is a phospho -specific 
interaction. The interaction with 14 -3 -3 Ç appears more complex in light of these data. 
Results presented in figures 4.16 and 4.17 suggests, for two reasons that CKIa does 
not bind in the central groove of the 14 -3 -3 dimer. First, mutation of residues 
involved in coordinating contact with phosphorylated Ser /Thr residues had no affect 
on binding (figure 4.16). Secondly, 14 -3 -3 `binding inhibitors' did not reduce either 
wt or mutant 14 -3 -3 (figure 4.17) binding to CKIa. Blocking all possible interaction 
with the amphipathic groove by using the Raf peptide and difopein, shows 14 -3 -3 Ç 
interaction with CKIa must be mediated through other regions of 14 -3 -3. Perhaps 
phosphorylation of residues 218 and 242 cause a structural change in CKIa that 
increases the affinity to 14 -3 -3, through regions outwith the binding groove, 
explaining the lack of requirement of the binding groove. 
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Figure 4.17 Inhibition of CK1 binding to 14 -3 -3 using 14 -3 -3 antagonists 
CKla was produced by IVTT, and incubated with the indicated 14 -3 -3 isoforms in 
binding buffer alone (nothing added), phosphorylated Raf peptide (Raf- p259), or a 
double R18 peptide, known as Difopein (Difopein peptide). The GST- 14 -3 -3 was 
captured by GSH beads, extensively washed and separated by SDS -PAGE. The 
bound CK1 was visualised by coomassie staining and autoradiography. 
Binding of CKIa to GST- 14 -3 -3 was similar to control lanes (compare lanes 3 and 4 
with 2), possibly reflecting general binding to the GST moiety. 
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4.2.14. CK1a mutants retain autophosphorylation and catalytic activity 
To ascertain if the mutations of S218A and S242A altered normal enzymatic 
function of CKIa, in vitro kinase assays were preformed. First was to assess 
autophosphorylation activity and then transphosphorylation activity. To this end, 
CKla w/t and mutants were overexpressed in parallel in HeLa cells, 
immunoprecipitated, washed and incubated with radiolabelled [32P] -ATP and excess 
cold ATP (10011M) under kinase assay conditions. Transfected HeLa cells were 
chosen as the kinase source due to higher transfection efficiency (data not shown). 
Figure 4.18, top left panel shows an autoradiograph of CK1 a and mutants incubated 
in the presence of [32P] -ATP. Compared to wild type CKla, S218A shows a slightly 
lower level of autophosphorylation, whereas CKla S242A (with a Ser at 218) has a 
level similar to wild type. The S218A/S242A double mutant has a level similar to 
S218A mutant; suggesting that S218 is autophosphorylated in this assay. However, 
densitometry analysis of three repeat experiments show there is no significant change 
in phosphorylation of the mutants S218A and S242A, shown in figure 4.18, top left 
panel. It appears that mutation of these residues individually introduces more 
variation between experiments, whereas the double mutation S218A/S242A seems to 
have consistently lower phosphorylation levels, albeit by a small decrease of -15% 
±1.4. Equal amounts of CKla are present in each assay, as identified by coomassie 
blue staining shown in the panel below each autoradiograph panel, figure 4.18. 
Densitometry was performed on the autoradiographs and coomassie gel whereby each 
band was measured using ImageJ software (http: / /rsb.info.nih.gov /ij /) and the density 
of each mutation in CKla calculated as a percentage of wild type CKla in each 
experiment, therefore allowing a comparison between experiments to be made. 
To assess whether or not PKA could phosphorylate CKla in vitro, and if so 
on the sites 218/242, CK1 a was transfected and immunoprecipitated identically as 
described above, then incubated under kinase assay conditions with the inclusion of 
lU of recombinant PKA (New England Biolabs, USA). This had no appreciable 
effect on wild type CK1 a or on any of the mutants (figure 4.18, right hand panels). In 
fact these data most resemble the assay without PKA addition (left panels). 
Densitometry analysis of the autoradiographs from figure 4.18 and two repeat 
Chapter 4 - CK1 association with 14 -3 -3 154 
experiments are shown in figure 4.19. Identical analysis of the coomassie stained gels 
showed very little difference between each IP, indicating accurate loading and 
allowing a fair comparison of CKIa wild type and mutants (lower panels, figure 
4.19). 
These data suggest that PKA may not be the direct kinase that phosphorylates 
CK1. 


































Figure 4.18 Site -directed Mutagenesis of CK1 has little effect on 
autophosphorylation activity; Protein kinase A is unlikely to be the direct kinase 
responsible for phosphorylation of S218 and /or S242. 
15µg pcDNA3 (empty vector) or CK1a DNA was transfected into HeLa cells and 
lysed after 24 hours, immunoprecipitated with anti -HA pre- conjugated beads, washed 
in lysis buffer and equilibrated in kinase assay buffer, then incubated with [3 2P] -ATP 
for 30 min at 30 °C, with and without PKA (left and right panels), stopped in sample 
buffer, separated by SDS -PAGE, stained, dried and exposed to film. Autoradiographs 
are shown in the top panels and coomassie blue stained gels in the lower panels. 
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Figure 4.19 Densitometry of PKA incubation with CK1a. 
Autoradiographs from separate experiments were scanned and analysed using ImageJ 
software from http: / /rsb.info.nih.gov /ij /. Upper and lower error bars indicate standard 
deviation from the mean of three identical experiments, plotted using Sigmaplot 9.0. 
No significant difference is observed between mutants and wild type CK1. Lower 
panels indicate intensity of coomassie staining from each immunoprecipitation. 
Chapter 4 - CK1 association with 14 -3 -3 157 
4.2.15. CK1 site directed mutants phosphorylate a CK1- specific peptide 
with similar kinetics 
To assess transphosphorylation activity of CK1 mutants a similar experiment 
to that described in the previous section was performed, where HA -CK1 and mutants 
were incubated with a phospho -peptide substrate that is specific for CK1 - 
DDDEEpSITR, where pS is phosphorylated and which has a reported Km for CK1 of 
0.5 -1mM [452]. The purpose was to monitor if the mutations affect trans - 
phosphorylation by CK1 towards substrate, as the location of 5218 in particular has 
been postulated from the crystal structure to become autophosphorylated and 
potentially inhibit the enzyme [393]. The top left panel in figure 4.20 shows an 
autoradiograph of CKla wt and mutants in the same order as in figure 4.18, incubated 
under kinase assay conditions with [32P] -ATP. To visualise the peptides, the kinase 
reactions were stopped by boiling in Laemmli buffer and separated by 18% SDS- 
PAGE. Autophosphorylation of CK1 is visible near the top of the gel and it appears 
that S218/242A double mutation decreases autophosphorylation, consistent with the 
previous result (figure 4.18). Mutation of S218, S242 and double S218/S242 mutation 
appear to allow increased phosphorylation of peptide substrate. The right panel shows 
densitometry analysis of three identical experiments that report a slight increase, in 
the ability to phosphorylate the phospho -peptide. A coomassie stain did not reveal the 
peptides, but CK1 is visible, as indicated (bottom left panel, figure 4.20). These data 
suggest a slight, but consistent increase in kinase activity against a peptide substrate. 
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Figure 4.20 Effect of CK1 mutants on the ability of CK1 to phosphorylate a 
CK1- specific peptide substrate. 
CK1a w/t and mutants were immuno -precipitated from non -stimulated HeLa cells 
using anti -HA Abs, washed in lysis buffer, then incubated with a CK1 specific 
phospho- peptide and [321P -ATP for 30 minutes at 30 °C. Analysis of three separate 
experiments revealed no significant change in the ability of CK1 to phosphorylate 
substrate. Peptides could not be revealed by coomassie staining. Approximate 
positions of the markers are shown, although they are not widely separated on the 
18% gel. 
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4.2.16. 14 -3 -3 binds to other CK1 isoforms. 
To investigate the possibility of 14 -3 -3 binding to other CK1 isoforms, COS -7 
cells were transfected with HA -CK1s isoform and incubated with the GST- 14 -3 -3 r 
isoform, as previous experiments showed it to be the isoform that interacted with the 
highest affinity to CKla. The left hand panel in figure 4.21A shows a representative 
sample of 1% of transfected COS -7 lysate transfected with HA -CK1 c. The middle 
panel shows a GST- 14 -3 -3 ri pull down from the cell lysate. Equal amounts of GST 
or GST- 14 -3 -3 11 were incubated in the cell lysate for 2 hours, then after extensive 
washing, the bound CK 1 s was revealed by western blotting to the a -HA tag. Ponceau 
staining reveals equal amounts of GST and GST- 14 -3 -3 r) were incubated with the 
lysate (far right hand panel, figure 4.21A). The C- terminus of CKlc becomes 
hyperphosphorylated, causing autoinhibition of the enzyme [289] presumably by 
binding in or obscuring the active site such that it cannot access substrate. A similar 
regulatory mechanism has been observed for CK1S [395]. CKle contains an almost 
identical sequence around S218 compared to CKla and a totally conserved sequence 
around S242. The fact that CK1c binds 14 -3 -3 shows that the extended C- terminal in 
CK1c does not interfere with binding. As mentioned before, this region is highly 
conserved through CK1 isoforms, see alignment in figure 4.21B; it is likely therefore 
that other CK1 isoforms will also interact through the region around S218. 
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Figure 4.21 A, 14 -3 -3 'l binds to the CK1 s isoform in vitro. 
HA -CK1c was transfected into COS -7 cells, lysed and clarified by centrifugation. A 
sample of 1% of the lysate is shown in the left hand panel. Equal amounts of GST or 
GST 14 -3 -3 rl were incubated with the lysate for 2 hours, the GST /GST- 14 -3 -3 rl 
recovered by GSH beads and separated by SDS -PAGE. Western blotting with a -HA 
antibody revealed the presence of CKle in the GST- 14 -3 -3 pull down, but not the 
GST control (middle panel). Protein loading control is shown in the right hand panel. 
B, Sequence alignment around potential 14 -3 -3 binding region - showing conserved 
residues at positions 218 and 242. 
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4.2.17. PKC Phosphorylates Centaurin -a1 on residue S87 and T276. 
Intrigued by the behaviour of Centaurin -a1 and its inability to bind 
phosphorylated CK 1 a, experiments were designed to further investigate this 
interaction. Work in our laboratory by Thierry Dubois showed that centaurin -a1 could 
associate with CK1 through the same nonphosphorylated region, shown here to bind 
14 -3 -3 [419]. Further studies then identified centaurin -a1 not only as a binding 
partner of PKC, but also a substrate for all classes of PKC [453]. Phosphorylation 
may well affect the regulation of centaurin -a1 and in doing so possibly perturb some 
of the important roles of centaurin -a1, for example, centaurin -al is a PIPS dependent 
ARF6 GAP [454]. However, the particular interest here was the interaction of 
centaurin -a1 with CKIa and the potential involvement of 14 -3 -3 in this binding 
process. For example, if 14 -3 -3 binds phosphorylated CK1 a, could this block the 
ability to bind centaurin? If centaurin was phosphorylated, could this affect the 
interaction with CKla? 
Identification of the phosphorylation site(s) was therefore undertaken to 
determine which domain of centaurin -a1 may affected by phosphorylation. To this 
end centaurin -a1 was incubated with PKC in vitro, followed by trypsin digestion, 
separation of peptides by HPLC and solid phase sequencing. Figure 4.22A shows that 
Centaurin -a1 was phosphorylated by PKCa, H. and s. As PKCa phosphorylated 
centaurin -a1 with highest stoichiometry, this band was excised and digested with 
trypsin as outlined in Materials and methods. Cerenkov scintillation counting showed 
>50,000cpm in the band originally, with >20,000cpm recovered after trypsin 
digestion/peptide extraction. This provided plenty of activity to follow the elution 
profile over HPLC. After separation of the peptides by reverse phase HPLC (figure 
4.22B), the fractions containing the activity were first analysed by mass spectrometry 
(by Rob Wakefield to identify the peptides: (fractions 6 and 7) - FESK and ARFESK) 
and (fractions 43 and 46) - WFTMDDR and WFTMDDRR. Automated solid phase 
Edman degradation (by Alastair Aitken and Andy Cronshaw) further showed 
radioactivity released during cycle 3 and 5 in the first peptide and cycle 3 in the 
second peptide, corresponding to FES87K/ARFES87K and WFT276DDR respectively 
(figure 4.22C). The locations of these phosphorylation sites within the centaurin -a1 
primary structure are shown in figure 4.23C. 
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Figure 4.22 PKC phosphorylates Centaurin -a1 on residues S87 and T276 
A, Recombinant PKC from all classes was incubated with recombinant centaurin -al 
in the presence of [32P] -ATP. B After excision and tryptic digestion of the bands from 
A, the peptides were separated by reverse phase HPLC and the fractions counted by 
Cerenkov counting. Online ms analysis identified the peptides FESK, ARFESK in 
fractions 6/7 and WFTMDDR in fractions 43 /46. C, Solid phase sequencing revealed 
which residue was phosphorylated. Figure published in [453]. 
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4.2.18. Phosphorylation of Centaurin -a1 by PKC negatively affects 
interaction with CK1 a 
Having established the phosphorylation sites on centaurin -ai, binding assays 
were performed on phosphorylated centaurin -a1 to assess the effect of 
phosphorylation on the interaction with CKla. To this end, CKla was produced by 
IVTT, using 35S incorporation, followed by incubation with GST or GST- centaurin -a1 
that had been phosphorylated (prior to binding) by PKCc. Controls incubations were 
preformed whereby the bait proteins, GST and GST- centaurin -a1, were incubated 
under kinase assay conditions for 30 minutes prior to incubation with the CKla 
lysate. After incubation at 4 °C for 2 hours and extensive washing in NP -40 buffer, the 
pull downs were analysed by SDS -PAGE, coomassie staining and autoradiography. 
The top panel in figure 4.23A shows an autoradiograph of CKla captured to varying 
degrees by GST- centaurin -al. A representative 5% of the CKla lysate is shown in 
lane 1. A GST control is shown in lane 2, followed by GST- centaurin -a1, also 
incubated under kinase assay conditions, but lacking PKC and lane 3 shows GST- 
centaurin-ai incubated with PKCE. PKCE phosphorylation of centaurin -a1 reduces 
association with CKla, by a small, but reproducible amount, as demonstrated in 
densitometry analysis of three separate experiments, shown in the right hand panel. 
Further studies are required to ascertain if phosphorylation of one or both 
residue(s) S87/T276 is required to abrogate the interaction with CKla. The residue 
S87 lies outwith any recognised functional domain and T276 lies N- terminal of the 
second PH domain (figure 4.23C). However, phosphorylation on T276 is unlikely to 
perturb binding to phosphoinositides, as the alignment of several PH domains places 
T276 a considerable distance from the residues that contact bound phosphoinositides 
(see figure 4.23B). Of course, the three dimensional structure of the intact protein 
may well position the other phosphorylation site (S87) near the phosphoinositide 
binding site. The data shown here suggests that CK1 a could bind close to either 
phosphorylation site, or that phosphorylation creates a larger structural change in 
centaurin -a1, obscuring another CK1 binding site. 
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Figure 4.23 Phosphorylation of centaurin -a1 by PKCE impairs association with 
CK1a. 
A, HA -CK 1 a was produced in an IVTT system and incubated with GST and GST- 
centaurin -a1 that had been previously phosphorylated by PKCB. Mock assays lacking 
PKCB showed that the kinase assays conditions (DAG mimetic/PS and 30 °C for 30 
minutes) did not affect binding. Densitometry of three repeat experiments is shown in 
the right panel. B, Left panel, Sequence alignment of PH domains from crystal 
structures complexed with phosphoinositides, including the second PH domain in 
centaurin -a1 (top sequence). T276 is indicated by the arrowed box. Right panel shows 
the crystal structure of the PH domain from PDK1, bound to Ins(1, 3, 4, 5)P4 in red 
and the relative position of the phosphorylation site at T276 in blue. C, location of 
centaurin -a1 phosphorylation sites in the primary structure. 
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4.2.19. Computer modelling of 14 -3 -3 and CK1a 
14 -3 -3 has been shown to be a substrate for CKla and the fact that 14 -3 -3 
binds to CK 1 a in a phospho- dependent manner from data presented here suggests the 
possibility of simultaneous binding and phosphorylation of 14 -3 -3. A possible 
explanation for the result of CK1a binding 14 -3 -3 in figure 4.15 where S242A 
mutation had significantly more impact than S218A on 14 -3 -3 binding, could be that 
S242 is the high affinity binding site, followed by S218 binding as the low affinity 
site, suggested as a general binding mechanism by Yaffe [139]. As the crystal 
structure of a truncated CK1 and 14 -3 -3 are known [131, 393], computer docking 
simulations were performed to identify a possible binding conformation and see if (at 
least in silico) 14 -3 -3 could bind CK1 in a conformation where each 14 -3 -3 monomer 
contacts a phospho -S218 and phospho -S242. The structure co- ordinates 1 QJB.pdb 
and 1 CKI.pdb were manually edited to remove water molecules, before being 
uploaded to the ClusPro site ([447] and http: / /nrc.bu.edu /cluster /) and modelled using 
the ZDOCK program under standard parameters. Figure 4.24 shows one of the most 
probable conformations between the two molecules. In figure 4.24A and B are shown 
wire mesh representations of the modelled interaction. When residues 218/242 are 
binding into the binding groove (purple and orange residues, respectively) it can be 
seen that S233 (marked in pink) would be unlikely to reach residue D136 of the 
active site, marked in dark blue. Panels C and D show the close proximity of the CK1 
218/242 regions to the 14 -3 -3 binding pocket; with S218 considerably further from 
the binding pocket compared to S242. Distances were calculated using PyMol and are 
shown between residues corresponding to S218/S242 peptide backbone and residues 
within the phosphate binding pocket of 14 -3 -3 (panels E and F, figure 4.24) and are 
summarised in the table in figure 4.24. For comparison, distances between a phospho 
peptide bound to 14 -3 -3 are shown in panel G. In this orientation, the distances 
appear to be too great for a pS218 and a pS242 to bind in the phospho- binding 
pockets of the same 14 -3 -3 dimer, i.e. the CK1 molecule would have to undergo large 
conformational changes to reach both pockets simultaneously. The rigid structure of 
14 -3 -3 would be unlikely to change conformation to accomadate simultaneous 
binding of these two residues. Another combination (not shown) placed 5218 of CK1 
near a 14 -3 -3 binding pocket, but concordantly S242 was moved out of reach of the 
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other binding pocket. Further manual analysis was performed by Paul Taylor (The 
University of Edinburgh) who also found the likelihood of two site binding unlikely 
without large structural changes. As always with computer modelling, these results 
must be interpreted with caution, but they do suggest that CK1 could comfortably 
bind either of the S218 or S242 residues, but perhaps not at the same time. 
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Distances to Ser peptide backbone at: 
S218 S242 1QJB 
K49 11.68 6.33 6.47 
R56 11.81 4.80 7.83 
R60 10.23 4.80 9.20 
R127 15.65 11.60 5.63 
Y128 15.95 10.74 7.17 
Figure 4.24 A -F Predicted CK1:14 -3 -3 interaction. CK1 is represented in blue, 14- 
3-3 in green; residues that co- ordinate ligand binding to 14 -3 -3 are in red; D136 in the 
active site of CK1, dark blue; S218 of CK1, purple; S242 of CK1, orange; S233 of 
14 -3 -3, pink. Produced using PyMol from coordinates from 1QJB.pdb (14 -3 -3 zeta) 
and 1 CKI.pdb, using ZDOCK, on the ClusPro server [447], see text for further 
details. Measurements in table are in Angstroms. 
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4.2.20. Discussion 
In this chapter, several approaches were used to examine the interaction 
between 14 -3 -3 and CK1. CK1a was shown to bind all 14 -3 -3 isoforms, but to 
differing degrees and also depending on assay type. Initial experiments showed a 
phosphorylated peptide corresponding to 214 -226 (CFNRTpS218LPWQGLKA) of 
CKla preferentially bound 14 -3 -3 isoforms q, y, ß, i, E, Ç and a sigma, in a 
phosphorylation dependent manner, in that order. This region is conserved among 
CK1 isoforms (see figure 4.21B). In other experiments, the binding varied slightly, 
see table 4.1, but in vivo binding studies were in broad (except E, see below) 
agreement with the in vitro experiments (using intact 14 -3 -3 and CK1a) in identifying 
14 -3 -3 11 and y as the strongest interacting proteins. 14 -3 -3 c binding seemed of 
higher affinity in vivo (figure 4.10). Another result that suggested isoform specificity 
is that the isoform 14 -3 -3 a was unable to bind intact CK1a from cell extracts (figure 
4.11). 
Table 4.1 summary of 14- 3 -3:CK1 interactions 
Experiment 
Phospho -peptide 
GST- 14 -3 -3 pull down 
CK1a IP, WB 14 -3 -3 





T1, y, j3, r, E, Ç and a* 
11, y, ß, t, Ç, a* 
11, y, 8, i3, 
* 14 -3 -3 a was barely detectable 
+ 14 -3 -3 i or a were not detected in HEK293 cell lysates used, therefore they are not 
included. 
There are many examples in the literature of 14 -3 -3 binding in an isoform- 
specific manner, for example: Cbl, CLIC4, IGF -1, NFAT3, PKCÇ and Par3a, as 
discussed in section 1.2.6 and see table 1.3, although the issue of isoform binding 
specificity is often not fully addressed in the literature. Data presented here suggests a 
binding preference exists for CKIa, listed in the table above. Binding experiments 
using a phosphorylated peptide incorporating residue S218 revealed not only 
differences in 14 -3 -3 isoform binding, but also differences in phospho- dependent 
binding. Further analysis of the data revealed a difference in sensitivity toward 
phosphorylation, represented in figure 4.4B. After dephosphorylation, most 14 -3 -3 
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isoforms displayed a very similar reduction in binding (-70-80% reduction). 14 -3 -3 
showed the biggest reduction (-92%) of binding and 14 -3 -3 11 showed the smallest 
change in binding (-43% reduction). Of course these data are only for one interaction 
site on CK1 a; presence of another binding site would be expected to alter overall 
interaction of 14 -3 -3 and CK1. 
The interaction with intact CK1 appears to be phospho -specific, as inhibition 
of phosphatases in the IVTT lysate (figure 4.7) led to a decrease and an increase in 
binding respectively; in agreement with the phosphopeptide studies. However, the use 
of CK1 truncation mutants identified at least one other binding site on CK1 a (figure 
4.8C). The truncation mutants of CKla were all produced by IVTT and incubated 
with phosphatase inhibitors to maximise phosphorylation of the CK1 fragments. 
To assess the in vivo binding characteristics of intact 14 -3 -3 and intact CK1, 
HA- tagged CKla was immunoprecipitated from cells and western blotted for 14 -3 -3 
isoforms (figure 4.10). These data showed an isoform binding preference very similar 
to the phospho 5218 peptide binding results, although ß and were substantially 
lower. In vitro binding studies in which GST- 14 -3 -3 isoforms were incubated with a 
cell lysate enriched with CK1 a (figure 4.11) produced a similar result (see table 4.1). 
Confidence that the pS218 region is a valid interaction site was drawn from these 
results as it has very similar binding preferences as the phosphorylated peptide 
experiment, indicating involvement of this site. 
To try to identify further binding sites on 14 -3 -3, as suggested by the 
truncation mutant data, site directed mutagenesis of residues 5218 and another serine 
(S242) within a potential 14 -3 -3 binding site was performed. S242 was detected as 
the only other canonical 14 -3 -3 consensus, using the scansite facility [272]. Before 
transfecting these mutants into cells, preliminary experiments designed to increase 
phosphorylated CKIa in vivo were performed on wild type CKIa. To this end, cells 
that had been transfected with HA -CKIa were stimulated with the cAMP mimetic 
dibutyryl cAMP (db -cAMP) and a -HA -CKIa immunoprecipitates were then probed 
with a- 14 -3 -3 ri antibody to assess binding. A time -dependent increase in binding was 
observed and for further studies a stimulation time of 10 minutes was used - 
identified as the time point that showed maximal binding. Mutagenesis of 5218 to 
alanine reduced binding to 14 -3 -3, a S242 -A mutant dramatically reduced 14 -3 -3 
Chapter 4 - CK1 association with 14 -3 -3 170 
interaction and the double S218/S242 double mutation completely abrogated binding 
in cells (figure 4.14). A further experiment was performed using an inhibitor of PKA, 
which was shown to reduce the interaction with 14 -3 -3 (figure 4.15). Modulation of 
PKA activity in HEK293 cells affected the amount of 14 -3 -3 association with CK1, 
suggesting the interaction can be regulated in vivo, even if not directly by PKA. 
Experiments were performed to check the integrity of the CK1 a S- *A mutants by 
way of in vitro kinase assay. Although unlikely, mutations to alanine could alter the 
local structure of CKla in such a way as to decrease binding to 14 -3 -3, not just due to 
removal of a phosphorylatable residue. In vitro kinase assays of CK1 S-+A mutants 
revealed that the region responsible for phospho -specific binding to 14 -3 -3 may play 
a role in substrate recognition, as a double S218/S242A mutation increased the 32P 
incorporation into a CK1- specific substrate. After these experiments had been 
performed, the group of Pinna et al showed various point mutations (Q -*(), near the 
S218/S242 region altered the specificity of CKIa towards pre -phosphorylated 
substrates [455], discussed further in chapter 6. 
To investigate exactly how CKIa interacts with 14 -3 -3, a mutant of 14 -3 -3 
was employed whereby residues known to contact phosphorylated residues within 14- 
3-3 ligands had been mutated to alanines. The mutant, known as R5660A, showed 
surprisingly little difference in its ability to bind CKIa from an IVTT system, which 
had been incubated with phosphatase inhibitor. Even repeating the experiment with 
50 times less 14 -3 -3, in a bid to remove `background' binding, resulted in no 
difference between wild type and mutant. 
Further experiments using established inhibitors of 14 -3 -3 binding were used 
for in vitro binding assays. One was a phospho -peptide corresponding to residues 
around Raf pS259 and the other a tandem repeat of the peptide `R18', called difopein. 
Both 14 -3 -3 antagonists abrogated binding to 14-3-31, but had the curious affect of 
increasing binding with 14 -3 -3 wt or R5660A mutant (figure 4.17); firmly 
indicating that CKIa binds into the central groove of 14 -3 -3 r, but creating a 
complex picture of how 14 -3 -3 binds. 
The highly conserved nature of 14 -3 -3, in particular within the binding 
pocket, suggests very subtle binding differences must exist - to explain exactly how 
the same ligand can preferentially bind different 14 -3 -3 isoforms. The interaction of 
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CK1 a occurs, most probably, through contact with the basic pocket within 14 -3 -3 ri, 
and is potentially further mediated through different contacts within the 14 -3 -3 dimer, 
perhaps aiding the observed isoform binding specificity. 
One rationale to explain 14 -3 -3 i binding to CKIa in a phospho dependent 
manner within the amphipathic groove, in contrast to 14 -3 -3 (, must be that 
phosphorylation of CKl a causes an unknown structural change that increases its 
affinity toward 14 -3 -3 . 
Further experiments to investigate other CK1 isoform binding 14 -3 -3 showed 
that CK1e bound 14 -3 -3 p. 14 -3 -3 may interact with all CK1 isoforms, as the region 
-214 -226 is highly conserved. However this region may well have a specific 
repertoire of binding molecules, as recent studies have found this region in CK16 
could not interact with MAP1A [456], suggesting it is not the only interaction region 
within CK1. The region around S242 is slightly less conserved (figure 4.21B) and 
may help to confer more 14 -3 -3 isoform binding specificity. 
Computer modelling of CK1 and 14 -3 -3 produced a feasible model as to how 
the two may interact. It placed S242 within binding distance of one binding pocket 
and 5218 close to the other, but with a fairly large structural movement required to 
accomadate simultaneous binding (figure 4.24). 
Centaurin -al was shown to bind only the dephosphorylated sequence around 
S218 on CK1 (figure 4.6). Phosphorylation of CK1 could therefore modulate the 
interaction with centaurin -a1 and thus its localisation. Further experiments using mass 
spectrometry and solid phase sequencing identified the PKC phosphorylation sites on 
centaurin -al. In addition, preliminary data suggest PKC phosphorylation of these sites 
negatively affects the interaction with CKIa. The location of the phosphorylation 
sites within centaurin -a1 suggests phosphorylation is unlikely to interfere with 
phosphatidylinositol binding (see figure 4.23). 
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CHAPTER 5 
Antibody Purification 
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5. Phospho- specific antibodies against 14 -3 -3 
5.1. Introduction 
14 -3 -3 binding can be regulated by phosphorylation of 14 -3 -3 itself, as 
discussed in chapter 1. We have previously shown that a and 8 were phosphorylated 
forms of f3 and respectively and are more than 50% phosphorylated on Ser185 in 
brain 14 -3 -3 [7], but we have found no evidence for phospho -forms in a wide range 
of other tissue types and cell lines. 14 -3 -3 ß,l1 and isoforms of 14 -3 -3 (but not E 
and y although they also contain serine at the equivalent site) are phosphorylated by a 
sphingosine- dependent kinase, SDK1, now identified as the kinase domain of PKCS 
produced after caspase -3 cleavage [166]. Phosphorylation on Ser58 may disrupt 
dimer formation, but has had different reported outcomes in regard to binding 
partners (see chapter 1). Phosphorylation of 14 -3 -3 by BCR could affect the ability of 
14 -3 -3 to bind other signalling proteins, for example our laboratory has shown that 
phosphorylation of 14 -3 -3 by CK1 negatively regulates binding to Raf in vivo [172]. 
Phosphorylation of S185 increases the efficacy of 14 -3 -3 as an inhibitor of PKC [7]. 
Serine 185 is located in the tertiary structure adjacent to residue 233 [421] and the 
group of Gotoh [ 170] have recently shown that activated JNK promotes Bax 
translocation to the mitochondria through phosphorylation of 14 -3 -3 a and at sites 
equivalent to Ser185 which led to dissociation of Bax. Expression of phosphorylation 
defective mutants of 14 -3 -3 blocked JNK- induced Bax translocation to mitochondria, 
cytochrome C release and apoptosis. 
To further examine the functional consequence of 14 -3 -3 phosphorylation, 
attempts were made to produce phospho -specific antibodies to the S185 and S233 
sites of 14 -3 -3 Ç, as outlined in this chapter. 
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5.2. Purification of Phospho S185 antibody using peptide affinity 
chromatography 
The peptide EILNpS185PEKAC (` SPEKA' peptide) was coupled to maleimide 
activated KLH and injected subcutaneously into three sheep, carried out by 
Diagnostic Scotland (see Materials and methods for details). The serum from the one 
animal that responded well was clarified by centrifugation at 40,000RPM (125,000g) 
for 1 hour and then passed through a 0.2 micron filter. The SPEKA peptide was 
coupled to sulfolink beads in the same way as in chapter 4 and detailed in Materials 
and methods. A separate peptide was synthesised with exactly the same sequence, but 
without a phosphorylated serine. The clarified serum was passed first through the 
dephospho SPEKA column four times, before being passed through the phospho- 
SPEKA column four times. After extensive washing of each column, the antibodies 
were eluted with 200mM acetic acid directly into Tris base to neutralise each fraction 
immediately. Each fraction was checked to ensure that pH 7 -8 had been reached, 
before being incubated with dot blots onto nitrocellulose paper that had either the 
phospho or dephospho peptide spotted onto it. Figure 5.1 shows the scheme for 
purification and representative dot blots from fraction 3. The antibody seemed very 
specific toward the phospho peptide (compare bottom panels, left versus right). Also, 
the dephospho peptide elution had a preference for the dephospho peptide (compare 
top panels, left with right, figure 5.1). 
However, to see how the antibody performed on intact proteins, each elution 
was incubated by western blot with recombinant 14 -3 -3 ß, and homogenised sheep 
brain (figure 5.2). Fraction 3 gave the clearest difference between sheep brain (where 
approximately 50% of the 14 -3 -3 is phosphorylated [7]) and recombinant 14 -3 -3 
(unphosphorylated). Considering the molar amount of 14 -3 -3 in the recombinant 
protein lanes compared to whole brain lysate, the specificity seemed good. However 
many cross -reacting bands can be seen, especially in fractions 3 -6, so this would limit 
the use of the antibody to western blotting. 
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Figure 5.1 A Scheme showing stages of antibody purification. After passing serum 
through each peptide column (1 and 2), 4 Column columns of wash buffer was passed 
through (3), finally the antibody was eluted using acetic acid (4) into Tris base (5). B. 
Dot blots of SPEKA /pSPEKA peptides. Each peptide was dissolved in water at a 
concentration of 1 mg /ml and the indicated amount spotted onto nitrocellulose. After 
blocking, each nitrocellulose strip was incubated with fraction 3 at a dilution of 
1:500. HRP conjugated anti -sheep antibody was used at 1:2000, before being 
developed with ECL 
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Figure 5.2 A. Western blotting of recombinant 14 -3 -3 ß, and sheep brain 
extract. 10µg of recombinant protein and 20µg total protein from a sheep brain lysate 
was loaded, as indicated onto an SDS -PAGE gel and transferred to nitrocellulose. 
After ponceau staining, the nitrocellulose was cut into strips, blocked and incubated 
with antibody elutions 1 to 6. The strips were re- aligned, incubated with ECL and 
exposed for the same length of time. A ponceau load control panel is shown in B. 
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5.2.1. Sensitivity of the pSPEKA antibody 
To ascertain the lower detection limit of the antibody, serial dilutions of brain 
homogenate were separated by SDS -PAGE, transferred to nitrocellulose membrane 
and blotted with the same concentration of pSPEKA antibody. Figure 5.3 shows the 
pSPEKA antibody incubated with increasing amounts of sheep brain homogenate and 
recombinant 14 -3 -3 Ç A ponceau stain is shown as a load control underneath. As 
little as 21.1g total brain homogenate, is sufficient to provide a strong signal at 30kDa, 
however more bands are recognised as the amount of protein is increased, see the 
right hand lanes. 
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Figure 5.3 Serial dilutions of sheep brain, incubated with pSPEKA antibody. 
Fraction 3 was diluted 1:1000 into a 1% BSA solution, in TBS -T and incubated as 
described in Materials and methods. A ponceau stain of the western blot is shown in 
the lower panel, indicating overall protein loading. 
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5.2.2. Purification of Phospho S233 antibody 
Phosphorylation of S233 on 14 -3 -3 isoforms has important regulatory 
consequences as discussed above and in chapter 1. In an attempt to produce 
antibodies against phosphorylated (pS233) 14 -3 -3 two phospho peptides were used, 
corresponding to the region around S233, as described in Materials and methods. One 
peptide had a cysteine at the N- terminus (CWTSDpT233QGDE), the other at the C- 
terminus (WTSDpT233QGDEC); however these peptides did not elicit an 
immunogenic response from the animal, despite using a number of strategies. This 
included multiple antigenic peptides (MAPs) that were used to immunise the sheep. 
The MAP system [457] allows a large number of peptides to be chemically coupled 
directly onto radially branched lysine side chains, allowing significantly increased 
exposure of the antigen. Different combinations of boost immunisation using BSA 
and MAP linked peptides were used, but no serum collected from these animals 
produced a good immunogenic response. 
In a bid to circumvent this problem, a longer peptide corresponding to this 
region (CTLWTSDTpT233QGDEAEAG) was produced for the production of a 
phospho -specific antibody. This relatively long peptide was chosen with the intention 
of creating a good antigenic response, although the large size may trigger production 
of several different, non -pS233 specific antibodies. To try and purify specific 
antibodies from the serum, two shorter peptides used for the original immunisation 
were used to affinity purify the antibodies. The peptides were immobilised using the 
sulfolink beads and binding efficiency estimated using Ellman's reagent (see 
Materials and methods). The serum was clarified by centrifugation and passed 
through each N- or C- terminal linked peptide column in the same manner as in figure 
5.1, except without a dephospho peptide column first. Figure 5.4 shows each antibody 
elution incubated against recombinant 14 -3 -3 and 20µg sheep brain homogenate. 
The antibody clearly recognises 14 -3 -3 from both sources, indicating little 
phosphorylation specificity. However the amount of 14 -3 -3 used was, in molar terms, 
very high compared to that found in 2O111 total sheep brain. The antibody however 
does recognise 14 -3 -3 with very little or no background. 
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Figure 5.4 Testing of anti S233 antibody 
Odd numbered lanes show 5µg of recombinant 14 -3 -3 (. Even numbered lanes show 
20µg whole brain lysate. Fractions 1 -6 are acetic acid elutions, G and G2 are 2M 
guanidine elutions. Ponceau stain confirmed equal loading as in 5.2 (data not shown). 
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5.2.3. Cross reactivity of the 233L antibody 
The sequence used to create the antibody corresponds to a relatively variable 
region of 14 -3 -3, with mainly conserved substitutions around residue 233. A 
sequence alignment around this region, between all 14 -3 -3 isoforms, is shown in 
figure 5.5C, with the zeta sequence in bold, underlined. Experiments were therefore 
performed to ascertain which isoforms would cross react with the 233L antibody. 
Recombinant 14 -3 -3 isoforms were prepared as described in Materials and methods, 
separated by SDS -PAGE and western blotted using the 233L antibody as shown in 
figure 5.5A. Two exposure times are shown, for each N- and C- terminal peptide 
elution (upper and lower panels in 5.5.A), ponceau load controls are shown in 5.5B. 
The antibody did predominantly recognise 14 -3 -3 , but was not specific; other 
isoforms are visible on the longer exposure (60 min) - the cross reactivity with y, r), s 
is summarised in figure 5.5C. 
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Figure 5.5 Cross reactivity of T233L antibody with other 14 -3 -3 isoforms. 
A, All GST- 14 -3 -3 isoforms were purified as described in Materials and methods. 
Approximately equal amounts of protein were separated by SDS -PAGE, transferred 
to nitrocellulose and western blotted using a 1:500 dilution of each (N- or C -) elution 
of the T233L antibody. A longer exposure (60 min.) is shown in the lower panel. B, 
Ponceau stain shows equal 14 -3 -3 loading. C, sequence alignment of 14 -3 -3 isoforms 
around the sequence used to raise the T233L and a summary of the findings in A, 
indicating cross reactivity between isoforms. 
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5.2.4. Immunoprecipitation of 14 -3 -3 using T233L antibody. 
Immunoprecipitation of endogenous 14 -3 -3 from cell or tissue lysates would 
be an advantageous method for studying 14 -3 -3 binding partners. However many 
antibodies are not suitable for this purpose, perhaps due to most being raised to 
sequences that are inaccessible in the tertiary structure. A good example is our N- 
terminal 14 -3 -3 antisera where the epitope is in the dimer interface. The use of an 
epitope that corresponds to an exposed region may be poorly immunogenic. The 
mechanism that prevents animals from recognising `self would be unlikely to 
produce significant amounts of Ig against an antigen found within the animal itself. 
As this antibody was raised to a sequence within the C- terminal region of 14 -3 -3, that 
is an exposed, unstructured region [131], experiments were performed to determine if 
the antibody could immunoprecipitate 14 -3 -3 from cell lysates. A cell lysate was 
prepared fresh from HEK293 cells and also a rat brain was homogenised as described 
in Materials and methods. Approximately 2.5mg of each lysate was incubated first 
with 101.ig of the T233L antibody, overnight at 4 °C, with gentle rotation, followed 
by addition of protein A:G sepharose beads to capture the antibody. After extensive 
washing, the immunoprecipitations were separated by SDS -PAGE and stained with 
coomassie blue (figure 5.6). Control immunoprecipitations were performed with an 
antiserum raised against a non -cognate peptide (control IgG). It is apparent that the 
control antibody consists of a different class of Ig molecules, as observed by 
coomassie staining (middle lanes of each panel). A 20µg sample of the cell/brain 
lysate incubated with the antibodies is shown in the left hand lane of each panel. 
Immunoprecipitated 14 -3 -3 is indicated with an arrow and was purified from both 
cell lysates. This does not suggest that 14 -3 -3 is phosphorylated in these cell lines. 
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Figure 5.6 Immunoprecipitation of 14 -3 -3 from cell and tissue lysates 
l00111 of the 233L antibody from fraction 3 was incubated with either clarified 
HEK293 lysate or rat brain lysate overnight at 4 °C, with gentle rotation. Equal 
amounts of protein A:G beads were added to capture the antibodies, the beads were 
extensively washed, boiled and visualised by SDS -PAGE and coomassie blue 
staining. 
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5.2.5. Discussion 
The production and purification of phospho- specific antibodies is an 
extremely useful, if not essential, process to fully understanding protein 
phosphorylation events in biological systems. The characterisation here of an 
antibody specific for phosphorylated S185 on 14 -3 -3 will greatly aid future work 
regarding 14 -3 -3 regulation. The discovery during these studies of the kinase capable 
of phosphorylation of 14 -3 -3 on S185 [170] also opens up many possibilities for 
future work. 
Although the pSPEKA antibody recognises proteins of different molecular 
sizes (see figure 5.3) it is worth noting that even monoclonal antibodies against 
pSer /pThr motifs have broad sequence specificity. For example, the Biomol (Exeter, 
UK) antibody 16B4 recognises pSK as well as the pSP motif [458]; other 
monoclonal antibodies recognise similarly variable sequences [458]. Therefore, it is 
likely to be impossible to purify the antibody further, as removal of the Ig class that 
recognise other bands in the lysate (not at 30K), would be the very antibodies that 
recognise phosphorylated 14 -3 -3. 
Attempts to produce a phospho -specific antibody to phosphorylated S233 on 
14 -3 -3 were unsuccessful, but did produce a very clean antibody, that would be 
useful for in vivo staining of 14 -3 -3 by indirect immunofluorescence or 
immunoprecipitation, as suggested in figure 5.6. The antibody does show cross - 
reactivity to other isoforms that would preclude its use for identifying specific 14 -3 -3 
isoforms. 
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CHAPTER 6 
General Discussion 
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6. General Discussion 
The aim of this investigation was to further characterise the interactions 
between 14 -3 -3 and other signalling molecules, in particular kinases that 
phosphorylate 14 -3 -3. 14 -3 -3s have a history of regulating enzyme activity through 
molecular constraints or directing the sub -cellular distribution of bound enzymes (see 
chapter 1). The interaction of BCR and CK1 with 14 -3 -3 was examined in separate 
studies using a number of methods including in vitro binding assays, peptide affinity 
assays, kinase assays, site directed mutagenesis and immunoprecipitation from cell 
lysates. The use of antibodies specific to 14 -3 -3 isoforms and purified recombinant 
14 -3 -3 protein allowed the identification of isoform binding specificity to be 
determined for both BCR and CK1, discussed in chapters 3 and 4 respectively. 
This chapter provides a summary of results presented in this thesis and 
potential roles for association of BCR and CK1 with 14 -3 -3 are discussed. 
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6.1. BCR 
The number of 14 -3 -3 isoforms known to bind BCR is herein increased to six: 
ß, Ç, r, rl, y and s, with a shown not to interact in vitro. The fact that only i and are 
substrates for BCR (figure 3.4) suggests that all the isoforms may be binding for 
reasons other than for the purpose of phosphorylation, perhaps to modulate kinase 
activity or alter subcellular location. The isoforms that are not phosphorylated do not 
possess a Ser /Thr residue at position 233. This, combined with site directed 
mutagenesis firmly proved residue 233 as the site of phosphorylation. It is pertinent 
to note that the isoforms rl and y are not substrates, yet have the highest binding 
affinity to BCR. Phosphorylation of the 14 -3 -3 ß, , and a isoforms, on S185, reduces 
the binding capacity of 14 -3 -3 [145, 170, 172]. Phosphorylation of 5233 also reduces 
interaction with ligands [ 145, 172], therefore the binding of unphosphorylatable 14 -3- 
3 isoforms could allow a longer association time. For example, the binding of the n, y, 
E, and ß isoforms to BCR could allow a more stable interaction with Raf -1 kinase 
[187]. Indeed the tertiary complex observed in COS cells for BCR, 14 -3 -3 and Raf -1 
was with the 14 -3 -3 ß isoform [187]. No functional consequence has been reported 
for the association of BCR with Raf -1 through 14 -3 -3, but 10 times more BCR/Raf 
complex was found in the membrane fraction compared to the cytosolic fraction 
[ 187]. Raf -1 kinase can associate with a great number of proteins and the activation 
and regulation is therefore particularly complex [279]. Recently, BCR has been found 
localised at the cell membrane in polarised Calu -3 (lung epithelial) cells [253]. The 
authors also found BCR co- localising with proteins associated with coated vesicles 
and the trans -Golgi network [253], indicating a potential role for BCR in these 
processes. BCR was also shown to associate with two PDZ domain containing 
proteins called PDZK1 and Mint3 [253]. Both interact through the C- terminal 
`STEV' domain of BCR at intracellular junction of cultured epithelial cells [253]. It is 
interesting to note that BCR does not interact with 14 -3 -3 a as shown in this study 
(figure 3.5), when considering that 14 -3 -3 a is highly expressed in this cell type [2, 
189]. That the two cannot interact, suggests the potential outcome of binding would 
be highly deleterious to the cell, perhaps by 14 -3 -3 a recruiting another protein which 
would affect BCR activity. 
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BCR has been shown to negatively affect Raf activation by phosphorylating 
and binding to AF -6, leading to increased affinity of AF -6 for Ras, preventing the 
interaction between Raf and Ras [252]. The proposed model, in quiescent cells, 
involves the formation of a trimeric complex of BCR, Ras and AF -6. This causes 
downregulation of Ras -mediated signalling, maintaining cells in a non -proliferative 
state at points of cell to cell contact [252]. Tyrosine phosphorylation [of BCR] 
inactivates BCR kinase activity, leading to release of AF -6, therefore eliminating 
competition for Ras, resulting in activation of the Raf signalling cascade [252]. The 
binding of 14 -3 -3 could add an extra layer of complexity to this sequence of events, 
by potentially recruiting other molecules to these locations, or altering kinase activity 
of BCR. As another substrate of BCR, AF -6 and 14 -3 -3 both play a role in 
modulation of the Raf /MEK/ERK pathway; AF -6 by altering Ras levels and 14 -3 -3 
by interaction with Raf. 
BCR has both PH and C2 domains (see figure 1.9) that could aid targeting to 
the membrane, perhaps explaining the observed location, by Malmberg et al [253], of 
BCR at the membrane of Calu -3 cells. Additionally, BCR was shown to reside at the 
same location as ß -COP vesicles in non -polarised BHK cells [253]. In a different 
study, 14 -3 -3 ß mediated retrograde transport of HCNK3 channels by binding to a 
non -canonical 14 -3 -3 binding motif, displacing binding of ß -COP (that was bound to 
a distinct, dibasic motif) allowing HCNK3 to escape to the membrane [64]. In another 
study, 14 -3 -3 ands were shown to bind the (ATP) channel alpha subunit, Kir6.2, in 
a similar mechanism, displacing COPI and allowing release of Kir to the membrane 
[459]. It is tempting to speculate on the existence of a ternary complex, involving 
BCR, 14 -3 -3 and COP vesicles based on the observation that 14 -3 -3 associates with 
BCR and the latter is predominantly in the same location as ß -COP. 
During this investigation, it was hypothesised that endogenous CK1 may bind 
to endogenous 14 -3 -3, forming a trimeric complex with BCR. This tertiary complex 
could have explained the phosphorylation of residue 233 on t and Ç, a known 
phosphorylation site of CK1 [172]. The use of two highly specific inhibitors of CK1 
ruled out this possibility. Combined with site directed mutagenesis, I identified that 
BCR is directly responsible for phosphorylation of 14 -3 -3 on residue 233 [460]. 
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In a preliminary experiment to ascertain the best lysis buffer for preparation of 
BCR kinase, it was found that preservation of tyrosine phosphorylation had a positive 
effect on the ability of BCR to phosphorylate 14 -3 -3 i (figure 3.3). This is generally 
contradictory to previous work [267, 269], although the tyrosine residue(s) 
phosphorylated in the preparation used here, were not determined. Phosphorylation of 
BCR by Fes kinase on residue Y177 reduced the ability of BCR to phosphorylate 14- 
3-3 [267]. A similar result was reported for the phosphorylation of Y360 [269]. The 
authors showed expression and purification of BCR in cells co- expressing BCR and 
BCR -ABL under conditions designed to preserve tyrosine phosphorylation, had 
reduced kinase activity toward casein and histone [269]. However, experiments 
described in chapter 3 were from cells expressing only BCR, therefore it is unlikely 
that the residues Y177 and Y360 are phosphorylated by these kinase(s) and thus data 
shown in figure 3.3 indicated phosphorylation on distinct tyrosine residues. 
Interestingly, tyrosine phosphorylation did not seem to affect 14 -3 -3 association in 
BCR -FLAG immunoprecipitations (figure 3.3). 
This investigation also revealed that a PKA -like kinase, from cell lysates, can 
associate with the M2 a -FLAG antibody (see chapter 3). The discovery was 
accidental due to the use of recombinant protein with an incorporated PKA motif, 
which was not thought to be relevant. Use of a specific PKA inhibitor further 
implicated the kinase as PKA. The specific PKA inhibitor had no effect on BCR - 
FLAG immunoprecipitates, ruling out PKA as a contaminating kinase 
phosphorylating 14 -3 -3 on residue 233. This may not be a problem with a -FLAG 
antibodies generally, as the substrate used in this kinase assay had an optimal PKA 
motif, thereby making the assay very sensitive. 
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6.2. CK1 
Chapter 4 explores the interaction of CK1 with 14 -3 -3, identifying a specific 
and direct interaction both in vitro and in vivo. Previous work in our laboratory 
identified CK1 as a 14 -3 -3 S/T 233 kinase [172], but the interaction had not been 
further investigated. A physiological consequence of 14 -3 -3 T233 phosphorylation 
is to negatively affect interaction with Raf [ 145, 172] (and perhaps other ligands), 
therefore by phosphorylating 14 -3 -3 on residue 233, it is possible that CK1 could 
negatively affect its own interaction. Considering this, observations outlined in 
chapter 4 suggest that CK1 has a greater affinity for 14 -3 -3 isoforms other than 
irrespective of this possibility. Firstly, in vitro binding experiments using a phospho 
peptide incorporating residue pS218 of CKla showed that 14 -3 -3 isoforms 11, y, ß, s 
and T bound with considerably more affinity than Ç (figure 4.5). Using a peptide 
corresponding to CK1 interacting region eliminates the possibility of CK1 
phosphorylating 14 -3 -3 and thus negatively affecting the interaction. Secondly, 
performing binding experiments from cell lysates at 4 °C would be expected to inhibit 
all enzymatic activity. 14 -3 -3 T has a phosphorylatable residue at position 233 and 
although no published data has shown that phosphorylation of this residue negatively 
other the sequence and structure conservation of 
14 -3 -3 isoforms suggests phosphorylation would have a similar outcome. It is 
interesting to note from figure 4.12 that 14 -3 -3 'c binds intact CK1 with a similar 
affinity as . 
Truncation mutants of CKla suggested another 14 -3 -3 binding site and 
further experiments identified S242 as an essential residue for interaction with 14 -3 -3 
in HEK293 cells (figure 4.15). Analysis of 14 -3 -3 isoform specificity was also 
addressed in vivo by immunoprecipitating transfected HA -CKIa from cultured cells 
and analysing the precipitates with isoform specific antibodies. Although the 
antibodies have very similar titres, firm conclusions cannot be drawn for a particular 
isoform binding with greater affinity. Aside from the titre variation, 
heterodimerisation (discussed in 1.2.6.) will preclude definitive analysis in vivo. 
Nevertheless, from these data it is clear that r) and y give a much better signal than the 
other isoforms tested; ß, and E. The low abundance of 14 -3 -3 a and t in cell lysates 
precluded analysis, see figure 4.11. For the reason of highest affinity, antibodies to 
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14 -3 -3 rl were used predominantly throughout these studies. The interaction could 
potentially be regulated though PKA activation, as the use of the PKA stimulant db- 
cAMP caused an increase in 14- 3 -3:CK1 association in HEK293 cells. Antagonising 
PKA activity by a myristoylated PKA inhibitor peptide also reduced CK1:14 -3 -3 
interaction. 
CK1 and 14 -3 -3 are both ubiquitous, abundant proteins and the exact mode of 
interaction is complex. The ubiquitous nature of CK1 and large number of substrates 
recorded for the kinase (see table 1.7), suggests changes in local concentrations of the 
enzyme as a way of regulation. In the next part of this chapter the findings outlined 
above and in chapter 4 will be discussed. The results support a role for 14 -3 -3 in 
regulation of CK1 activity, with the involvement of centaurin -al. 
CK1 associates with several molecular scaffold -type proteins, 
including axin [420], CG- NAP /AKAP450 [415] and centaurin -a. -a1 [419] with little 
or no effect on kinase activity. In this study, the interaction of centaurin -a1 with 
CK1 a was shown to be negatively affected by two mechanisms. One is 
phosphorylation of 5218 on CK1a (figure 4.6) and the other, by phosphorylation of 
centaurin -a1 by PKC (figure 4.24). CK1 associates with centaurin -a and -a1 in cells 
[419] and because centaurin -a1 associates with PIPS [425], it has been suggested as a 
mode of recruiting CKl a to the plasma membrane [419]. CK1 may well play a role at 
the membrane, despite being largely cytoplasmic, as immunocytochemistry has 
identified CK18 localising with membranous structures [339]. Also, in S. cerevisiae, 
three out of the four isoforms (YCKI, YCK2, YCK3) carry a consensus for 
isoprenylation at the C- terminus and are indeed found tightly associated with the 
membrane [461]. The fourth isoform, HRR25, does not contain this sequence and is 
found predominantly in the nucleus [461]. Interestingly, results from our laboratory 
have shown that HRR25 associates with the yeast 14 -3 -3 isoform BMH1 and is the 
principal 14 -3 -3 kinase in yeast (manuscript under revision). CK1 a has no 
isoprenylation consensus and so association with membrane bound proteins would be 
one method of bringing CK1 in contact to substrates at the membrane. Centaurin -a 
and -al associate through a region containing 5218 and the interaction does not affect 
CK1 kinase activity [419]. Continued CKI activity at the plasma membrane would 
most probably be detrimental to the cell; therefore one mode of regulation would be 
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to limit CK1 access to the membrane. The finding here that centaurin -a1 can only 
associate with the dephosphorylated S218 peptide suggests phosphorylation of CK1, 
potentially through a protein kinase A regulated pathway, would prevent association 
and remove CK1 from the membrane. A further consequence of CK1 
phosphorylation would be the association with 14 -3 -3. Data presented in chapter 4 
suggests CKIa associates with 14 -3 -3 in a phosphorylation dependent manner, 
mediated through two phosphorylated Ser residues: S218 and S242, although the 
mode of binding of CKl a to specific 14 -3 -3 isoforms is distinct, for the following 
reasons. Point mutations designed to disrupt phosphorylation dependent binding 
through the binding groove of 14 -3 -3 (R5660A) had no effect on CKl a binding 
(figure 4.17). Similarly, competition experiments using high affinity 14 -3 -3 binding 
peptides, which bind into the binding groove of 14 -3 -3, did not disrupt binding to 14- 
3 -3 (figure 4.18). In contrast, the data obtained using high affinity 14 -3 -3 binding 
peptides and 14 -3 -3 r, showed that CK1a does interact through the 14-3-311 binding 
groove (figure 4.18). Therefore to explain the fact that 14 -3 -3 does bind CK1a in a 
phosphorylation dependent manner (figure 4.4, 4.8, 4.14 and 4.15) suggests the 
interaction must be by an uncharacterised mechanism. This binding mechanism may 
be conserved for kinases that phosphorylate 14 -3 -3. Indeed, it is worth noting that 
BCR binds a similar pattern of 14 -3 -3 isoforms as CKIa; with both kinases binding 
the phosphorylatable 14 -3 -3 isoforms, Ç and T, with low affinity (compared to the 
other isoforms). 
Association of 14 -3 -3 with CK1 would likely prevent association with 
centaurin -a1, as they share the same interaction site, thereby providing another mode 
of removing CK1 from the membrane. Association with 14 -3 -3 may also reduce CK1 
activity; a mode of action often attributed to 14 -3 -3, for example 14 -3 -3 reduces the 
kinase activity of PKC [462], CamKII [35], MAPKAPKII [41], PKD (PKCp.) [42], 
PDK1 [463] and BMK1 /ERK5 [33]. 
In the later part of chapter 4, the PKC phosphorylation sites on centaurin -a1 
were determined (figure 4.23) [453]. Analysis of the primary structure of centaurin -a1 
shows that S87 is outwith any known functional domain and S276 is N- terminal to 
the second PH domain. Additionally, comparison of the location of this residue, with 
other PH domain crystal structures, shows it is unlikely to affect PtsIns binding. 
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Phosphorylation does, however, reduce the affinity to CK1 a in vitro (figure 4.24). 
This potentially defines another regulatory mechanism to reduce CK1 presence at the 
cell membrane (figure 6.1). 
Mutation of S218/S242 reduced the amount of 32P incorporated (figure 4.19), 
suggesting that these are autophosphorylation sites. Therefore autophosphorylation 
could provide another mechanism to reduce CK1 localisation to the membrane. 
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Figure 6.1 Proposed model for CK1a recruitment to the cellU membrane 
Growth factors induce activation of tyrosine kinase receptors and activation of PI3K. 
Generation of PIP3 recruits centaurin -a1 to the membrane, CK1 binds centaurin-a1; 
localising to the membrane. CK1 activity at the membrane is attenuated by 
phosphorylation through a PKA mediated system, by two routes. One is 
phosphorylation which blocks interaction directly (a) and the second is 
phosphorylation to create a binding site for 14 -3 -3, also blocking interaction (b). 
Recruitment of CK1 to membrane is also impaired by PKC phosphorylation of 
centaurin (c). PKA activity can also be phosphorylated and activated by PDK1 [464], 
the net effect on recruitment of CKla could therefore be either increased or decreased 
by growth factors. 
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Immobilised peptide columns are a useful way of identifying proteins that 
interact with a specific region. An additional benefit is the large binding capacity, 
enabling the capture of sufficient protein for accurate determination of proteins by 
mass spectrometry, an approach that led to this study [419, 421]. The region around 
S218 is clearly important for 14 -3 -3 association (figure 4.4, 4.15) and may well be 
important for catalytic activity of CK1 (figure 4.21). A basic region immediately C- 
terminal from residues 228 -231 has recently been shown to be essential for 
association with axin [420]. Binding of axin to CK1 a did not affect kinase activity of 
CK1 a toward casein or a specific peptide substrate [420]. A further paper, using the 
same K -+A mutants, suggested that the ability of CK1 to discern between phosphate 
primed substrates and non -canonical substrates was lost [455]. Mutation of the basic 
region increased the km up to 40 fold for a ps -4 peptide, 6 fold for ps -3 primed 
peptide', however a single mutation of K232 ->A had the same detrimental effect as 
mutation of the whole basic region [455]. The authors also noted that a peptide from 
ß- catenin containing a `non -canonical' consensus motif was phosphorylated 
regardless of the mutation carried in CK1. In summary, the lysine residue 232 is 
essential for recognition of phosphorylated substrates. This region is very near the site 
of proposed 14 -3 -3 interaction (see figure 6.1). If 14 -3 -3 was interacting through this 
region, this could interfere with substrate recognition and therefore activity of the 
enzyme. 
Also indicated in figure 6.2 is a residue corresponding to T44 in CK16. A 
missense mutation (T44 ->A) of which causes Familial advanced sleep phase 
syndrome (FASPS) [465]. Analysis of kinetic parameters of the T44A mutant CK1 
showed the Vmax to be 60 % of wild type CK16, and the km was 82% [465]. The 
overall effect on catalytic efficiency (Vmax /Km) is therefore decreased (to 73% of wild 
type). The mutant also showed variable levels of phosphorylation depending on 
substrate, suggesting that residue Thr 44 is involved in substrate recognition. This 
residue is some distance from the active site (see figure 6.2), yet the T44A mutation 
clearly exerts an effect on CK16 activity, implying extensive contacts are made 
between CK1 and binding partners. Incubation of CK1a with phosphatase inhibitors, 
as described in chapter 4, may well result in phosphorylation of residues other than 
pS -n refers to a `primed' substrate, where n is the position of the pre -phosphorylated residue, N- 
terminal to the target Ser /Thr, for example: pS -3 = pSXXS /T, underlined residue is the target residue. 
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S218 and S242. Phosphorylation of residue T44, or other residues, could cause a 
structural change in CK1, increasing the affinity toward 14 -3 -3, explaining how 14 -3- 
3 binding mutants of 14 -3 -3 and blocking peptides had no effect on 14 -3 -3 binding. 





























Figure 6.2 crystal structure of CK1, indicating interaction sites 
A, S218 is shown in purple, with surrounding binding motif in red. S242 is coloured 
orange, with binding motif in blue. Lysines required for co- ordinating recognition of 
canonical substrates as demonstrated by Bustos et al [455] are coloured pink. Mgt+ 
ATP is shown in yellow, sulphate ions are in grey. The residue corresponding to T44 
of CK1 S is shown in black. B, alignment of CK1a sequence around region 210 -240. 
Lysines 229, 230 and 232 are indicated in pink, lysine 231 (peculiar to the zebra fish) 
was mutated to glutamine (sequence below alignment) for the study in [420, 455], see 
separate sequence, below; other colourings are the same as in A. 
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The crystal structures of CK1 and 14 -3 -3 have been known for some time 
[131, 393] and allow for computer modelling to suggest how the two might interact. 
Biochemical evidence gathered in this investigation suggested S218 and S242 as the 
prime interaction sites and the computer modelling carried out in chapter 4.25 was 
centred on these residues. The residues 218/242 were placed very near the 14 -3 -3 
binding pocket, by an automated web based interface, using the molecular modelling 
software ZDOCK (figure 4.25) [447], suggesting an energetically favourable 
conformation. The orientation of 14- 3 -3:CK1 binding predicted by the ZDOCK 
program (figure 4.23) suggests that the residue S/T233 on 14 -3 -3 could not undergo 
phosphorylation when bound to 5218 on CK1. The modelling does, however, suggest 
a rationale for results obtained in figure 4.17 and 4.18, where 14 -3 -3 is shown to 
interact outwith the central 14 -3 -3 binding groove. If 14 -3 -3 were to interact with 
CK1 a through this groove, whilst in contact with residues 5218 and /or S242, 
unfeasibly large structural changes would have to occur to allow S233 access to the 
active site on CK1 and subsequent phosphorylation. Therefore 14 -3 -3 must interact 
with CKl a elsewhere, presumably in a conformation that allows phosphorylation. 
6.3. CONCLUSION 
The interaction of 14 -3 -3 with two well studied kinases was examined. BCR 
phosphorylates 14 -3 -3 on an important, known, phosphorylation site, S233. Thus 
providing an explanation of results obtained in the original identification of 14 -3 -3 as 
a BCR substrate [147]. This kinase associated preferentially with the 14 -3 -3 ri and y 
isoforms. CKIa was shown to interact with 14 -3 -3 rl through the classical 
amphipathic binding groove in a phosphorylation dependent and isoform specific 
manner. The interaction provides an attractive model for regulating a highly 
ubiquitous and second messenger independent kinase. 
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Chapter 7 
Future work 
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7 Future work 
The present study has identified the phosphorylation site on 14 -3 -3 by the 
BCR kinase as residue 233. Further studies are required to examine, in vivo, when 14- 
3-3 is phosphorylated, or what cellular conditions induce the phosphorylation. Few 
studies have addressed the physiological role of BCR [207] and the physiological 
effect of 14 -3 -3 interaction with BCR also remains to be studied. The identification of 
the 14 -3 -3 binding site(s) on BCR would provide a basis for further study of the 
interaction. This could be accomplished by the generation of point mutations within 
putative 14 -3 -3 binding sites on BCR - of which there are many candidates, see figure 
1.9. Cell localisation studies on such mutants of BCR after cell stimulation could shed 
light on the involvement of 14 -3 -3. 
An interaction between CK1 and 14 -3 -3 was investigated and a number of 
insights into the interaction have been discussed in chapter 4, however, further studies 
would be needed to fully understand the nature of the interaction. Firstly, it would be 
useful to produce a phospho -peptide corresponding to the region around pS242 - to 
compare binding affinity to the S218 peptide. Secondly, production of phospho- 
specific antibodies to S218 and S242 would allow intricate examination of how and 
when CK1 becomes phosphorylated. Identification of the CK1 kinase(s) would allow 
in vitro phosphorylation of CK1 and subsequent analysis of binding kinetics using 
techniques such as surface plasmon resonance. Immunoprecipitation of CK1 
S218A/S242A mutants, which may act like pseudosubstrates, may allow sufficient 
levels of kinase(s) to bind for identification by mass spectrometry. Use of different 
cell stimulators /inhibitors, known to activate specific kinases would also lead to clues 
as to the identity of the kinase. Mutation of other phosphorylation sites (possibly 
Y161, T164 and S179 proposed by Xu et al [393]) could potentially help to remove 
background phosphorylation, aiding observation of phosphorylation by other 
kinase(s). 
The finding that 14 -3 -3 Ç and II bind to CK1u in a different manner, and 
different affinity, warrants further investigation. Generation of both neutral and 
charge reversal mutations within the 14 -3 -3 ti and y isoform binding pockets would 
allow further characterisation of the interaction with CKIa. 
Future work 202 
Colocalisation studies involving CK1a, centaurin -a1 and 14 -3 -3 following cell 
stimulation would be a useful approach to observe subcellular location, perhaps after 
cell stimulation with growth factors. 
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Appendix figure Al 
Purification of recombinant GST- 14 -3 -3 isoforms from bacterial lysates. 
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Specificity of 14 -3 -3 isoform dimer interactions and phosphorylation 
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Abstract 
Proteins that interact with 14 -3 -3 isoforms are 
involved in regulation of the cell cycle, intra- 
cellular trafficking /targeting, signal transduction, 
cytoskeletal structure and transcription. Recent 
novel roles for 14 -3 -3 isoforms include nuclear 
trafficking the direct interaction with cruciform 
DNA and with a number of receptors, small G- 
proteins and their regulators. Recent findings 
also show that the mechanism of interaction is also 
more complex than the initial finding of the novel 
phosphoserine /threoninemotif. Non- phosphoryl- 
ated binding motifs that can also be of high 
affinity may show a more isoform- dependent 
interaction and binding of a protein through two 
distinct binding motifs to a dimeric 14 -3 -3 may 
also be essential for full interaction. Phos- 
phorylation of specific 14 -3 -3 isoforms can also 
regulate interactions. In many cases, they show a 
distinct preference for a particular isoform(s) of 
14 -3 -3. A specific repertoire of dimer formation 
may influence which of the 14 -3 -3- interacting 
proteins could be brought together. Mammalian 
and yeast 14 -3 -3 isoforms show a preference for 
dimerization with specific partners in vivo. 
Introduction 
The name 14 -3 -3 was given to an abundant 
mammalian brain protein family due to its par- 
ticular migration pattern on two -dimensional 
Key words: phosphorylation, protein -interaction motif, signalling. 
Abbreviations used: PKC, protein kinase C; AANAT, arylalkyl- 
amine N- acetyltransferase. 
'To whom correspondence should be addressed (e -mail 
Alastair.Aitken @ ed.ac.uk). 
DEAE -cellulose chromatography and starch gel 
electrophoresis [1]. The first function ascribed to 
this family of proteins was activation of tyrosine 
and tryptophan hydroxylases, the rate -limiting 
enzymes involved in catecholamine and sero- 
tonin biosynthesis, essential for the synthesis 
of dopamine and other neurotransmitters [2]. 
Subsequently we showed that 14 -3 -3 could regu- 
late (inhibit) activity of protein kinase C (PKC) 
[3,4]. 14 -3 -3 was then implicated as a novel type 
of chaperone protein that modulates interactions 
between components of signal -transduction path- 
ways [5]. A large number of publications began to 
appear in the mid -1990s showing that 14 -3 -3 
proteins could interact with a range of protein 
kinases, phosphatases and other signalling pro- 
teins. This implied a role for the 14 -3 -3 family of 
proteins to mediate the formation of protein 
complexes involved in signal transduction, traf- 
ficking and secretion, perhaps to bind to different 
signalling proteins on each subunit of the dimer, as 
a novel type of adapter protein'. It is now clear 
that 14 -3 -3 isoforms are involved in many other 
cell functions and this is only one of their many 
roles. A number of intrinsic enzymic activities 
have been ascribed to 14 -3 -3, but none have been 
substantiated in the literature. 
The five major mammalian brain 14 -3 -3 
isoforms are named a -ri in order of their respective 
elution positions on HPLC [2,6] and we showed 
that a and 8 are the phosphoforms of ß and 
respectively [7]. Two other isoforms, z and Q, are 
expressed in T -cells and epithelial cells respect- 
ively, although the former is also widely expressed 
in other tissues, including brain. 
Muslin and co- workers [8] showed that tar- 
get- protein phosphorylation is important for 
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14 -3 -3 binding via a novel phosphoserine se- 
quence motif. It has subsequently been shown 
that while many 14 -3 -3- interacting proteins con- 
tain this motif, many others do not, indicating 
that additional sequences and modes of inter- 
action /contacts also allow 14 -3 -3 binding. Co- 
crystal structures with non -phosphorylated motifs 
suggest that the same binding pocket or ' groove' 
is involved [9]. Not only can phosphorylation of 
the motif be an important regulatory component 
of the interaction but dephosphorylation can also 
lead to creation of an interaction motif. Waterman 
et al. [10] showed that ionizing radiation led to 
dephosphorylation of Ser -376 in the sequence 
KGQS376TS378RH /G in the p53 tumour - 
suppressor protein (see Table 1), creating a con- 
sensus binding site for 14 -3 -3 proteins which led 
to association of p53 with 14 -3 -3. This in turn 
increased the affinity of p53 for sequence- specific 
DNA. 
I4 -3 -3 isoforms and sequence 
conservation 
The 14 -3 -3 family is highly conserved over a wide 
range of mammalian species, where the individual 
isoforms ß, e, rl, y, r (also called B), ( and a are 
either identical or contain a few conservative 
substitutions. Homologues of 14 -3 -3 proteins 
have also been found in a broad range of eukaryotic 
organisms and are probably ubiquitous (reviewed 
in [11,12]). In every organism studied, at least two 
isoforms of 14 -3 -3 have been observed. 
The chromosomal location of 14 -3 -3 isoforms 
has been deduced from the human genome data- 
base. The haemopoietic e sequence variant, ... 
VELDVE ... , where the underlined D replaces T 
in this most highly conserved 14 -3 -3, is on 
chromosome 2 in the current draft genome se- 
quence. No variants in the amino acid sequence of 
e are otherwise known in any mammalian species. 
We have identified this haemopoietic tissue e 
variant in human, ovine, bovine and rodent 
e 14 -3 -3, in the same individual animal ([13] and 
A. Aitken, A. Toker and Y. Soneji, unpublished 
results). This form may also be present at low 
levels in keratinocytes. Structure analysis of the 
variation on the outer surface of e 14 -3 -3 suggests 
this may have an important effect on interaction 
with other proteins. The most striking finding in 
the genome analysis is a large number of sequences 
matching the isoform ; at least nine protein 
translations in a number of chromosomes, most of 
which are presumably pseudogenes. 
© 2002 Biochemical Society 354 
14 -3 -3 proteins are quite distinct in sequence 
and structural topology from other protein fami- 
lies in the database. Exceptions may be tertiary 
structure similarity with tetratricopeptide repeat 
(`TPR') helices [14] and primary structure 
similarity with a- synuclein in particular regions 
[15]. 
I4 -3 -3 dimers, binding motifs and 
their interactions 
Crystal structures of both the r and isoforms of 
14 -3 -3 [16,17] show that they are highly helical, 
dimeric proteins. Each monomer is composed of 
nine anti -parallel a- helices, organized into an 
N- terminal and a C- terminal domain. The dimer 
creates a large negatively charged channel. Those 
regions of the 14 -3 -3 protein which are invariant 
throughout all the isoforms are mainly found 
lining the interior of this channel, while the 
variable residues are located on the surface of 
the protein. 
This channel would recognize common 
features of target proteins, so the specificity of 
interaction of 14 -3 -3 isoforms with diverse tar- 
get proteins may involve the outer surface of the 
protein. The N- terminal residues of all 14 -3 -3 
homologues are variable, and as these residues are 
important for dimer formation there may be a 
limit to the number of possible homo- or hetero- 
dimer combinations. Residues involved in dimer- 
ization are 5 -21 in the A -helix of one subunit and 
residues 58 -89 of the C and D helices of the other 
(see Figure 1). 
After the demonstration by Muslin and co- 
workers [8] that a novel phosphoserine- containing 
motif initially identified in Raf kinase was im- 
portant for interaction, the motif was further 
refined into two subtypes and the structural details 
of the interaction with 14 -3 -3 were elucidated 
[18,19]. The binding site for the phosphoserine 
consists of a basic pocket composed of Lys -49, 
Arg -56 and Arg -127, as well as Tyr -128, within 
the C and E helices (see the underlined residues in 
Figure 1). 
The proline residues are in different confor- 
mations in the two classes of phosphopeptide con- 
sensus motif. In the mode 1 phosphopeptide [18] 
the proline is in a cis -conformation while in the 
mode 2 phosphopeptide [19] the proline has a 
trans -conformation. Nevertheless, both proline 
conformations result in a sharp alteration in chain 
direction, allowing the peptide to exit the binding 
groove. This is also clear in the recent deter- 
mination of the arylalkylamine N- acetyltrans- 
ferase (AANAT) /14 -3 -3 co- crystal structure [20]. 
The ligand- binding groove runs in opposite 
directions in the two subunits of the dimer and a 
highly stable and isoform- specific interaction may 
result, distinct from the involvement of 14 -3 -3 
dimer in binding two distinct target proteins 
together in a chaperone -like role. 
Many of the 14 -3 -3- interacting proteins con- 
tain either one or both of two consensus motifs, 
R(S/Ar)( + )pSXP and RX(Ar)( + )pSXP [18] 
where pS is phosphoserine, Ar is an aromatic 
residue (particularly Tyr or Phe in mode 2) and + 
is a basic amino acid. Residue X following the 
phosphoserine is commonly Leu, Glu, Ala or Met. 
The phosphorylated residue may also be a thre- 
onine. Although most motifs contain Ser some 
well- characterized ones, e.g. AANAT, have Thr 
and there seem to be no structural reasons why this 
residue could not fit equally well into the cleft. 
Other motifs that are listed in Table 1 may be 
categorized as RSXpS motifs, RXl_2SX2_3S motifs 
and non -phosphorylated motifs. 
When phosphopeptide libraries were tested 
on six of the 14 -3 -3 isoforms and the yeast BMH1 
and BMH2, all the isoforms were found to have 
very similar preferences for the individual residues 
14 -3 -3 Proteins in Cell Regulation 
within each consensus motif. There are seven 
mammalian isoforms of 14 -3 -3 that are all highly 
conserved and one supposes that each isoform 
would have a distinct function or subset of func- 
tions. For example, several isoforms of 14 -3 -3 
are involved in the G2 /M cell -cycle checkpoint: 
14 -3 -3 a is responsible for sequestering the Cdc2- 
cyclin B1 complex in the cytoplasm, while the ß 
and e isoforms bind Cdc25C [21]. 
The complete sequence conservation in the 
observed ligand- binding regions of 14 -3 -3 would 
support the hypothesis that there may be little 
isoform specificity in the interaction between 
14 -3 -3 and protein ligands; therefore many iso- 
form- specific functions of 14 -3 -3 observed in vivo 
may result either from subcellular localization or 
transcriptional regulation of particular isotypes 
rather than from inherent differences in their 
ability to bind to particular ligands. However, 
the finding that phosphorylated 14 -3 -3 negatively 
regulates the interaction with the Raf N- terminal 
domain [22] suggests that additional interactions 
may occur on the outer surface of 14 -3 -3 or its 
dimer. A number of publications in the literature 
confirm recently that for full functionality in at 
least some cases the dimer of 14 -3 -3 is essential 
[23]. 
Figure I 
Human 14 -3 -3 phosphorylation sites and motifs 
The positions of the known phosphorylation sites on various isoforms are shown in large type and the phosphopeptide- binding residues are 
underlined. Ac denotes the N- terminus of the monomer (this is N- acetylmethionine, residue I in most isoforms). The numbering 
is that of the alignment of the correctly processed longer members of the family (i.e. e and longer form of fi that commence at 
residue I) and the introduction of gaps of two residues maximize the alignment. 
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RRS SWRW SS I EQK TEGAEKKQQMAREYREKIET 
89 
RSX PSXP motif binding 
SLLEKFLIPNASQAESKVFYLKMKGDYY RYLAEVAAGDDKKG IVDQ S QQAYQEAFE I S 
ELRDICNDVL 
185 
KKEMQPTHP IRLGLALNFSVFYY E I LN S PEKA CSLAKTAFDEAIAELDTLSE 
233 
ESYKDSTLIMQLLRDNLTLCaTSD 1 m QGDEAEAGEGGEN 
CK1a 
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Recent findings relating to the structures and 
mechanism of interaction of 14 -3 -3 with its part- 
ners strengthen the evidence that interaction is 
not simply mediated by the canonical phospho- 
serine- containing motif. Some well- characterized 
interacting proteins such as Raf kinase have been 
shown to have additional binding site(s) for 14 -3 -3 
on their cysteine -rich regions. Bcr and Ksr also 
bind via serine -rich regions. The interaction be- 
tween 14 -3 -3 and Raf is complex and the exact role 
of 14 -3 -3 remains controversial. The fact that Raf 
contains a third interaction domain in the cys- 
teine -rich region would add further complexity. 
This could also confer isoform specificity. It has 
also been suggested that due to the very common 
occurrence of two binding sites or motifs on one 
polypeptide chain of an interacting protein, the 
synergy between the two may also lead to isoform 
preference of interaction. Interaction motifs that 
are near the optimum, as determined by surface 
plasmon resonance spectroscopy [18], show no 
specificity but less optimal ones do. The binding 
of a protein in both (lower) affinity sites may 
greatly increase target -protein specificity of rec- 
ognition and affinity. This suggests a dual site - 
recognition mechanism in which, for example, a 
14 -3 -3 dimer interacts with both glycoprotein I 
(GPI)ba (unphosphorylated motif) and GPIbß 
(with a phosphorylation -dependent binding site), 
resulting in high-affinity binding (see Table 1). 
The 14 -3 -3 phosphoserine- binding motif is 
also a common feature in plant and other eukary- 
otic species [24]. The plant plasma membrane 
1+- ATPase motif, QQYpT647V -c001-1, is note- 
worthy in that it has so far been found only in 
plant proteins [25]. 
Around 100 proteins have been shown to 
interact with 14 -3 -3. The well- characterized 
14- 3- 3- interacting proteins and the motif(s) that 
have been identified are listed in Table 1. Some 
target proteins contain more than one motif that 
has been shown to be involved in 14 -3 -3 binding 
and they are listed only once. In many cases the 
actual residue numbers will be different in mam- 
malian species other than the one(s) that were 
studied, although the site will be equivalent; for 
example, Ser -178 is the most important in mouse 
HDAC7. The equivalent residues in the human 
sequence are Ser -156, Ser -318 and Ser -446 in the 
motif RAQS446SP. 
In addition to those listed in Table 1, mam- 
malian proteins that have been shown to interact 
include the following. (a) Protein kinases; CK1a, 
Chkl kinase, MEKK1, -2 and -3, type I PKC 
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(a,ß,y), PKCe, PKCO and PKUa. (b) Phos- 
phatase Cdc25B; see also (g). (c) Receptors; a2- 
adrenergic, y- aminobutyric acid (GABA) (B), 
glucocorticoid, adrenergic, a and ß oestrogen, 
nuclear receptor co- repressor RIP140 and small 
G- proteins and their regulators, Rad and Rem. 
(d) Proteins involved in apoptosis including 
a- synuclein and the neurotrophin receptor 
(p75NTR)- associated cell death executor NADE. 
(e) Adaptor /scaffolding molecules pl30Cas, Grb2 
and Shc (p66). (f) Transcription factors and other 
proteins involved in transcriptional control, 
TATA box -binding proteins TBP and TFIIB, 
histone acetyltransferase 1, Msn2p and 4p, other 
forkhead family members, the co- activator YAP 
(Yes- associated protein), myocyte enhancer bind- 
ing factor 2 (MEF2D) proteins in the MADS 
[MCM1, AGAMOUS, DEFICIENS and SRF 
(where SRF is serum response factor)] box family 
of transcription factors, FKBP12- rapamycin- 
associated protein (FRAP), primary response 
gene BRF1, PHDfinger -HD, topoisomerase IIa, 
initiation factor EIF2a, integrin CD18 chain, 
TLX -2 homeodomain transcription factor and 
histones. (g) Enzymes and others including tryp- 
tophan hydroxylase, catalytic subunit (p110) of 
phosphoinositide 3- kinase, calmodulin, mito- 
chondrial uncoupling protein (UCP) and CMP- 
NeuAc: GM1 a-2,3 -sialyltransferase ; structural 
and cytoskeletal proteins including keratin K8, 
Kif1C, Tau and vimentin; proteins involved in 
cell -cycle control including cell -cycle phosphat- 
ase Cdc25B and telomerase catalytic subunit 
(TERT). 
I 4-3-3-binding motif kinases 
Kinases that have been shown to phosphorylate 
the phosphoserine or threonine in the phos- 
phorylated binding motifs include protein kinase 
B (also called Akt), cAMP- dependent protein 
kinase, p21- activated protein kinase 1 (PAK), Ras - 
mitogen- activated protein kinase (RSK1, also 
known as MAPKAP -K1), MAP kinase -activated 
protein kinase -2 (MAPKAP -K2) and PKC, as 
would be expected from their substrate specificity. 
In most cases the physiological kinases(s) have not 
been demonstrated but those that co- localize in 
the cell would be prime candidates; e.g. Cdc25C 
has been reported to be phosphorylated by a 
number of kinases such as Cds- 1 /Chk2, Chkl 
and Cdc25C- associated kinase 1 (C- TAK1). The 
first two are nuclear -located. In addition, Ca'- 
calmodulin-dependent kinase II (CAM kinase II), 
p90 ribosomal S6K, protein kinase D (also known 
as PKC,u) and casein kinase II (CKII) have also 
been implicated in phosphorylation of the motifs. 
I4 -3 -3 isoform phosphorylation 
Our sequence analysis of brain 14 -3 -3 separated 
by reversed -phase HPLC failed to show any 
differences between a and ß on the one hand and 8 
and on the other [26]. We subsequently showed 
by mass spectrometric analysis that a and S were 
the phosphorylated forms of ß and respectively 
and we identified the site as Ser -185 [7] using the 
numbering of the generic mammalian 14 -3 -3. 
The acetylation at the N- terminus of 14 -3 -3 iso- 
forms, with or without removal of the initiator 
methionine, has been verified by mass spectro- 
metry for all isoforms except o- [26]. 
ß 14 -3 -3 is expressed at alternate start sites, 
40 % of which is co- translationally processed, 
resulting in an additional threonine residue at the 
N- terminus. There is no evidence that this would 
affect dimer formation. 
This phosphorylation of Ser -185 may not 
`turnover', as high levels of the phospho -forms 
are recovered without precautions taken to inhibit 
phosphatases. Although the s and u isoforms 
contain a serine residue in equivalent positions 
(SPDR and SPEE respectively), they are not 
known to be phosphorylated at this site. The 
a isoform is particularly abundant in brain; 
therefore it would have been identified by mass 
spectrometric analysis when we characterized the 
a and 8 isoforms. We have found no evidence for a 
and 6 phospho -forms in a wide range of tissue 
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types and cell lines other than brain. Inspection of 
the many two -dimensional gel electrophoreto- 
grams that are in the literature lend support to the 
idea that this phosphorylation may be specific to 
brain 14 -3 -3. 
We identified casein kinase 1a (CKIa) as 
the brain kinase that phosphorylated 14 -3 -3 and 
r isoforms on Thr- and Ser -233 respectively. 
14 -3 -3 is phosphorylated on Thr -233 in HEK- 
293 cells [22]. Residue 233 is located within a 
region involved in the association of 14 -3 -3 with 
target proteins. In vivo phosphorylation of 14 -3 -3 
at this site negatively regulates its binding to 
c -Raf, and may be important in Raf- mediated sig- 
nal transduction. We have also shown (S. Nlackie, 
T. Dubois and A. Aitken, unpublished work) 
that CKla binds to 14 -3 -3 isoforms in vitro. 
Some isoforms of 14 -3 -3 have been shown to 
be phosphorylated by a sphingosine- dependent 
kinase [27] and PKB /Akt [27a]. The site these 
authors determined, Ser -59, is masked in the 
dimer interface [16]. If phosphorylation occurs, 
it could be a mechanism for regulation of dimer 
formation. However, it might be difficult under 
physiological conditions for a kinase to gain 
access, since the 14 -3 -3 dimer is very stable under 
normal conditions (see Figure 2). Our results 
have shown that while brain PKC did phosphoryl- 
ate some 14 -3 -3 isoforms on an adjacent residue, 
Ser -64, the phosphorylation did not appear to 
occur to any physiologically significant extent [6], 
although there is an excellent motif in this region. 
In contrast, in our deletion mutants that exposed 
Figure 2 
Structure of the r 14 -3 -3 dimer interface 
The interface between the monomers is mainly hydrophobic, comprising 70% of the total 2150 Â2 of inaccessible surface [ 16]. 
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this site [28] there are very high levels of phos- 
phorylation. We also showed that large synthetic 
peptides are also stoichiometrically phosphoryl- 
ated at Ser -59 and there were low levels of 
phosphorylation at Ser -64 [29]. 
Van Der Hoeven et al. [30] showed that 
14 -3 -3 ß and T were substrates for PKC -( (sites 
not determined) and Autieri and Carbone [31] 
showed phosphorylation of human 14 -3 -3 y by 
PKC isoforms on undetermined site(s). However, 
their cDNA sequence was quite different from 
previous y sequences (including that in the human 
genome) and included changes in residues known 
to be invariant. 
Reuther and co- workers [32] showed that 
14 -3 -3 T interacted with c -Bcr and with Bcr /Abl. 
Their results indicated that 14 -3 -3 r was a sub- 
strate for the Bcr serine /threonine kinase and was 
also phosphorylated on tyrosine by Brc /Abl but 
not by c -Abl. On attempting to identify this site(s) 
of phosphorylation on these and other 14 -3 -3 
isoforms we have evidence (S. Clokie, S. Mackie 
and A. Aitken, unpublished work) that the phos- 
phorylation is due to a co- immunoprecipitating 
kinase at a known site of phosphorylation. 
Dimerization of mammalian and yeast 
14 -3 -3 isoforms in vivo 
In many cases, interaction between 14 -3 -3 and 
other signalling proteins shows a distinct pref- 
erence for particular isoform(s) of 14 -3 -3. The 
existence of particular combinations of hetero- 
dimeric 14 -3 -3 isoforms in vivo has important 
implications for function as an adaptor protein in 
signalling. This may allow the interaction between 
signalling proteins that do not directly associate 
with each other. Bcr and Raf, for example, do not 
associate directly but form a complex mediated 
through 14 -3 -3 [33]. ß and r 14 -3 -3 associate with 
Bcr while the and ß 14 -3 -3 isoforms interact 
with Raf. We have shown that isoforms of 14 -3 -3 
can form homo- and hetero- dimers in vivo and in 
vitro and a specific repertoire of dimer formation 
may influence which of the 14 -3 -3- interacting 
proteins could in turn be brought together [34]. 
Since the residues involved in dimerization ex- 
hibit some isoform variation, this may limit the 
possible homo- or hetero -dimer combinations and 
may confer specificity on 14 -3 -3 function. 
The dimers of 14 -3 -3 are stable and do not 
readily exchange unless they are denatured and 
renatured [34]. It should be noted that a single 
recombinant 14 -3 -3 isoform will form homo- 
dimers regardless of the actual preference in vivo 
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since a monomeric form would be thermo- 
dynamically unstable. 14 -3 -3 proteins also have a 
slow rate of turnover. 
We analysed the pattern of dimer formation 
for two of the most abundant isoforms of 14 -3 -3 e 
and y, following their stable expression in the 
neuronal pheochromocytoma PC12 cell line 
(M. Chaudhri and A. Aitken, unpublished work). 
This revealed a distinct preference for particular 
dimer combinations that is largely independent of 
cellular conditions. y 14 -3 -3 formed homo- 
and hetero- dimers, mainly with e. In turn, the 
e isoform formed heterodimers with all the 14 -3 -3 
isoforms tested (ß, n, y and ), but no homodimers 
were detected. This suggests that the observed 
dimer combinations may be due to structural 
properties of the dimer interface of the individual 
isoforms. This pattern may be generally applic- 
able since the dimerization patterns of y and e 
isoforms in transiently transfected COS cells were 
also similar overall. The pattern of dimer forma- 
tion was not simply a reflection of the amounts of 
available 14 -3 -3 isoform present in the cell or in a 
particular subcellular location. Analysis of the two 
14 -3 -3 homologues, BMH1 and BMH2, from the 
budding yeast Saccharomyces cerevisiae also re- 
vealed that between 65 and 80 % are heterodimers 
(M. Chaudhri and A. Aitken, unpublished work). 
Homo- and hetero- dimers of 14 -3 -3 proteins 
may play different roles. It is possible that homo- 
dimers of a particular isoform will function to 
sequester or chaperone a protein, while hetero- 
dimers are more likely to act as adaptor proteins, 
modulating the interaction of two distinct pro- 
teins, each of which specifically associates with one 
of the isoforms of the heterodimer. The y isoform 
may be more involved in sequestration functions, 
while the e isoform is more likely to function as an 
adaptor protein in signal -transduction events. 
Indeed, y 14 -3 -3 has been found to be the major 
isoform in Golgi and is implicated in secretion and 
protein trafficking while the e isoform is more 
generally found in association with proteins in- 
volved in signal transduction. 
In conclusion, association with 14 -3 -3 iso- 
forms has led to the activation or stabilization of 
some proteins, and the inactivation of others, while 
for many proteins 14 -3 -3 isoforms have played an 
organizational role as a `scaffold'. In the complex 
multistep process of Raf activation, 14 -3 -3 appears 
to play several of these roles. It is likely that its 
ability to form homo- and various heterodimeric 
combinations is crucial and the analysis of the 
exact combinations of homo- and hetero- dimers of 
14 -3 -3 isoforms that are present within cell com- 
partment(s) and that are involved in interactions 
with particular proteins will be important. 
The work in the authors' laboratory was supported by the Medical 
Research Council. 
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Abstract 
The 14 -3 -3 proteins are a family of phospho- 
serine /phosphothreonine -binding molecules that 
control the function of a wide array of cellular 
proteins. We suggest that one function of 14 -3 -3 is 
to support cell survival. 14 -3 -3 proteins promote 
survival in part by antagonizing the activity of 
associated proapoptotic proteins, including Bad 
Key words: apoptosis, ASKI, Bad, difopein. 
Abbreviations used: PKB, protein kinase B; ASK I , apoptosis signal - 
regulating kinase I ; EYFP, enhanced yellow fluorescent protein. 
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and apoptosis signal -regulating kinase 1 (ASK1). 
Indeed, expression of 14 -3 -3 inhibitor peptides in 
cells is sufficient to induce apoptosis. Inter- 
estingly, these 14 -3 -3 antagonist peptides can 
sensitize cells for effective killing by anticancer 
agents such as cisplatin. Thus, 14 -3 -3 may be part 
of the cellular machinery that maintains cell 
survival, and targeting 14- 3- 3- ligand interactions 
may be a useful strategy to enhance the efficacy of 
conventional anticancer agents. 
Introduction 
14 -3 -3 proteins can bind a variety of proteins that 
are critical mediators of intracellular signalling 
14 -3 -3 Proteins in Cell Regulation 
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Abstract 
14 -3 -3 proteins are involved in signalling pro- 
cesses in neuronal cells. Using isoform- specific 
antibodies we have examined the variation in 
14 -3 -3 isoform neurolocation in normal and 
scrapie- infected murine brain and show that in 
defined areas of the brain there are significant 
changes associated with the pathology of the 
disease process. The appearance of 14 -3 -3 proteins 
in the cerebrospinal fluid (CSF) is a consequence 
of neuronal disease and the detection of specific 
isoforms of the 14 -3 -3 proteins in the CSF is 
characteristic of some neurodegenerative diseases. 
In this study, monitoring specifically for the y 
14 -3 -3 isoform in the CSF by both Western -blot 
analysis and ELISA we can show a level of 
correlation between the assays. 
Introduction 
Transmissible spongiform encephalopathies are a 
group of diseases which affect both humans and 
animals. These are commonly called prion diseases 
[1] and include the human diseases sporadic 
Creutzfeldt -Jakob disease (CJD), variant CJD 
and iatrogenic CJD and the animal diseases bovine 
spongiform encephalopathy (BSE) and natural 
scrapie in sheep [2]. All of these involve rapid 
neurodegeneration and are invariably fatal. De- 
finitive diagnosis of prion diseases is currently 
only carried out post -mortem by neurohistopatho - 
logical examination for the detection of abnormal 
form of the prion protein. 
Concern over the link between BSE and 
variant CJD and the requirement for early or pre - 
mortem diagnosis of CJD has resulted in the 
evaluation of a number of proteins identified in 
the cerebrospinal fluid (CSF) of patients with 
Key words: CSF, ELISA, immunocytochemistry, neurodegener- 
ation. 
Abbreviations used: BAD, BcI -2- associated death promoter; 
BSE, bovine spongiform encephalopathy; CSF, cerebrospinal fluid; 
CJD, sporadic Creutzfeldt -Jakob disease; LGN, lateral geniculate 
nucleus. 
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neurodegenerative diseases for uses as surrogate 
markers. These include 14 -3 -3 proteins [3,4], 
neuron -specific enolase [5], S100ß [6] and Tau 
protein [7], and of these proteins 14 -3 -3 has the 
highest specificity. At present only Western -blot 
analysis of 14 -3 -3 has been advanced by the World 
Health Organization as a pre- mortem biochemical 
indicator to aid early diagnosis of clinically 
characterized sporadic CJD. 
The 14 -3 -3 proteins are a highly conserved 
family of multifunctional proteins that are pri- 
marily found in high levels in neurons but which 
are expressed in a wide range of other cells and 
tissues. 14 -3 -3 proteins have a typical monomeric 
molecular mass of approx. 30 kDa and have been 
shown to form homo- and hetero- dimeric struc- 
tures which complex with other proteins. There 
are seven distinct isoforms (ß, y, e, (, z, ri and a), 
named from their reversed -phase HPLC elution 
profile [8]. The ß and C forms have also been 
isolated as phosphorylated forms, which are 
named a and S respectively [9]. Multiple isoforms 
of 14 -3 -3 have been shown to interact with distinct 
regulatory proteins of the signalling, regulatory 
and apoptotic pathways [10]. Many of these 
protein -protein interactions have been shown to 
be modulated by phosphorylation of the inter- 
acting 14 -3 -3 partner [11,12]. This is exemplified 
in the regulation of the Bc1-2 apoptotic path- 
way; here sequestration of phosphorylated BAD 
(Bcl -2- associated death promoter) in the cytosol 
by 14 -3 -3 proteins results in inhibition of the pro - 
apoptotic action of BAD [13]. 
Early immunohistochemical studies of the 
human brain showed that the 14 -3 -3 proteins are 
predominantly localized in neuronal cells [14]. 
Gene expression studies have shown that the e, y, 
1, ß and C isoforms are expressed in neuronal cells 
in the grey matter area of the brain, including the 
hippocampus, thalamus and the cerebellar cortex 
[15,16], but that the r isoform (also known as 0) is 
also expressed in white matter areas of the brain 
[17]. Characterization of the subcellular location 
of 14 -3 -3 [18] had shown the a, y, r ß and C 
isoforms to be present in synaptic vesicle mem- 
387 © 2002 Biochemical Society 
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branes whereas r, g and y isoforms are located at 
the synaptic junction and that the e isoform binds 
to the synaptic plasma membrane through its 
N- terminal domain [19]. 
Using two -dimensional analysis an increase 
of the levels of the g and r/ isoforms has been shown 
in the cortical region of the brain in both Alz- 
heimer's disease and Down's syndrome [20]. 
Studies on the immunolocalization of 14 -3 -3 
isoforms in neurodegenerative brain disease has 
shown 14 -3 -3 to co- localize with neurofibrillary 
tangles in the brain of patients with Alzheimer's 
disease [21] and in the Lewy bodies in Parkin- 
son's disease and in Diffuse Lewy Body disease 
[22]. 
Immunocytochemistry 
In a comparative analysis of the neurolocation of 
the individual 14 -3 -3 isoforms in normal and 
scrapie- infected murine brain we have shown that 
in areas where severe pathological changes occur 
there are distinct changes in the isoform labelling 
[23]. This is clearly shown in the hippocampus 
and in the thalmus. In the hippocampus there is a 
loss of labelling of the T isoform and the number of 
pyrimidal cell bodies in the CA1 decreases with a 
corresponding loss of labelling of the ß, r1, y and 
isoforms (Figure 1), yet in the molecular layer of 
the dentate gyrus there is a significant increase 
in the intensity of labelling. In the lateral genicu- 
late nucleus (LGN) of the thalmus we observe a 
marked decrease in the isoform labelling in the 
dorsal LGN but this is not observed in the ventral 
LGN. As the 14 -3 -3 isoform labelling in the 
central nervous system in terminal scrapie is lost 
in some areas, but increases in others, this would 
suggest that the processing of these proteins 
during neurodegeneration may be much more 
complex than previously recognized. 
Although the pathogenic role of the 14 -3 -3 
isoforms in the prion diseases is unknown these 
proteins do modulate the apoptotic pathway by 
interaction with the Bc1-2 complex and by in- 
hibiting the pro -apoptotic action of BAD. 
Since changes in distribution pattern of vari- 
ous 14 -3 -3 isoforms is provoked by transmissible 
spongiform encephalopathy infection it is of in- 
trinsic importance to determine the fate of these 
proteins in the disease process. 
CSF 
As 14 -3 -3 proteins are not normally detected 
in the CSF the appearance of small quantities of 
specific 14 -3 -3 isoforms in the CSF during the 
disease processes tends to suggest that the pathway 
from neuron to CSF may be isoform- specific. 
Here it is of importance to note that of the six 
isoforms, ß, y, a, , r and i , that are normally found 
in the brain, only four of these, the ß, y, a and ri 
isoforms, are present in the CSF of patients with 
sporadic CJD [24,25]. It is also noteworthy that 
the only isoform consistently observed in the CSF 
of patients with Alzheimer's disease is the i 
isoform [24] and that the 14 -3 -3 isoform is not 
typically found in the CSF in either of these 
diseases. Currently the World Health Organiz- 
ation protocol for the use of 14 -3 -3 proteins as 
surrogate markers in CSF of sporadic CJD 
patients uses Western -blot analysis, which is not 
isoform- specific. 
Figure 
Immunolabelling of ß14 -3 -3 isoform 
ß- Labelling of the cell bodies of pyramidal cells in CAI hippocampus (a) in normal brain and (b) in ME7 scrapie -infected mucine brain. 
Scale bar, 100 pm. 
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Western analysis 
Of the ß, e, y and ri 14 -3 -3 isoforms typically 
identified in the CSF of patients with sporadic 
Figure 2 
Western -blot analysis of CSF from CJD patients using 
14 -3 -3 isoform -specific antisera 
(A) A standard mixture of 14 -3 -3 isoforms isolated from sheep 
brain and CSF samples from patients 2 and 4 were analysed using 
y, e, 7 and ß 14 -3 -3 isoform -specific antisera, (B) CSF samples from 
CJD patients 1-4 were analysed using y 14 -3 -3 isoform -specific 
antisera with the following scoring regime: -, no detectable 
signal; +, very faint signal; + +, faint signal; + + +, moderate signal; 
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14 -3 -3 Proteins in Cell Regulation 
CJD the y isoform appears to be the most abun- 
dant. Figure 2(A) shows specific detection of the y 
14 -3 -3 isoform in the CSF of sporadic CJD 
patients after treatment by SDS /PAGE followed 
by Western -blot analysis. The SDS gels were 
blotted and probed for the presence of the y 
isoform using a polyclonal antibody raised to a 
14 -3 -3 y N- terminal peptide and the bands were 
semi -quantitatively classified into five groups ac- 
cording to the strength of the signal. Clearly there 
is a distinct difference in the levels of the individual 
isoforms found in the CSF after the onset of 
sporadic CJD (see Figure 2B). 
ELISA 
In developing our present ELISA procedures the 
capture antibody used was a monoclonal antibody 
raised against a heterogeneous 14 -3 -3 peptide. 
The detecting antibody used is a biotinylated form 
of the polyclonal anti -y 14 -3 -3 antibody used 
in the Western analysis, followed by strepta- 
vidin- horseradish peroxidase- conjugated second- 
ary antibody and tetramethybenzidine peroxide 
substrate. The absorbance was measured at 
450 nm. The standard mixture of 14 -3 -3 isoforms 
used in the study was isolated from sheep brain 
and the isoform ratio in this mixture was quantified 
by calibration of the isoform HPLC profile using 
purified y 14 -3 -3 protein as a standard. The 
Figure 3 
(A) Two -site ELISA for y 14 -3 -3 and (B) correlation between Western - 
blotting and ELISA y14 -3 -3 isoform -specific analysis of CSF from CJD patients 
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coefficients of variation for the within -batch and 
between -batch precision of the assay were 25 % 
and 13 % respectively. Our current ELISA pro- 
tocol has a working range of 10 -100 ng /ml. A 
typical standard curve is shown in Figure 3(A). 
Testing of CSF samples from patients 
with neurodegenerative diseases 
The CSF samples contain dimeric 14 -3 -3 proteins 
complexed with other interacting proteins. In this 
heterogeneous mixture the 14 -3 -3 proteins are not 
as readily detectable by ELISA as by Western - 
blot analysis and for this reason all of the 
protein samples were concentrated ( x 5) and heat - 
treated before being assayed. 
In our preliminary studies the ELISA pro- 
tocol was used to determine the levels of y 14 -3 -3 
in the CSF of patients with two neurological 
disorders: (a) from patients with sporadic CJD 
and (b) from patients with multiple sclerosis. 
Elevated levels of 14 -3 -3 in the CSF of multiple 
sclerosis patients has previously been reported by 
Sathoh et al. [26]. 
As shown in Figure 2(B), each of the CJD 
patients tested by ELISA recorded positive for y 
14 -3 -3 with good correlation between the scoring 
analysis from Western blotting and the differential 
levels of 14 -3 -3 recorded by the ELISA. In 
contrast, the multiple sclerosis samples tested were 
all below the detectable limit for the y 14 -3 -3 
protein. However, it may be that the CSF of 
multiple sclerosis patients contains other isoforms 
of 14 -3 -3 protein. 
Conclusion 
Kenney et al. [27] have shown the total 14 -3 -3 
protein content present in the CSF of sporadic 
CJD patients during neurodegeneration to be in 
the ng /ml range. If the appearance of small 
quantities of specific 14 -3 -3 isoforms in the CSF is 
consistent with the loss of neurons in neuro- 
degenerative conditions, then the variation in 
the pattern of isoforms suggests that control 
of the pathway from neuron to CSF may be 
isoform- specific. 
While our analysis indicates that at present 
the Western -blot analysis of 14 -3 -3 in CSF is 
more sensitive than the current ELISA, the 
positive correlation between the assays indicates 
that development of an isoform- specific ELISA 
© 2002 Biochemical Society 390 
using adaptations of the method is valid. The 
optimization of selectivity and sensitivity of our 
ELISA protocol is in progress. 
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Abstract 
The insulin- stimulated phosphoinositide 3- kinase 
(PI 3- kinase) /3- phosphoinositide -dependent kin - 
ase-1 (PDK1) /protein kinase B (PKB) kinase 
cascade is believed to play a critical role in 
metabolic control and cell survival, largely medi- 
ated through PKB phosphorylation of many 
proteins. Recent findings demonstrate that the 
transcription factors FKHR (forkhead in rhabdo- 
myosarcoma), AFX (ALLI fused gene from chro- 
mosome X) and FKHRLI (FKHR -like 1 ; termed 
FKHR isoforms) are phosphorylated by PKB in 
cells, leading to their exit from the nucleus. 
These exciting results suggest that FKHR iso- 
forms may be critical effectors of PI 3- kinase/ 
PDK1 /PKB signalling in vivo. 
Introduction 
Many of insulin's intracellular actions are trans- 
mitted through a conserved kinase cascade. In 
brief, insulin -stimulated autophosphorylation of 
the insulin receptor brings about the activation 
of phosphoinositide 3- kinase (PI 3- kinase), lead- 
ing to the recruitment of protein kinase B (PKB) 
Key words: AKT, CKI, dual -specificity tyrosine -phosphorylated 
and -regulated kinase (DYRK), forkhead, nuclear exclusion. 
Abbreviations used: PI 3- kinase, phosphoinositide 3- kinase; PKB, 
protein kinase B; PDKI , 3- phosphoinositide -dependent kinase- I ; 
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to the plasma membrane and its activation by 
3- phosphoinositide -dependent kinase -1 (PDK1). 
The PI 3- kinase /PKB signalling pathway has a 
critical role in metabolic control and cell survival 
[1]. These effects are largely mediated through 
PKB phosphorylation of many proteins, of which 
the first to be identified was glycogen synthase 
kinase -3 (GSK3) [2]. 
Given that insulin alters the transcription of 
at least 100 genes [3] it is likely that many of the 
effects of PI 3- kinase /PKB signalling are due to 
altered gene expression. Until recently, however, 
no PKB -regulated transcription factor had been 
identified. This situation changed in 1999, when 
we and others reported that the transcription 
factors FKHR (forkhead in rhabdomyosarcoma), 
AFX (ALL1 fused gene from chromosome X) 
and FKHRL1 (FKHR -like 1) are phosphorylated 
directly by PKB in cells, preventing them from 
stimulating gene transcription and leading to their 
exit from the nucleus [4 -10]. These findings 
have stimulated much more detailed analysis of 
the effect of phosphorylation on the regulation 
of FKHR isoforms, the results of which are the 
major focus of this review. 
DAF 16 regulation by an insulin -like 
signalling pathway 
Mechanistic evidence suggesting that FKHR iso- 
forms are regulated by PKB was initially obtained 
from genetic studies in Caenorhabditis elegans 
[11,12]. An insulin- receptor -like signalling path- 
way regulates dauer formation, a developmental 
stage of the nematode that causes animals to shift 
metabolism towards fat storage and to live longer 
[13,14]. Inactivating mutations in the insulin/ 
insulin -like growth factor 1 (IGF -1) receptor 
homologue DAF -2 (where DAF stands for dauer 
arrest phenotype) [15], in the PI 3- kinase hom- 
39I © 2002 Biochemical Society 
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Abstract 
Centaurin -ai is a member of the family of ADP -ribosylation factors (ARF) GTPase activating proteins (GAPS), although ARF 
GAP activity has not yet been demonstrated. The human homologue, centaurin -ai functionally complements the ARF GAP activity 
of Gesl in yeast. Although Gcsl is involved in the formation of actin filaments in vivo, the function of centaurin remains elusive. We 
have identified a number of novel centaurin-al binding partners; including CKIa and nucleolin. In this report, we have focused on 
the interaction of centaurin-al with PKC. All groups of PKC associate directly through their cysteine rich domains. Centaurin-at is 
also a substrate for all PKC classes and we have identified the two sites of phosphorylation. This is the first report of a kinase that 
phosphorylates centaurin -a.1. 
© 2003 Elsevier Inc. All rights reserved. 
Keywords: Centaurin; Ptdlns- (3,4,5) -P3- binding protein; PKC; Protein kinase C; Isoforms; PKD; Phosphorylation site; Mass spectrometry; Affinity 
chromatography 
Centaurin -a1 was purified from rat brain as a Ptdlns- 
(3,4,5)-P3- binding protein [1]. The human homologue, 
centaurin -a1, functionally complements the ARF GAP 
activity of Gcsl, a yeast centaurin homologue [2], al- 
though it is not yet known whether centaurin -a has this 
activity. The latter has a common domain of 70 amino 
acids that includes a zinc finger motif that has been 
shown to be essential for GAP activity [3]. In addition, 
a Abbreviations: ARF, ADP -ribosylation factors; CKI, casein 
kinase I; GAP, GTPase activating proteins; GFP, green fluorescent 
protein; GST, glutathione S- transferase; PAGE, polyacrylamide gel 
electrophoresis; PCR, polymerase chain reaction; PKC, protein kinase 
C; CI, cysteine rich domain; MS -MS, tandem mass spectrometry. 
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centaurins contain two pleckstrin homology (PH) do- 
mains [1]. Centaurin -a1 is found in the cytoplasm as well 
as in the nucleus [2,4] and in support of a possible in- 
volvement of centaurin -a1 in nuclear processes, we have 
shown the association of centaurin -a1 with the nucleolar 
protein nucleolin [4]. Centaurin -a1 is ubiquitously ex- 
pressed, with particularly high levels in brain [5]. The 
main location is the neurons of hippocampus, cortex, 
cerebellum, and in the hypothalamus [6]. 
Centaurin -a has recently been shown to be upregu- 
lated in neurons in patients with Alzheimer's disease [7]. 
Apart from their potential GAP activity, the in vivo 
function of centaurins remains elusive. However, it has 
been shown that Gcsl is involved in the formation of 
actin filaments in vivo [8]. Involvement in actin reorga- 
nisation has also been shown for other members of the 
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Fig. 1. PKC),. and associate with the centaurin -al column. Protein 
(5 µg) eluted from the GST -centaurin -al (Cent. -a1) and GST column 
was separated on 10% SDS -PAGE, transferred onto nitrocellulose, 
and Western blotted with PKC7,. and antibodies. A brain extract 
(Brain) was used as a positive control for the antibodies. The position 
of one of the molecular weight markers (kDa) is indicated. 
ARF GAP family; such as ASAPI [9] which supports 
the idea that ARF GAP proteins are involved in cyto- 
skeletal reorganisation, possibly in Ptdlns- (3,4,5) -P3 
A GST 
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signalling. We showed the association of centaurin -al 
with casein kinase Ia (CKIa) [10], a kinase that has been 
shown to be involved in membrane trafficking and /or 
actin cytoskeleton rearrangement [11,12]. 
PKCs comprise a family of serine /threonine kinases 
classified into different groups according to activation 
parameters: conventional PKCs (PKC a, 3I, [3II, and 'y), 
novel PKCs (PKCS, s, rl, and 0), atypical PKCs (PKCÇ 
and t /X), and PKD /PKCµ, which can be considered as a 
separate class [13]. Among many other functions, PKC 
isoforms are involved in the regulation of cytoskeletal 
organisation and in mediating muscle contraction. PKC 
isoforms are also involved in nuclear functions such as 
cell proliferation, differentiation, and apoptosis. Mem- 
bers of the PKC family are regulated by several lipid 
second messengers, such as Ptdlns- (3,4,5) -P3 [13]. In this 
report, we show that centaurin -al binds to all members 
of the PKC family and is phosphorylated by isoforms 
from all PKC classes. We also identified the two PKC 
phosphorylation sites. 
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Fig. 2. Centaurin -a1 associates with all PKC isoforms tested. (A) Centaurin -al associates with all PKC isoforms. PKCa, X, µ, and were expressed 
and labelled with [35Slmethionine in a reticulocyte lysate and incubated for 15 min at 30 °C with 5 µg GST and GST -centaurin -a1 in the presence of 
1% Nonidet P -40. Glutathione -Sepharose beads were added and incubated at room temperature for 1 h. Beads were washed and samples analysed by 
10% SDS -PAGE followed by autoradiography (panel "Pull- down "). An aliquot of the lysate was loaded on the gel to visualise expressed PKCs 
(panel "Input "). The positions of the molecular weight markers (kDa) are indicated. (B) Centaurin -a1 directly associates with PKC isoforms from all 
sub -families. Five micrograms each of GST, GST- 14 -3 -3, and GST- centaurin -al was incubated with 0.114 of human recombinant PKCa, PKCe, 
PKCµ, and PKC. The samples were analysed on 10% SDS -PAGE, transferred onto nitrocellulose, and Western blotted with PKCa, e, µ, and 
antibodies as indicated. Top panels represent an aliquot of the assays to visualise the PKCs (panels "Input "). Bottom panels represent the GST pull - 
down assays (panel "Pull- down "). The positions of molecular weight markers (kDa) are indicated. 
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Materials and methods 
Plasmids and recombinant proteins. Centaurin -a] cloned within 
EcoRI /Sall sites into pGEX -4T3 was from Venkateswarlu and Cullen 
[1]. PKCa (pCO2) was from Peter Parker and PKC (pcDNA3) from 
Terje Johansen. The construction of PKCµ mutants (WT, 1 -340, AAC, 
and APH) in pcDNA3 has been described [14] and PKC /pcDNA3.1 
was obtained from Feng Liu. GST- centaurin -a1 was constructed and 
purified as previously described [10]. 
Affinity chromatography on a centaurin -a, column. The affinity 
chromatography was performed as described previously [4]. Eluted 
proteins from the GST and GST- centaurin -al columns were analysed 
by 10% SDS -PAGE, transferred onto nitrocellulose, and Western 
blotted using PKCX (Transduction Laboratories, all 1:1000) and PKC( 
antibodies (W.J. van Blitterswijk, 1:1000). 
In vitro binding between purified PKC isoforms and centaurin -at. 
GST, GST- 14 -3 -3K, and GST- centaurin -al (5 µg) were incubated with 
human recombinant PKCa, e, p, and (1 U) (Calbiochem) in binding 
buffer (20 mM Tris, pH 7.4, 100 mM NaCI, 10% glycerol, 1 mM DTT, 
1% Nonidet -P40 [NP40], and 0.1% BSA) for 2h at 4 °C. GSH beads 
were then added and incubated for a further 1 h. Bead precipitates were 
then washed 4 times with binding buffer and bound proteins were 
eluted using SDS sample buffer. The samples were analysed by 10% 
SDS -PAGE, transferred onto nitrocellulose, and Western blotted us- 
ing PKC antibodies. 
In vitro transcription and translation and GST pull -down assays. 
PKCa, k, IA, and were expressed in vitro using a T7 TNT coupled 




The reactions (50 µl) were performed following the manufacturer's 
instructions using [35S]methionine (Amersham) for 90 min at 30 °C. 
Samples were then diluted 3 -fold with binding buffer (20 mM Tris, pH 
7.4, 100mM NaCI, 10% glycerol, 1 mM DTT, and 1% Nonidet -P40 
[NP40]) and incubated for 15 min at 30 °C with 5µg of GST, GST-14- 
3-K and GST- centaurin -al . GSH beads and binding buffer (300 pl) 
were added to the reactions and incubated at room temperature for a 
further I h. The beads were washed 5 times with 1 ml of binding buffer 
and electrophoresed on 12.5% SDS -PAGE. After staining/destaining, 
the gels were incubated for 30 min with Amplify (Amersham Phar- 
macia), dried, and exposed to film. 
Phosphorylation of centaurin -at by PKC. Centaurin -al (5 pg) was 
incubated with I U of PKCa, PKCs, PKCµ, and PKC I in a buffer 
containing 40 mM Hepes, pH 7.4, 20 mM MgC12, 2 mM EGTA (for 
PKCa 3 mM CaCl2 was included), 30 pg/ml phosphatidylserine, 8 µg/ 
ml diacylglycerol, and 50 pM ATP including [y- 32P]ATP). The reaction 
was performed at 30 °C for 15 min in a final volume of 40 pl. The re- 
actions were stopped by the addition of SDS sample buffer and anal- 
ysed on 12.5% SDS -PAGE. Gels were stained with Coomassie blue 
and autoradiographed. 
Identification of the PKC in vitro phosphorylation sites. Re- 
combinant human centaurin -al phosphorylated by PKCa was loaded 
on 12.5% SDS -PAGE to separate phosphorylated substrate from the 
autophosphorylated PKC. Centaurin was visualised on the gel by 
Ge1CODE (Pierce) staining. The band containing centaurin -al was 
digested with trypsin and peptides extracted as described [15]. The 
peptides were purified by reverse phase HPLC on a Surveyor AS 
(ThermoFinnigan) with a PepMap C18 150 mm, 1.0 mm diameter, 
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Fig. 3. Centaurin-al binds to the CI domain of PKCp. (A) Schematic representation of the known functional domains of PKCp. (B) Centaurin -a] 
binds to the Cl domain of PKCµ. PKCp wt and PKCp deletion mutants AI -340 (AC); A336 -391 (SAD); and A417 -553 (APH) were expressed in a 
reticulocyte lysate, and incubated with 5 pg each of GST and GST -centaurin -al as described in Fig. 2A. GST pull -down assays were analysed by 
SDS -PAGE and autoradiographed (panel "Pull- down "). An aliquot of the lysate was loaded on the gel (panel "Input "). The positions of molecular 
weight markers (kDa) are indicated. 
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0.5 pm 100 A column (LC Packings), using a flow rate of 50 pl /min with 
a gradient 0 -1% B over 0-4 min, 1 -3% B over 4-20 min, 3 -23% B over 
20 -25 min, 23 -40.5 % B over 25 -95 min, 40.5 -48 % B over 95 -110 min, 
48 -68 °/, B over 110 -150 min, and 68 -85% B over 150 -155 min. Solvent 
A was aqueous 0.1'/ formic acid, and solvent B was 100% acetonitrile 
with 0A% formic acid. Fifty microliter fractions were collected. The 
elution positions of the 32P- labeled peptides were determined by Ce- 
renkov counting and the phosphopeptide fractions were analysed by 
ion -trap mass spectrometry as described [15]. LC ESI -MS /MS was 
carried out on a LCQ Deca ion trap (ThermoFinnigan, Hemel 
Hempstead). The instrument settings for an on -line LC flow rate of 
50 pl /min were as follows: Sheath Gas Flow Rate 100, Tube Lens offset 
30 V, ESI Spray Voltage 4.50 kV, capillary voltage 3.0 V, and capil- 
lary temperature 325.0 °C. The MS data were acquired in the `Triple - 
Play' data- dependent mode that included three scan events: a full - 
range (50 -2000 m /z) MS scan; a narrow -range, high resolution zoom 
scan on a selected ion from the MS scan; and an MS MS scan of the 
selected ion. 
Solid phase sequencing. After phosphorylation of the protein and 
separation of the centaurin-al from ATP and autophosphorylated 
PKC by SDS PAGE, followed by trypsin digestion, release of 32P 
from the phosphopeptides was measured at each cycle of automatic 
Edman degradation. Peptides were covalently coupled to arylamine 
membrane and sequenced in an ABI Procise sequencer as in [16]. 
Results and discussion 
Centaurin -at binds to c, n, and aPKCs and PKDIPKCp 
We identified novel centaurin-al interacting proteins 
by affinity chromatography of sheep brain lysate, pre - 
incubated with GST to remove non- specific binding. 
Western blotting revealed that PKC2, and associated 
with the GST- centaurin -at (Fig. 1). 
To investigate whether all PKC isoforms associated 
with centaurin-al, PKCa, X, µ, and were expressed in 
an in vitro transcription /translation (IVTT) assay and 
incubated with GST, GST- 14 -3 -3, and GST- centaurin- 
at. All four PKC isoforms associated with GST --cen- 
taurin-al but not with GST (Fig. 2A). 
In order to analyse whether the association between 
centaurin-al and PKC isoforms was direct, binding 
assays were performed using purified recombinant pro- 
teins. The results in Fig. 2B show that GST- centaurin- 
al directly bound to all PKC isoforms tested in an in 
PKC CC E 
35 
vitro GST pull -down assay. In addition, as a control for 
specificity of interaction, 14 -3 -3 directly associated with 
PKCE and PKCµ, but not with PKCa or PKC. Our 
results in Fig. 2B are in agreement with a reported in- 
teraction between 14 -3 -3 and the Cl domain of PKCµ 
[17]. We have shown that centaurin -al specifically and 
directly associated with PKC. The fact that centaurin -al 
interacted with all PKC isotypes suggested that it asso- 
ciated with a domain common to all PKC isoforms, i.e., 
the cysteine rich domain (C1) or the kinase domain. 
Centaurin -ai binds to the CI domain of PKC# 
PKCµ isoform was used to map the centaurin -ai 
binding site. PKCµ wt and PKCµ deletion mutants, M- 
340 (AC); A336 -391 (AAD); and A417 -553 (APH) 
(Fig. 3A) were expressed with [35S]methionine and incu- 
bated with GST and GST- centaurin -al . PKCµ wt bound 
to GST- centaurin -at (Fig. 3B). Deletion of the acidic 
domain or the PH domain of PKCµ did not affect the 
binding to centaurin -al. No binding was observed be- 
tween centaurin -al and PKCµ Al -340 (Fig. 3B), there- 
fore residues 1 -340 of PKCµ were necessary for the 
association, indicating that the Cl domain of PKCµ could 
represent the target region for binding. This is not unex- 
pected as several proteins have been identified in associ- 
ation with the Cl region of PKCµ [14,17]. Since all PKC 
isoforms have at least one Cl domain [13] these results 
complement those from Figs. 2A and B showing that all 
PKC isoforms associated in vitro with centaurin -al . 
Phosphorylation of centaurin-ai by distinct PKC isoforms 
Using recombinant purified PKC isoforms, we 
showed that centaurin -al (5 jig) was phosphorylated in 
vitro with PKCa, E, µ, and Ç (1 U each, Fig. 4). 
Identification of the PKC phosphorylation sites 
The sites of phosphorylation by PKCa on centaurin- 
al were identified as S87 (peptide ARFESK) and T276 
PKC '_1 
- Pk C' f3- 




Fig. 4. Centaurin -ai is phosphorylated by all classes of PKC. One unit each of PKCa, e, p, and Ç was incubated with 5 pg centaurin-al in the presence 
of 50 pM [y- 32P]ATP and kinase buffer at 30 °C for 15 min and for 30 min (by which time phosphorylation was near maximal). The samples were 
analysed on 10% SDS PAGE followed by autoradiography. 
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Fig. 5. Sites of phosphorylation by PKC. (A) Recombinant human centaurin was phosphorylated by PKCa and separated on SDS -PAGE. The 
radioactive band was located by autoradiography, then subjected to trypsin digestion and extraction [15]. Upper panel shows the separation of 
the peptides by reverse phase HPLC as described in Materials and methods. The eluted fractions were analysed by Cerenkov counting to determine 
the presence of 32P- labelled peptides (lower panel). Two regions of phosphopeptide were identified (fractions 6 and 7, and multiple peaks from 
fractions 40 -46). On -line MS -MS analysis indicated the presence of two peptides in fractions 6 and 7 (FESK and ARFESK) and peptides 
WFTMDDR and WFTMDDRR in fractions 43 and 46. (B) Represents the release of 32P at each cycle of Edman degradation of the phosphorylated 
peptide (fraction 6) after covalently coupling to arylamine membrane [16]. Sequence data from fraction 7 were similar (not shown). The results 
indicate that the radioactivity incorporated into the peptide is released in cycle 3 and cycle 5 corresponding to Ser87 within the peptides FESK and 
ARFESK. The presence of multiple peptides from the same site has resulted from partial cleavage as expected from the known endoproteolytic 
behaviour of trypsin. (C) Edman degradation of the phosphorylated peptide from fraction 43 indicated that the radioactivity is released in cycle 3, 
corresponding to Thr276. Sequence analysis of fraction 46 gave similar results. Fraction 40 gave a poor recovery of 32P (only around 150 cpm 
Cerenkov were loaded) but this could represent the peptide(s) RWFTDDR(R). The additional arginine residue(s), which is /are hydrophilic, results in 
the peptide eluting earlier. In contrast, for the peptide ARFESK there is an additional (slightly hydrophobic) alanine as well as arginine. These would 
compensate for each other resulting in no significant difference in hydrophobicity from the peptide FESK. We observed no separation of these two 
peptides on reverse phase HPLC (both eluted in fractions 6 and 7). 
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(peptide WFTMDDRR) (Fig. 5). We noted that in the 
PepMap column the phosphoform of the peptide eluted 
2 min later than the dephospho -form using this partic- 
ular gradient and 0.1% formic acid. This is a similar 
situation to that in a Vydac "low TFA" column which 
also uses a much lower level of ion -suppression agent 
(less than 0.01% TFA). This is in contrast to the general 
situation in reverse phase HPLC where phosphopeptides 
elute with a typical gradient around 1 min earlier when 
0.1% TFA is used. 
The identification of the peptides was confirmed by 
tandem MS -MS (data not shown). Fig. 5A indicates 
that around 60% of the radioactivity is incorporated 
into Ser87 and 40% into peptides originating from 
Thr276. Since the latter site is more hydrophobic, it is 
possible that these peptides were extracted less efficiently 
and the true ratio might be more equal. The phos- 
phorylation site analysis was carried out twice after 
phosphorylation of centaurin -a1 with PKCa and once 
with PKCc. A similar pattern of phosphopeptides was 
obtained each time. Under the phosphorylation condi- 
tions used the stoichiometry was around 0.3 mol /mol. 
Centaurin -al is expressed at particularly high levels in 
brain [5] and PKC isoforms are also widely distributed 
in different tissues including brain [18]. Centaurin -a1 is 
mainly found in the nucleus of different cell lines, but 
also associates with the plasma membrane and is present 
in the cytosol [2,4,19,20]. 
Most PKC isoforms have also been identified in the 
nucleus and increasing evidence has implicated a role for 
PKC in nuclear functions, such as cell proliferation, cell 
differentiation, and apoptosis, reviewed in [21]. The 
presence of a Ptdlns- (3,4,5) -P3- binding site in centaurin- 
al suggests possible roles for centaurin -al and PKC in 
signalling downstream of PI 3 -K. Since novel and 
atypical PKC isoforms are activated by lipid second 
messengers including the PI 3 -K products Ptdlns- (3,4)- 
P2 and Ptdlns- (3,4,5) -P3 [13] this could link PKC 
isoforms and centaurin -a1 to the phosphoinositide sig- 
nalling pathway. The interaction between PKC and 
centaurin -a, also further strengthens the possibility of 
involvement of centaurin -ai in cytoskeletal processes. 
Our identification of a major PKC site on centaurin -al 
at Thr276 in the C- terminal PH domain suggests that 
phosphorylation at this site may affect phosphoinositide 
binding to centaurin -a1. The other phosphorylation site 
that we identified, Ser 87, is in the putative ARF -GAP 
domain. 
In this study, PKC was identified as a novel centau- 
rin -ai interacting protein by affinity chromatography 
and GST pull -down assay. Centaurin -a1 associated di- 
rectly with all PKC isoforms possibly via their Cl do- 
main. Centaurin -al was also phosphorylated by all 
PKCs tested probably on the same two sites that we 
identified in this study, using PKCa. This is the first 
report of a kinase that phosphorylates centaurin -a1. 
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The breakpoint cluster region protein, BCR, has protein kinase activity 
that can auto- and trans -phosphorylate serine, threonine and tyrosine resi- 
dues. BCR has been implicated in chronic myelogenous leukaemia as well 
as important signalling pathways, and as such its interaction with 14 -3 -3 is 
of major interest. 14 -3 -3T and Ç isoforms have been shown previously to be 
phosphorylated in vitro and in vivo by BCR kinase on serine and threonine 
residue(s) but site(s) were not determined. Phosphorylation of 14 -3 -3 iso- 
forms at distinct sites is an important mode of regulation that negatively 
affects interaction with Raf kinase and Bax, and potentially influences the 
dimerization of 14 -3 -3. In this study we have further characterized the 
BCR- 14 -3 -3 interaction and have identified the site phosphorylated by 
BCR. We show here that BCR interacts with at least five isoforms of 
14 -3 -3 in vivo and phosphorylates 14 -3 -3T on Ser233 and to a lesser extent 
14 -3 -3Ç on Thr233. We have previously shown that these two isoforms are 
also phosphorylated at this site by casein kinase 1, which, in contrast to 
BCR, preferentially phosphorylates 14- 3 -3ï,. 
The term breakpoint cluster region (BCR) refers to an 
area of 5.8 kb on chromosome 22 that by a reciprocal 
translocation event with the oncogene Abl, from chro- 
mosome 9, produces the chimera BCR -Abl [1]. It is 
this reciprocal translocation event that creates an aber- 
rant chromosome called the Philadelphia chromosome 
(ph1) that is the hallmark of chronic myeloid leukaemia 
(CML) and which is found in over 90% of patients 
with CML [2]. BCR -Abl proteins can vary in size, 
depending on the breakpoint within the BCR. The 
resultant fusion protein, containing different amounts 
of the BCR gene fused to ABL, gives rise to different 
clinical outcomes with ranging clinical severity [3,4]. 
The constitutively active tyrosine kinase activity of 
Abl, essential for the progression of CML [5], has been 
the focus of many studies to find an effective inhibitor 
[6], of which the compound Gleevec or Imatinib has 
proved to be highly successful. However, the many 
varied domains of BCR are also essential for the trans- 
forming potential of BCR -Abl [1]. 
The normal BCR product is 160 kDa and contains 
a number of domains (Fig. 1) (reviewed in [1]). These 
include an oligomerization domain [7], an atypical S/T 
kinase domain [8 -10], a Src homology 2 (SH2)- binding 
domain [11], guanine nucleotide exchange factor 
(GEF) domain [12,13] and a GTPase activity (GAP) 
Abbreviations 
BCR, breakpoint cluster region; CK1, casein kinase 1; CML, chronic myeloid leukaemia; D4476, 4- {4 -(2,3- dihydro -benzo (1,4)dioxin-6-yl1-5- 
pyridin-2-yl-1H- imidazol- 2- yl }benzamide; ERBIN, ERB2 interacting protein; GAP, GTPase activity; GEF, guanine nucleotide exchange factor; 
JNK, c -Jun N- terminal kinase; ph1, Philadelphia chromosome; PI3K, phosphatidylinositol 3- kinase; PKC, protein kinase C; SH2, Src homology 
2; XPB, xeroderma pigmentosum group B protein. 
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Fig. 1. Domains of BCR. Possible 14 -3 -3 binding sites are indicated as filled circles on top. These and the kinase domain are located within 
exon 1. The positions of the RacGAP, GEF, oligomerization and SH2 binding domains are indicated; the tyrosine residues in SH2 domains by 
short lines. 
domain [14]. BCR binds 14 -3 -3 [9], Xeroderma pig - 
mentosum group B protein (XPB) [15] and chromatin 
[16]. BCR binds to Grb2 when phosphorylated on 
Tyr177 in the SH2 binding domain, thus linking it to 
a role in the Ras pathway [11]. Recently a functional 
PDZ binding domain was identified in BCR, associ- 
ating through a motif consisting of S- T -E -V, with the 
ERB2 interacting protein (ERBIN) [17]. 
The 14 -3 -3 family forms protein complexes involved 
in neurodegeneration, apoptosis, signal transduction, 
trafficking and secretion [18 -20]. In many cases, these 
complexes show a distinct preference for a particular 
isoform(s) of 14 -3 -3. 14 -3 -3 proteins are established 
adaptors of signalling proteins that bind primarily, 
but not solely, to proteins containing phosphorylated 
serine /threonine residues. Using a phosphopeptide 
library, an optimal motif for 14 -3 -3 binding was identi- 
fied as R(S)XpS/TXP [21] which was later refined to 
RXXXpS/TXP where pS is phosphoserine and X is 
any amino acid [22]. The crystal structures of 14 -3 -3 
dimers [23,24] led to identification of the binding site 
of the novel phosphopeptide motif RSX1,2SpXP and 
unphosphorylated motifs [22,25]. 
Recent findings also show that the mechanism of 
interaction is more complex than simply acting 
through the phosphoserine /threonine motif. Nonphos- 
phorylated binding motifs can also be of high affinity 
and may show more isoform- dependence in their inter- 
action [25]. Some well- characterized interacting pro- 
teins such as Raf kinase have been shown to have 
additional binding site(s) for 14 -3 -3 on their cysteine- 
rich regions. BCR also binds via a serine -rich region. 
Binding of a protein through two distinct binding 
motifs to a dimeric 14 -3 -3 may also be essential for 
full interaction [26]. Dimerization with specific iso- 
forms in vivo has important implications for the role 
of 14 -3 -3 in the formation of signalling complexes [19], 
and phosphorylation of specific 14 -3 -3 isoforms can 
also regulate interactions [18,20]. 
The BCR protein has four potential R(S)XXpSXP 
motifs [27] and the association with 14 -3 -3 is of major 
biological significance due to their respective involve- 
ment in signalling pathways including the association 
with Raf kinase [28]. 14 -3 -3 has been shown to bind 
the p110 subunit of phosphatidylinositol 3- kinase 
(PI3K) [29] and the authors suggested that 14 -3 -3 neg- 
atively regulates the activity of PI3K in activated 
T cells by >_ 50 %. Interestingly the authors noted 
enhanced binding of 14 -3 -3T to PI3K with inclusion of 
the tyrosine phosphatase inhibitor pervanadate to the 
lysis buffer, suggesting that 14 -3 -3 may bind through 
phosphotyrosine residues as well as phosphoserine/ 
threonine residues. 
We showed that a and ö were phosphorylated 
forms of ß and , respectively, and are more than 
50% phosphorylated on Ser185 in brain 14 -3 -3 [30], 
but we find no evidence for phospho -forms in a wide 
range of other tissue types and cell lines. Casein 
kinase 1 (CK1, reviewed in [31,32]) colocalizes in neu- 
rons with synaptic vesicle markers and can phos- 
phorylate some synaptic vesicle associated proteins. 
We identified CK1a as the brain kinase that phos- 
phorylated 14 -3 -31 on Thr233 [33]. 14 -3 -3T and yeast 
14 -3 -3s (BMH1 and 2) were also phosphorylated 
on the equivalent sites. In vivo phosphorylation of 
14 -3 -3t at this site negatively regulates its binding to 
c -Raf and may be important in Raf mediated signal 
transduction [28,33]. 
The [3, 11 and isoforms of 14 -3 -3 (but not a and y 
although they also contain serine at the equivalent site) 
are phosphorylated by a sphingosine- dependant kinase, 
SDK1, now identified as the kinase domain of protein 
kinase C (PKC) ö produced after caspase -3 cleavage 
[34]. 
Phosphorylation of 14 -3 -3 by BCR could affect the 
ability of 14 -3 -3 to bind other signalling proteins; for 
example we have shown that phosphorylation of 14 -3 -3 
by CK1 negatively regulates binding to Raf in vivo [33]. 
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Ser185 is located in the tertiary structure adjacent to 
residue 233 [19], and Gotoh's group [35] have recently 
shown that activated c -Jun N- terminal kinase (JNK) 
promotes Bax translocation to the mitochondria 
through phosphorylation of 14 -3 -36 and at sites equiv- 
alent to Ser185, which led to the dissociation of Bax. 
Expression of phosphorylation defective mutants of 
14 -3 -3 blocked JNK- induced Bax translocation to mito- 
chondria, cytochrome c release and apoptosis. 
14 -3 -3T isoform has been shown to interact with full 
length BCR and with BCR -Abl [9]. The authors indi- 
cated that 14 -3 -3T was a substrate for the BCR serine- 
threonine kinase activity and in this study we have 
determined the site to be residue 233. This is of major 
potential physiological relevance since this C- terminal 
region has recently been proposed as a general inhib- 
itor of 14- 3- 3 ligand interactions [36]. The observation 
here that BCR phosphorylates 14 -3 -3 on the same 
residue, 233, as CK1 indicates a conserved mode of 
regulation, whereby phosphorylation could affect the 
ability of 14 -3 -3 to bind target proteins. 
Results 
BCR associates with 14 -3 -3 isoforms in vitro and 
in vivo 
14 -3 -3 isoforms T and ; and ß have previously been 
shown to interact with BCR [9,10]. To investigate the 
possibility that additional isoforms may also interact 
with BCR, two approaches were taken. Firstly BCR 
FLAG was overexpressed in 293 cells, GST- 14 -3 -3 
fusion proteins were incubated with the lysate, 
Fig. 2. (A) BCR interacts with all 14 -3 -3 isoforms in 293 cells. 
HEK293 -cells were transfected with BCR FLAG, lysed and incuba- 
ted with the indicated GST- 14 -3 -3 isoform. A loading control for 
14 -3 -3 stained with Ponceau S is shown in the lower panel. 
GST- 14 -3 -3 T233D construct was also assayed, right -hand lane. 
An equivalent amount of 1% of the lysate used for each incubation 
is shown in lane 1, and a GST -only incubation is shown in lane 2. 
(B) 293 cells were transfected with BCR FLAG, the lysates pooled 
and divided into seven aliquots for immunoprecipitation with anti - 
FLAG lg. An aliquot containing 1% of the input of each lysate was 
western blotted with anti- 14 -3 -3 Igs to verify endogenous levels (top 
panel). The input lysate (1%) was western blotted with anti -FLAG 
Igs (middle panel) to check expression levels of the BCR construct. 
The 14 -3 -3 isoforms were coimmunoprecipitated with anti -Flag Ig 
and each anti -FLAG immunoprecipitation was western blotted with 
antibodies specific for a 14-3 -3 isoform [541 as indicated (bottom 
panel). To demonstrate that 14 -3 -3 isoforms do not bind nonspecifi- 
cally to the resin beads, the left lane is an immunoprecipitation with 
control IgG followed by a western blot with antibodies that recog- 
nize all 14 -3 -3 isoforms (PAN). 
glutathione beads added and the `pull downs' were sub- 
jected to SDS /PAGE and western blotted using anti - 
FLAG (Fig. 2A). Recombinant GST fusion constructs 
of all 14 -3 -3 isoforms pulled down BCR FLAG from 
transfected cells which verified that all 14 -3 -3 isoforms 
have the ability to interact with BCR. However, relat- 
ively more BCR associated with the 14 -3 -311 and y iso- 
form constructs (Fig. 2A). Pull down experiments were 
repeated, with consistent results. The example shown 
was carried out at a time when the phosphorylation site 
had been identified, which is the reason for the inclu- 
sion of the T233DÇ- 14 -3 -3 construct. Secondly, BCR 
FLAG was overexpressed in cells, immunoprecipitated, 
and western blotting used to detect interaction with 
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14-3-313, y, E, , t and 11 isoforms associate with BCR - 
FLAG (Fig. 2B). Taul4 -3 -3 is expressed at low levels 
in 293 cells; nevertheless interaction with this isoform 
can be seen. 14 -3 -3a is expressed at high levels only in 
epithelial cells and is present at such low levels in the 
293 cell line that the interaction could not be detected. 
Negative controls using nonimmune sera were added to 
BCR -FLAG transfections. These showed that none 
of the isoforms tested associate with the agarose 
bead/antibody matrix. 
As well as verifying the binding of 14 -3 -3 isoforms 
ß, ( and r shown previously [9,10] we have thus shown 
in this study that y, rl and 614 -3 -3 can also associate 
with BCR in vivo and in vitro. 
BCR phosphorylates 14 -3 -3r and 14 -3 -31 in vitro 
BCR kinase has previously been shown to phosphory- 
late 14 -3 -3 on serine /threonine residues [9]. It has also 
been shown that BCR when treated with alkaline phos- 
phatase reduced ability to associate with 14 -3 -3 [37]. 
However it is not known if association of BCR with 
14 -3 -3 facilitates phosphorylation. Two vectors suitable 
for mammalian expression containing full length BCR 
were produced; an N- terminal GST fusion construct 
and a C- terminal FLAG construct. The purpose of cre- 
ating a GST N- terminal fusion was to determine whe- 
ther the dimerization ability of GST could increase the 
kinase activity of BCR, because Maru et al. [38] showed 
that GST could replace the oligomerization domain of 
BCR. It has also been shown that BCR purifies as an 
oligomer [8]. A C- terminal FLAG tag construct was cre- 
ated in case the GST itself would create steric hindrance 
between BCR and 14 -3 -3 as substrate. In addition, pro- 
duction in mammalian cells would allow any necessary 
post -translational modifications such as phosphoryla- 
tion and correct processing and folding of BCR. The 
tagged BCR transcripts were overexpressed in COS -1 
and human embryonic kidney (HEK) 293 cells, and 
lysed in NP -40 buffer designed to maintain the phos- 
phorylated state of BCR. GST -BCR was affinity puri- 
fied using glutathione -Sepharose beads, extensively 
washed and incubated with exogenous 14 -3 -3 under 
appropriate assay conditions. In agreement with previ- 
ous studies, the 14 -3 -3r and ( isoforms were phosphoryl- 
ated (Fig. 3), the latter to a much lower level than r. 
None of the other mammalian isoforms ß, y, a, rl and a 
were phosphorylated. BCR -FLAG constructs immuno- 
precipitated with M2 a -FLAG antibody gave a slightly 
higher level of phosphorylation and so were used for 
further studies. There was no difference in substrate spe- 
cificity between GST -BCR and BCR -FLAG (data not 
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Fig. 3. BCR kinase phosphorylation of isoforms of 14 -3 -3. GST- 
BCR was 'pulled down' and a protein kinase assay with each mam- 
malian 14 -3 -3 isoform was carried out, followed by autoradiography 
of the SDS /PAGE. The lower panel shows the loading control of 
each 14 -3 -3 isoform (stained with Coomassie blue). 
sequences indicate that the only Ser/Thr residues com- 
mon to r and Ç, but not present in the other isoforms, 
are S233 in 14 -3 -3r and T233 in 14 -3 -3Ç. Using Ala 
mutants of these phosphorylation sites, kinase assays 
were carried out as previously. The Ser -Ala mutant 
(S233A) of 14 -3 -3r (Fig. 4A) and the Thr -->Ala mutant 
(T233A) of 14 -3 -3ï, were not phosphorylated by BCR 
(Fig. 4B). There was no change in phosphorylation 
by BCR of the Ser --Ala mutant (S185A) of 14 -3 -3( 
(Fig. 4B). The phosphorylation of the 14 -3 -3g constructs 
at residue T233 was very poor in comparison to phos- 
phorylation of wild type 14 -3 -3r and mutation of this 
residue to Ala completely abolished phosphorylation. 
The lack of phosphorylation of the T233A construct 
of 14 -3 -3( indicates that BCR does not phosphorylate 
residue 185 in 14 -3 -3Ç, which was shown by Gotoh's 
group to be a substrate for JNK [35]. 
Ser58, common to all 14 -3 -3 isoforms except a, is 
phosphorylated by a variety of protein kinases (SDK1 
[39], PKB [40] and by PKC in a synthetic peptide cor- 
responding to residues 49 -68 of the other isoforms 
[41]). We show that there is complete lack of phos- 
phorylation of 14 -3 -3a (Fig. 3), which acts as a natural 
negative control. The S185A mutant of 14 -3 -3( as well 
as the S233A and T233A variants still include Ser58, 
which rules out the possibility of Ser58 being a site of 
phosphorylation by BCR. 
Phosphorylation of 14 -3 -3 isoforms is not 
due to coimmunoprecipitation of CK1 
Casein kinase 1 has been shown to phosphorylate 
14 -3 -3r and ( specifically on residue 233 both in vitro 
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Fig. 4. Ala mutation at residue 233 abolishes phosphorylation by 
BCR in vitro. (A) BCR -FLAG and the empty flag vector were trans - 
fected into 293 cells and ìmmunoprecipitated with anti -FLAG Igs as 
described in the Experimental procedures. Kinase assays of 14 -3 -3r 
were performed and SDS /PAGE of the radiolabelled protein was 
carried out. The top panel shows an autoradiograph of tau 14 -3 -3 
wild type (left 3 lanes) and tau 14 -3 -3 S233A (right 3 lanes). The con- 
trol (middle lanes) is a transfection with the GST -BCR construct, 
which we then attempted to pull down with the anti -FLAG Ig to 
verify the specificity of the immunoprecipitation. The bottom panel 
shows the 14 -3 -3 protein levels (Coomassie blue stained) in the cor- 
responding lanes of the autoradiograph. (B) A similar experiment 
was carried out with the zeta 14 -3 -3 T233A and zeta S185A con- 
structs. Wild type tau and zeta 14 -3 -3 were phosphorylated in paral- 
lel. The bottom panel shows the 14 -3 -3 protein levels (Coomassie 








Fig. 5. CK1 specific inhibitors do not affect BCR kinase activity. 
The figure shows an autoradiograph of 14 -3 -3 r wt protein phos- 
phorylated by BCR (left 4 lanes) and by CKkt (right 4 lanes) in the 
presence and absence of the inhibitors as indicated. The bottom 
panels show the 14 -3 -3 protein levels (Coomassie blue stained) in 
the corresponding lanes of the autoradiograph. Dimethylsulfoxide 
was included as a vehicle control. CKI -7 and D4476 were both used 
at 20 1M. 
and in vivo [33]. We have also shown that CK1 associ- 
ates with 14 -3 -3 (S. Clokie and A. Aitken, unpublished 
results; [42]). The possibility existed that endogenous 
14 -3 -3 could be acting as a `molecular bridge' between 
BCR and endogenous CK1 and that the latter activity 
was phosphorylating 14-3-3-c. To exclude this possibility, 
the CK1 inhibitor CKI -7 was added to kinase assays at 
concentrations up to 100 pt. Little effect was seen, even 
at the highest concentration, and only slight inhibition 
was seen when BCR was preincubated with CKI -7 for 
1 h. However the IC50 of this compound is rather high 
and it is possible that it is causing a general inhibition of 
kinase activity when used at such high concentrations. 
We then used the newly developed inhibitor of CK 1 
4- {4- [2,3- dihydro -benzo (1,4)dioxin-6-y1]-5- pyridin -2 -yl- 
1H- imidazol- 2- yl }benzamide (D4476) [43]. This has an 
IC50 of approximately 1 µtut, and is therefore 10 -fold 
more inhibitory than CKI -7 towards CK1 and has been 
shown to be highly specific [43]. This had no effect on 
the phosphorylation of 14 -3 -3T or Ç by BCR kinase, but 
completely inhibited CK1 assayed in parallel with BCR 
(Fig. 5). 
Discussion 
Reuther et al. [9] showed that 14 -3 -3 binds to BCR 
downstream of residue 297 (Fig. 1), and these authors 
alluded to the possibility of 14 -3 -3 binding elsewhere 
on the protein, but to a lesser extent. Indeed BCR has 
many potential 14 -3 -3 binding sites - RASA- S95 -RP, 
RSG-S301-TS, RL -T310 -WPR, RSY- S317 -P and RSP- 
S371-QN [28,45] - four of them C- terminal to residue 
297. Recently the sequence RL -T310 -WPR has been 
shown to be phosphorylated in vivo [44]. 
FEBS Journal 272 120051 3767 -3776 © 2005 FEBS 3771 
BCR kinase phosphorylates 14 -3 -3r on residue 233 S. J. Clokie et al. 
We have now shown that the 14 -3 -3 isoforms (ß, y, 
E, and ri) that are expressed at a detectable level in 
293 cells bind BCR in vivo. The fact that 14 -3 -3T was 
detected in the BCR -FLAG immunoprecipitation, 
even though not detectable in the 293 lysate shows the 
interaction may be of higher affinity than the other 
isoforms. We also showed that 14 -3 -3 isoforms incuba- 
ted with a cell lysate containing BCR -FLAG were able 
to associate. Therefore, in addition to the T, Ç and ß 
isoforms previously shown, 14 -3 -3 E, rl and y can also 
interact with BCR. Our results suggest that while there 
is the capacity of all 14 -3 -3 isoforms to bind BCR, 
there is a preference for binding certain 14 -3 -3 iso- 
forms. It may be difficult to ascertain true binding spe- 
cificities, in vivo, due to the ability of 14 -3 -3 to form 
a limited repertoire of heterodimers [45]. A T233D 
mutant of 14 -3 -3 was incubated with the BCR lysate 
(Fig. 2A) to determine whether mimicking a phosphor - 
ylated T233 could negatively affect binding, as repor- 
ted previously [28,33]. However, the mutant had no 
significant effect, possibly due to the fact that some- 
times an Asp mutation that introduces a carboxyl 
group does not have the same effect as a phosphate 
group. 
The increased number of 14 -3 -3 isoforms that are 
shown here to bind BCR opens up further potential 
roles for BCR in cellular signalling. Even though these 
extra 14 -3 -3 isoforms are not substrates for BCR, they 
may well affect BCR activity and /or subcellular loca- 
tion. 
Using specific mutants of 14 -3 -3 we have shown that 
BCR phosphorylates the tau isoform on serine 233 
only. There is a rational explanation why phosphoryla- 
tion at Ser233 in this isoform led to the observation by 
Reuther et al. [9] of four phosphopeptide spots on thin 
layer electrophoresis. From our own extensive protein 
sequence analysis ([46] and A. Aitken, unpublished 
results) we have shown that tryptic cleavage of 14 -3 -3 
isoforms produces the following two C- terminal pep- 
tides: (R)DNLTLWTSDSAGEECDAAEGAEN(223- 
245) and (K)DSTLIMQLLRDNLTLWTSDSAGEE 
CDAAEGAEN(213 -245). This is due to partial clea- 
vage at Arg223 (underlined). The unique cysteine resi- 
due (also underlined) in the tau isoform may undergo 
modification, such as partial oxidation to cysteic acid 
during thin layer electrophoresis when exposed to air, 
which changes its electrophoretic mobility. Phosphory- 
lation at residue 233 would yield two radiolabelled 
phosphopeptides due to partial cleavage by trypsin, 
multiplied by two due to the partially modified cys- 
teine residues (which have a more acidic mobility), and 
producing a total of four spots on thin layer electro- 
phoresis. 
3772 
BCR has a clear preference for phosphorylation of 
14 -3 -3T rather than 14 -3 -3t (in agreement with previ- 
ous studies [9]), possibly due to increased binding 
affinity. In three separate experiments we observed an 
approximately 10 -fold higher phosphorylation of T 
than 14 -3 -3 (Fig. 3 and data not shown). This is in 
contrast to the preference of CKIa for 14 -3 -31 over 
14 -3 -3T [34]. It may be worth noting that 14 -3 -3T, the 
major isoform substrate for BCR is expressed in 
T -cells to a greater extent than in other tissues [47,48]. 
Western blots of immunoprecipitated BCR using 
phospho -Tyr antibodies showed the presence of phos- 
phorylated tyrosine residues (data not shown). One 
study has shown that tyrosine phosphorylation on resi- 
due 177 (by Fes kinase) actually reduced the associ- 
ation with 14 -3 -3, while at the same time increasing 
the SH2 binding to GRB2 [49]. The kinase that phos- 
phorylates BCR on Tyr177 in HEK293 cells is cur- 
rently not known. A study of the Philadelphia positive 
cell line K562 showed that Tyr177 is phosphorylated 
in vivo [44], but this residue is a known substrate for 
BCR -Abl, also expressed in this cell line [50,51]. The 
possibility remains that 14 -3 -3 association with BCR 
may perturb Tyr177 phosphorylation and /or affect 
SH2 binding at this site. 
Experimental procedures 
Materials 
All chemicals and reagents were from Sigma (St Louis, 
MO, USA), apart from Redivue [32P]ATP[yP] (triethyl- 
ammonium salt) from Amersham (Buckinghamshire, UK) 
and prestained protein markers from New England Biolabs 
(Beverly, MA, USA). Protease inhibitor tablets were from 
Roche (Indianapolis, IN, USA); recombinant CK1 was 
from Upstate Biotechnology (Lake Placid, NY, USA) and 
CKI -7 was from Seikagaku (Tokyo, Japan). 
A vector containing the bcr sequence was a kind gift 
from O. Witte (Department of Cell Biology, Harvard 
Medical School, Boston, MA, USA). The coding sequence 
for bcr was amplified by PCR using two oligonucleotides 
5'- GATCGCGGCCGCGCGCCATGGTGGACCCGGTG 
GGCTT -3' and 3'- GATCGAATTCGACTTCGGTGGAG 
AACAGGATGCTCTGTCT -5' creating the restriction sites 
Nod and EcoRl, respectively (underlined), and ligated into 
the pEBG -2T GST vector for mammalian expression (kind 
gift from D. Alessi, University of Dundee, UK) creating an 
N- terminally fused bcr construct. Two oligonucleotides 
( 5'- GATCGAATTCATGGTGGACCCGGTGGGCTTCG -3' 
and 3'- GATCGCGGCCGCTTAGACTTCGGTGGAGAA 
CAGGATGCTCTGTCT -5') were used to produce bcr cDNA, 
containing the restriction sites EcoRl and Not t for ligation 
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into the pCMV -4A vector (Stratagene, La Jolla, CA, USA), 
producing a C- terminal fusion with the FLAG tag. 
The cDNAs for 14 -3 -3 isoforms were from various 
sources. 14 -3 -3ß is an IMAGE clone (4843961/gi14060448), 
and was subcloned from the supplied vector (pOTB7) PCR 
with two oligonucleotides: 5'- GATCGAATTCATGACAA 
TGGATAAAAGTGAGCTGGTA -3' and 3'- GATCGTC 
GACTTAGTTCTCTCCCTCCCCAG -5', creating an EcoRI 
and a Sall restriction site, respectively (underlined). The 
PCR product was inserted into pGEX -4T1 (Amersham), 
creating an N- terminal GST fusion. 14- 3 -3r1, 14 -3 -3y and 
14 -3 -3a were a gift from H. Leffers (University of Copenha- 
gen, Denmark), the ri and y clones were present as an N -ter- 
minal GST fusion in the vector pGEX -2TK (Amersham). 
The 14 -3 -3a was subcloned from the vector pGPT -delta 6 
using the oligonucleotides 5'- GATCGAATTCATGGAGA 
GAGCCAGTCTGATC -3' and 3'- GATCGTCGACTCAG 
CTCTGGGGCTCCT -5' creating an EcoRl site and Sall 
site, respectively (underlined). The PCR product was inserted 
into pGEX -4T1. 14 -3 -3 was from a human T -cell cDNA lib- 
rary and has been produced as an N- terminal GST fusion in 
the pGEX -2T vector [33,47,52]. 14 -3 -3e was produced as an 
N- terminal maltose binding protein (MBP) fusion, from a rat 
cDNA (accession no. m84416) [53]. 14 -3 -3r was from a 
human source [48,49]. All cDNAs were checked by sequen- 
cing both strands (in house sequencing core and Cytomyx, 
Cambridge, UK). 
Tissue culture and immunoprecipitation 
SV40 transformed African green monkey kidney cells (COS - 
1) and adenovirus 5E1A/B transformed human embryonic 
kidney (HEK) 293 cells were transiently transfected with 
8 µg DNA with 24 µL Lipofectamine 2000 (Invitrogen, Car- 
lsbad, CA, USA). Cells were routinely cultured in Dulbecco's 
modified Eagle's medium (DMEM, Invitrogen) supplemen- 
ted with 10% (w /v) fetal bovine serum (Invitrogen), penicil- 
lin, streptomycin and L- glutamine at 1 UmL -r, 1 ggmL -' 
and 0.292 mgmL -I, respectively, at 5% (v /v) CO2 and 37 °C 
until lysis. For transient transfections, 2-4 x 106 cells were 
added to 100 mm plates, using antibiotic -free media, left 
until 80 -90% confluent, then incubated for 24 h after addi- 
tion of the DNA -Lipofectamine complex at 5% (v /v) CO,, 
37 °C. The plates were washed twice with ice cold NaCI /P; 
and lysed on ice with ice -cold NP -40 buffer using a cell scra- 
per. The lysate was clarified by centrifugation at 16 000 g for 
30 min at 4 °C, the addition of 50 µL washed Pansorbin A 
cells (Calbiochem) for 60 min to remove endogenous 1gG, 
then a further 30 min at 16 000 g, 4 °C. 
Giutathione 'pull -down' immunoprecipitation 
kinase assay 
Glutathione -Sepharose 4B (Amersham Pharmacia) beads 
or a 1 : 1 mix of protein A and G beads (Amersham) were 
used to pull down the GST fusion and immunoprecipitate 
the FLAG -tagged BCR, respectively. To the clarified cell 
lysates, GSH beads were added for 2 h before washing. 
For immunoprecipitation with FLAG antibody (M2) the 
antibody was incubated in the lysate overnight, then incu- 
bated with protein AG beads for 2 h. The beads were then 
centrifuged at 8000 g in a benchtop centrifuge for 20 s and 
washed three times in lysis buffer [50 mM Tris, pH 7.5, 
10% (v /v) glycerol, 137 mM NaCI, 2 mM 3- glycerol 
phosphate, 1 mM NaF, 1 mM NaVO4, I mM EDTA, 1 mM 
dithiothreitol and protease inhibitor cocktail tablet, EDTA - 
free (Roche)]. The beads were then washed twice in kinase 
assay buffer (see below, without ATP and dithiothreitol). 
After the last wash, the beads were resuspended in a final 
volume of 25 µL kinase assay buffer, with a final concen- 
tration of 50 mM Hepes, pH 7,05, 10 mM MgC1, 20 ltM 
ATP (containing 10 iiCi [32P]ATP) and 20 µM dithiothrei- 
tol, and 2 pg of 14 -3 -3 isoform was used for each assay. 
The reaction was carried out for 30 min at 30 °C and 
stopped in Laemmli buffer prior to SDS /PAGE, followed 
by autoradiography. 
Casein kinase 1 inhibitors 
CKI -7 was dissolved in dimethylsulfoxide as a 10 mM 
stock. For preincubation experiments with CKI -7, during 
the last wash of the IP, BCR -FLAG immunoprecipitates 
were turned end over end while suspended in kinase assay 
buffer including 100 µM CKI -7 (minus ATP). Where stated, 
CKI -7 was added just prior to addition of the substrate 
(20 gm). D4476 inhibitor was dissolved in dimethylsulfoxide 
to a stock of 1 mM and was used at 20 pM in the final 
assay. This was added immediately prior to addition of 
the substrate. No preincubation with D4476 was required 
to observe an inhibitory effect. Dimethylsulfoxide (2 µL) 
was used as a vehicle control. 
Recombinant protein purification 
All GST- 14 -3 -3 fusion cDNAs were transformed into 
E. coli BL21(DE3)pLysS competent cells (Novagen, Madi- 
son, WI, USA), using the appropriate antibiotic. The cells 
were grown at 37 °C until an attenuation of 0.9, then 
induced using isopropyl thio - 3- D- galactoside (ICN, Costa 
Mesa, CA, USA) for 3.5 h at 30 °C, in a shaking incuba- 
tor. The same procedure was used for the MBP- 14 -3 -3e, 
but with the addition of glucose at 2 gL -I at all stages. 
Cell pellets, resuspended in lysis buffer [NaCI /P;, I mM 
phenylmethanesulfonyl fluoride, 1 mM EDTA, 1 mM dithio- 
threitol, protease inhibitor tablet and 0.1% (v /v) Triton], 
were sonicated six times for 30 s with amplitude of 
5 microns. The Triton X -100 concentration was increased 
to 1%; the cell suspensions were rotated for 30 min at 4 °C 
and clarified by centrifugation at 16 000 g for 30 min. The 
supernatant was then passed through a 0.22 µm filter and 
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the GST fusion protein was recovered from the lysate using 
glutathione -Sepharose 4B beads (Amersham). The beads 
were washed extensively and the 14 -3 -3 cleaved from the 
GST tag using 50 U thrombin (Sigma) or 50 U Factor Xa 
(New England Biolabs) for MBP- 14 -3 -3e, for each litre of 
original culture. The 14 -3 -3 was then concentrated and buf- 
fer- exchanged into NaCI /P; containing protease inhibitors 
(Roche) using a Vivaspin 10K MWCO concentrator and 
stored in small aliquots at -70 °C until required. 
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